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Abstract
This thesis details the discovery and characterisation of biosynthetic enzymes implicated in the 
monoterpene indole alkaloid (MIA) pathway of the medicinal plant Catharanthus roseus. 
The MIA pathway is characterised by a plethora of different carbon skeletons, which are 
derived from the central pathway intermediate strictosidine aglycon. Given the biological 
importance of these compounds, there is great interest in identifying the enzymes that 
catalyse the formation of these different carbon skeletons, as well as understanding the 
mechanistic basis for how the pathway is controlled at this critical step in the pathway. 
The discovery of the first enzyme capable of reducing the reactive aglycon intermediate to a 
heteroyohimbine-type MIA (tetrahydroalstonine) opened the door to discovery of many other 
heteroyohimbine synthases (HYS, Chapter 2). These enzymes share a degree of sequence 
identity and are all members of the Medium-Chain Dehydrogenase/Reductases. Interestingly, 
these HYSs catalysed the formation of different ratios of several heteroyohimbine stereoisomers. 
A detailed mutation screen, together with protein crystallography, deuterium labelling, and in 
silico docking enabled us to propose a catalytic mechanism for these enzymes and how the 
ratio of products is controlled (Chapter 3). An investigation into a different family of reductases, 
the Short-Chain Dehydrogenase/Reductases, revealed another enzyme capable of reducing the 
reactive strictosidine aglycon intermediate (Chapter 4). After extensive NMR characterisation, 
the enzymatic product was found to possess an unusual carbon skeleton different to that of the 
heteroyohimbines. 
Characterisation of the phylogeny of these enzymes revealed that they have undergone numerous 
duplication events (Chapter 5). The HYSs appear to have undergone multiple duplications and 
neofunctionalisation that has given rise to at least one other biosynthetic enzyme which acts in 
one of the downstream MIA pathway branches. A study of a large reductase duplication locus 
provides evidence that pathway clustering in plants arises through translocation of biosynthetic 
genes. 
The discovery of these reductases has provided us with an unprecedented opportunity to study 
the dynamics of the branch-point of the MIA pathway. These discoveries constitute an 
important step towards the elucidation of the MIA pathway in C. roseus and in the many 




This PhD has been one of the hardest things I have ever done. Although I sometimes asked 
myself why I put myself through this ordeal, in the end I hope it has been worth it. The last four 
years have been a journey of discovery, and I am not the same person as I was when I began, 
professionally and personally. 
I have met some great people, made some amazing friends, and learned a lot about science 
and life. The Biological Chemistry department, and the whole John Innes Centre, has been an 
inspiring place to work in. There are so many brilliant people who are doing great science and 
who have fascinating stories to tell. I wish I had more time to talk with and learn from everyone. 
I owe this success to the excellent supervision that Sarah O’Connor offered over the years. She 
has been a great mentor, and she allowed me to follow through with my ideas and let me work 
independently. It would not have been possible without the support and help from Lorenzo 
Caputi and Evangelos Tatsis. Lorenzo has been a great friend over the years and has always been 
there to offer his help and expertise. He has also been the level-headed advisor in times of need 
and he was a real blessing to me and the team as a whole. Evangelos was indispensable for my 
education in the chemistry aspects of this PhD. He is a great lab partner and his work ethic never 
ceases to impress me. I am very grateful to have worked with him.
My time in the group would not have been the same without Dorota Jakubczyk. She is a great 
friend and could always lend me a shoulder to cry on when necessary. Thuy Dang is a very 
kind and inspiring person and I’m happy I had the chance to get to know her better over the 
years. Omar Kamileen will always hold a special place in my heart, his easy-going and cheerful 
personality brightens up the lab and always made my days a bit more manageable. 
I would also like to thank the past group member Weslee Glenn for being welcoming and for 
passing on his enzymes at the end of his PhD. Weslee taught me not to take things too seriously, 
and at the hardest times I made an effort to remember this lesson. Hajo Kries was also a great 
group member who encouraged me with my crazy projects and shared my enthusiasm when 
many others did not. Thank you to current members Don Nguyen, Benjy Lichman, and Scott 
Farrow with whom I had many interesting conversations.
Throughout my PhD one person has really stood out and supported me more than anyone else, 
even though he was miles away. I owe my sanity to my loving partner, Alex, who has never 
ceased to encourage me and was always there to hear my rants. He brought a breath of fresh air 
to my time as a PhD student and really helped me put things back into perspective when I lost 
sight of the path. I can’t express how grateful I am to have him in my life.
I owe a lot to my mother, Aileen, who has always been a role model to me. I admire her for her 
outgoing and happy personality and general optimism. She can always sense when I am down 
and is always there for me with kind words. She has been my crutch since my teenage years, and 
I would not have got this far without her love and support.
My father, Stavros, encouraged me to follow my passions and trusted my decisions. I know he 
would have been very proud of me and I wish he were here to share this moment with me. This 






List of Tables xi
List of Figures xi
List of Abbreviations xvii
Chapter 1 Introduction 1
1.1 Chemical diversity of medicinal plants 1
1.2 Indole alkaloids 2
1.3 Strictosidine Synthase 3
1.4 Deglycosylation of strictosidine 4
1.5 Spatiotemporal localisation 6
1.6 Structural rearrangements unlock chemical diversity in MIA 8
1.7 Dehydrogenases 14
1.8 The Medium-Chain Dehydrogenase/Reductase family 14
1.9 The Short-Chain Dehydrogenase/Reductase family 16
1.10 Stereoselectivity of Dehydrogenases/Reductases 17
1.11 Scope of this thesis 19
1.12 References 20
Chapter 2 Discovery and characterisation of heteroyohimbine synthases 
of Catharanthus roseus 25
2.1 Introduction 25
2.1.1 The heteroyohimbines 25
2.1.2 Heteroyohimbine biosynthesis in C. roseus  25
2.1.3 Known reduction steps in MIA biosynthesis 27
2.1.4 Discovery of the heteroyohimbine synthases 28
2.2 Results 29
2.2.1 Identification and sequence analysis of THAS1 29
2.2.2 Initial functional characterisation of THAS1 32
2.2.3 Characterisation of THAS1 product 35
2.2.4 Screening for similar enzymes with THAS activity 37
2.2.5 pH and temperature optima 42
2.2.6 Kinetics of THAS1 with strictosidine aglycon 44
2.2.7 ITC 45
2.2.8 Pull-down of THAS1 with SGD 46
vi
2.3 Discussion 47
2.3.1 Heteroyohimbines in C. roseus 47
2.3.2 THAS1 discovery and characterisation 48
2.3.3 Discovery of other HYS 49
2.3.4 Interaction with upstream enzymes 50
2.4 Conclusion 50
2.5 Materials and Methods 51
2.5.1 RNA extraction from C. roseus and cDNA synthesis 51
2.5.2 Identification of candidate gene 51
2.5.3 Polymerase chain reaction 51
2.5.4 Vectors 52
2.5.5 Cloning THAS1 52
2.5.6 Cloning of other candidate MDRs showing homology to THAS1 52
2.5.7 THAS1 protein expression and purification 54
2.5.8 Small scale protein expression and purification 54
2.5.9 Enzyme assays 55
2.5.10 Steady state kinetics for THAS1 55
2.5.11 Isothermic Titration Calorimetry  56
2.5.12 Secologanin purification from Symphoricarpos albus 56
2.5.13 Strictosidine synthase production 57
2.5.14 Production and purification of strictosidine 57
2.5.15 Determination of pH optimum of THAS1 57
2.5.16 Determination of temperature optimum of THAS1 58
2.5.17 Analysis of pH and temperature optima experiments 58
2.5.18 Determination of pH optimum of HYS 59
2.5.19 LC-MS measurements 59
2.5.20 Large-scale THAS1 reaction and product purification 60
2.5.21 Pull down of THAS1 with SGD 61
2.5.22 Alignment of protein sequences 62
2.6 References 62
Chapter 3 Achieving Stereoselectivity in Heteroyohimbine Synthases 65
3.1 Introduction 65
3.2 Results 66
3.2.1 Crystallisation of THAS1 66
3.2.2 Crystallisation of HYS 66
3.2.3 Comparison of crystal structures 71
3.2.4 Enzymatic labelling of products with 2H 78
3.2.5 pH effect on product profile 80
3.2.6 Docking of cathenamine into THAS1 active site 81
3.2.7 Mutagenesis of THAS1 and HYS 82
3.2.8 Loop swaps and mutations to HYS loop2 86
vii
3.2.9 Point mutations of HYS 87
3.2.10 Mechanism proposal for tetrahydroalstonine biosynthesis in THAS enzymes 88
3.2.11 Mechanism proposal for ajmalicine biosynthesis in HYS 89
3.2.12 Removal of zinc and functional assays 90
3.3 Discussion 92
3.3.1 Protein crystal structures 92
3.3.2 Steric course of hydrogen transfer 94
3.3.3 Effect of pH on product profile 94
3.3.4 Mutations to THAS1 95
3.3.5 Loop swaps between THAS1 and HYS 96
3.3.6 Reduction mechanism of HYSs 97
3.4 Conclusions 100
3.5 Materials and Methods 100
3.5.1 Site directed mutagenesis of THAS1 and HYS 100
3.5.2 Loop swap mutants 101
3.5.3 Expression of mutant THAS1 and HYS 102
3.5.4 SGD expression and purification 102
3.5.5 Expression and crystallisation of THAS1 102
3.5.6 Expression and crystallisation of HYS 103
3.5.7 Data collection 104
3.5.8 UPLC-MS and NMR analysis 104
3.5.9 2H labelling experiments 105
3.5.10 pH effect on product profile 106
3.5.11 CD spectra and analysis 106
3.5.12 Docking of cathenamine in THAS1 holo structure 107
3.5.13 Testing of Zinc-apo THAS1 and HYS 107
3.6 References 108
Chapter 4 Discovery and characterisation of a Short-Chain Dehydrogenase/Reductase 
capable of reducing strictosidine aglycon 111
4.1 Introduction 111
4.1.1 Short-chain Dehydrogenase/Reductase family 111
4.1.2 SDRs in C. roseus 111
4.2 Results 112
4.2.1 ADH10 cloning 112
4.2.2 Heterologous expression 113
4.2.3 pH assay with ADH10 114
4.2.4 Kinetic studies of ADH10 with strictosidine aglycon 115
4.2.5 High resolution Mass-spectrometry and fragmentation 116
4.2.6 NMR characterisation of the ADH10 product 117
4.2.7 Results of deuterium labelling 123
viii
4.2.8 Crystallisation 124
4.2.9 Crystal structure of ADH10 126
4.2.10 Comparison to Salutaridine Reductase 130
4.2.11 Mutations to ADH10 active site 133
4.2.12 Proposed mechanism for ADH10 product formation 136
4.2.13 Abundance of the pro-vitrosamine substrate in solution 136
4.3 Discussion 138
4.3.1 Vallesiachotamine-type alkaloids 138
4.3.2 Characterisation of ADH10 139
4.3.3 Comparison to heteroyohimbine biosynthesis 140
4.3.4 Mechanism of ADH10 product formation 141
4.3.5 Comparison to HYSs of C. roseus 143
4.3.6 Similarities of ADH10 and Salutaridine Reductase 144
4.3.7 Precedence for SDR imine reductases 144
4.4 Conclusions 148
4.5 Materials and Methods 149
4.5.1 General molecular biology techniques used 149
4.5.2 Cloning of ADH10 149
4.5.3 ADH10 expression assay 150
4.5.4 ADH10 large-scale expression and purification 150
4.5.5 Crystallisation and data collection 151
4.5.6 Accurate mass and fragment determination 151
4.5.7 Large scale reaction with deglycosylated strictosidine and product purification 152
4.5.8 Deuterium labelling of ADH10 product 152
4.5.9 pH assays of ADH10 with strictosidine aglycon 153
4.5.10 Spectroscopic assays 153
4.5.11 Combination of ADH10 and THAS1 154
4.5.12 Active site mutations 154
4.6 References 155
Chapter 5 Gene duplication in C. roseus has allowed the development of 
MIA chemical diversity through neofunctionalisation 159
5.1 Introduction 159
5.1.1 The birth of new enzymes through gene duplication 160
5.1.2 Gene duplication and heteroyohimbine biosynthesis 162
5.1.3 Overview of this chapter 163
5.2 Results 163
5.2.1 Genomic organisation of the C. roseus ADHs 163
5.2.2 Analysis of the ortholog groups present in the MDRs and SDRs of C. roseus 166
5.2.3 Phylogeny of the C. roseus MDRs 168
5.2.4 Phylogenetic analysis of the C. roseus SDRs 173
 ix
5.2.5 Comparison of C. roseus duplication blocks to other plant genomes 176
5.2.6 Phylogenetic analysis of syntenic blocks 178
5.3 Discussion 181
5.3.1 Genomic context of MDRs and SDRs in C. roseus 181
5.3.2 Ortholog groups in MDRs and SDRs 182
5.3.3 Phylogeny of MDRs in C. roseus 182
5.3.4 Phylogeny of SDRs in C. roseus 182
5.3.5 MDR duplication blocks in other plant genomes 183
5.4 Conclusions 183
5.5 Materials and Methods 185
5.5.1 Reductase sequences 185
5.5.2 MDR phylogenetic analysis 185
5.5.3 SDR phylogenetic analysis 186
5.5.4 Phylogenetic analysis of syntenic blocks 187
5.6 References 188
Chapter 6 Conclusions 193
6.1 Heteroyohimbine synthases 193
6.2 Enzymatic generation of the vallesiachotaman skeleton 193
6.3 Phylogenetics reveals evolution dynamics in the HYSs 194
6.4 Future directions 194








Annex 1 Stavrinides et al. 2015. Unlocking the Diversity of Alkaloids in Catharanthus roseus: 
Nuclear Localization Suggests Metabolic Channeling in Secondary Metabolism 263
Annex 2 Stavrinides et al. 2016 Structural investigation of heteroyohimbine alkaloidsynthesis 





Table 1: Results of Zinc coordinating amino acids prediction of THAS1 31
Table 2: Percentage of amino acid sequence identity between MDR candidates cloned 39
Table 3: Results of enzyme assay analysis by LC-MS of MDRs that were screened for 
heteroyohimbine synthase activity 42
Table 4: pH assay of HYS product formation 44
Table 5: Primers used for cloning the MDR candidates into the expression 
vector pOPINF 53
Table 6: Multiple Reactions Monitoring conditions 60
Chapter 3
Table 7: List of THAS1 mutants that were screened for heteroyohimbine synthase 
activity against strictosidine aglycon 84
Table 8: List of THAS1 and HYS loop swap mutants screened for heteroyohimbine 
synthase activity against strictosidine aglycon 87
Table 9: List of HYS point mutants that were screened for heteroyohimbine 
synthase activity against strictosidine aglycon 88
Table 10: List of primer pairs for mutagenesis of THAS1 and HYS 101
Table 11: Multiple Reactions Monitoring conditions 105
Chapter 4
Table 12: ADH10 product formed in different pH buffers in endpoint assays 115
Table 13: Crystallisation hit conditions used in optimisation screens 124
Chapter 5
Table 14: Catharanthus roseus Whole Genome contigs containing an ADH gene 163
Table 15: COG of MDRs from C. roseus 166
Table 16: COG of SDRs from C. roseus 167
Table 17: Plant species used in cluster duplication analysis 177
List of Figures
Chapter 1
Figure 1: Selected indole alkaloids with medicinal uses. 2
Figure 2: Chemical condensation of tryptamine and secologanin. 3
Figure 3: Strictosidine biosynthesis from tryptamine and secologanin. 3
Figure 4: Aglycon formation from strictosidine, dhurrin, and DIMBOAGlc. 5
Figure 5: C. roseus general MIA pathway. 6
Figure 6: Strictosidine aglycon numbering. 9
Figure 7: Strictosidine aglycon and its structural rearrangements. 10
Figure 8: Heteroyohimbine alkaloids of C. roseus. 11
Figure 9: Pathway of C. roseus up to the heteroyohimbine alkaloids. 12
Figure 10: Proposed pathway of C. roseus from the strictosidine dialdehyde onwards. 13
xii
Figure 11: Oxidation and reduction reactions. 14
Figure 12: Reduced nicotinamide adenine dinucleotide phosphate (NADPH). 15
Figure 13: Reaction catalysed by Sinapyl and Cinnamyl alcohol dehydrogenases. 15
Figure 14: Reduction of vomilenine by RsVR2. 16
Figure 15: Reactions catalysed by SalR and SanR, SDR enzymes of the BIA pathway. 17
Figure 16: Menthol biosynthesis pathway from the cyclised terpene limonene. 17
Figure 17: Stereoselective reduction of ( ̶ )-isopiperitenone to produce  
(+)-cis-isopulegone. Proposed reduction mechanism of Isopiperitenone Reductase (IPR), 
redrawn from (Lygidakis et al., 2016). 18
Chapter 2
Figure 17: Stereoselective reduction of ( ̶ )-isopiperitenone to produce (+)-cis-isopulegone. 
Proposed reduction mechanism of Isopiperitenone Reductase (IPR), redrawn from  
(Lygidakis et al., 2016). 25
Figure 18: The eight heteroyohimbines. The top row (with S stereochemistry at C-3) are 
derived from strictosidine, and the bottom row (with R stereochemistry at C-3)  
are derived from the strictosidine isomer, vincoside. 25
Figure 19: Proposed mechanism of biosynthesis of heteroyohimbines from 
dehydrogeissoschizine. 26
Figure 20: The MIA geissoschizine. 26
Figure 21: Reaction catalysed by 10-Hydroxygeraniol-Oxidoreductase (10HGO). 28
Figure 22: Conversion of the C. roseus MIA tabersonine into 3-hydroxy-2,3-
dihydrotabersonine by the action of a cytochrome P450 followed  
by reduction by T3R. 28
Figure 23: Expression profile of THAS1 in C. roseus tissues. 30
Figure 24: Reduction of sinapaldehyde to sinapyl alcohol, catalysed by 
Sinapyl Alcohol Dehydrogenase (SAD). 31
Figure 25: SAD reduction mechanism. 32
Figure 26: Gel filtration trace and LC-MS assays of THAS1 with 
dimer isozyme and monomer isozyme labelled. 33
Figure 27: Chromatograms of THAS1 reaction along with controls. 34
Figure 28: LC-MS trace of THAS1 reaction with THA and NADP⁺ as substrate. 34
Figure 29: TLC of THAS1 large scale reaction. 35
Figure 30: LC-MS trace of the TLC band corresponding to AJM. 36
Figure 31: NMR traces of an authentic standard of THA and the 
purified major product of the large-scale THAS1 reaction. 36
Figure 32: Expression level of the MDRs cloned in the initial HYS screen plotted against 
various tissues. 37
Figure 33: Protein alignment of candidate MDRs. 40
Figure 34: LC-MS traces of product formed after reaction of strictosidine aglycon 
with the HYSs. 41
Figure 35: pH optimum of THAS1. 42
Figure 36: Temperature optimum of THAS1. 43
Figure 37: Michaelis-Menten plot of THAS1 with varying concentrations of 
strictosidine aglycon. 44
xiii
Figure 38: Michaelis-Menten plot of THAS1 with varying concentrations of NADPH. 45
Figure 39: Isothermic titration calorimetry for NADPH binding to THAS1. 46
Figure 40: Cleavage or 6 x His tag of THAS1 and pull down with SGD. 47
Figure 41: Tetrahydroalstonine. 48
Chapter 3
Figure 42: Deglycosylation of strictosidine and equilibration into cathenamine and 
generation of the iminium form through tautomerization. 65
Figure 43: Equilibration of cathenamine and the iminium form of cathenamine. 66
Figure 44: Images of a typical SDS-PAGE gel analysis of purified HYS after only His-trap 
purification (left) and after both His-trap and size exclusion gel-filtration (right). 67
Figure 45: Optimisation screen for HYS apo crystals with 0.2 mM MMT Buffer (pH 5.0) 
with varying PEG sizes and concentrations. 67
Figure 46: Optimisation screen for HYS apo crystals with 0.2 mM Sodium Nitrate 
with varying PEG sizes and concentrations. 68
Figure 47: Optimisation screen for HYS apo crystals with 0.1 mM MMT Buffer 
with varying pH and PEG concentrations. 68
Figure 48: Optimisation screen for HYS apo crystals with 0.1 mM MMT Buffer (pH 5.0) 
with varying PEG sizes and concentrations. 68
Figure 49: Optimisation seeding screen for HYS holo crystals with 
0.1 mM MMT Buffer (pH 5.0) with varying PEG concentrations. 69
Figure 50: Thermofluor assay of HYS with addition of ethylene glycol, glycerol, or PEG at 
differing concentrations. 70
Figure 51: Thermofluor result with HYS and cofactor at varying concentrations. 70
Figure 52: NADP⁺ depicted in the electron density (turquoise mesh) which was 
experimentally phased after solving the structure and before any further refinement. 72
Figure 53: Crystal structure of THAS1 holo (top) and apo (bottom). 72
Figure 54: Overview of THAS1 active site. 73
Figure 55: 2-D figure of coordination of NADP⁺ in THAS1 chain A. 74
Figure 56: Interactions between NADP⁺ and THAS1. 75
Figure 57: Sequence alignment of C. roseus THAS1, THAS2, HYS, and P. tremuloides SAD. 75
Figure 58: Overview of THAS1 (top) and HYS (bottom) crystal structures. 77
Figure 59: Zinc coordination spheres of THAS1 (upper panels) and HYS (lower panels). 78
Figure 60: 1H-NMR spectra of [21α-2H]-THAS1 and HYS products. 79
Figure 61: 1H-NMR spectra of [21α-2H]-ajmalicine from large-scale HYS reaction. 79
Figure 62: 1H-NMR spectra of [21α-2H]-19-epiajmalicine from large-scale HYS reaction. 80
Figure 63: Heteroyohimbines with deuterium at α-position on carbon 21. 80
Figure 64: Product profile of THAS1, HYS, and NaBH4 dependence on pH from 5 to 8. 81
Figure 65: Cathenamine docked in the active site of THAS1. 82
Figure 66: Selected representative traces of THAS1 mutants with interesting effect 
on the product profile of the enzyme. 83
Figure 67: Mutations to THAS1 active site. 85
Figure 68: Product profile of THAS1 and HYS loop swap mutants. 86
xii
Figure 69: Circular dichroism of THAS1, HYS, and the corresponding loop 
swap mutants. 87
Figure 70: Results of point mutations on HYS active site amino acids. 88
Figure 71: Reduction mechanism of Tetrahydroalstonine Synthases and 
Heteroyohimbine Synthase for production of tetrahydroalstonine. 89
Figure 72: Reduction mechanism of Heteroyohimbine Synthase for 
production of ajmalicine. 90
Figure 73: Photos of zinc detection assay conducted on Zn-apo and Zn-holo THAS1 
and HYS. 91
Figure 74: Circular dichroism spectra of non-treated (red) and zinc-apo (blue) 
THAS1 (A) and HYS (B). 91
Figure 75: LC-MS chromatogram traces of THAS1-Zn-apo and HYS-Zn-apo protein 
assays compared to untreated control reactions. 92
Figure 76: Crystal structures of THAS1, THAS2, and HYS with the loop2 sections 
highlighted. 93
Figure 77: Mechanism proposal for reduction and production of tetrahydroalstonine 
(top row) and ajmalicine (bottom row). 98
Figure 78: Mechanism of cinnamaldehyde reduction by AtCAD, redrawn from 
Youn et al. (2006). 99
Chapter 4
Figure 79: Reactions catalysed by Iridoid synthase and Progesterone-5β-reductase. 111
Figure 80: Expression profile of ADH10 (in red) and other ADH’s on the same 
whole genome contig (WGC 27). 113
Figure 81: Alignment of predicted protein sequence of Cro013448 and the amino acid 
sequence of ADH10. 113
Figure 82: SDS-PAGE gel of expression trial of ADH10 with different temperatures 
and IPTG concentrations stained with Coomasie Blue. 114
Figure 83: SDS-PAGE gel of ADH10 large-scale purification. 114
Figure 84: Activity assay of ADH10 with strictosidine aglycon. 116
Figure 85: High-resolution MS-MS of the ADH10 product. 117
Figure 86: Large-scale purification of ADH10 product. 118
Figure 87: 1H-NMR of ADH10 product. 118
Figure 88: ROESY spectra of ADH10 product. 119
Figure 89: Deformyl-E-geissoschizine conformation. 120
Figure 90: Correlations between carbons and hydrogens of the ADH10 product,  
as measured by NMR in CDCl3. 120
Figure 91: HMBC correlations between carbons and hydrogens of the ADH10 product, 
as measured by NMR in CDCl3. 121
Figure 92: HMBC of ADH10 product. 122
Figure 93: Vallesiachotamine 123
Figure 94: NMR spectra of deuterated ADH10 product (top) compared to 
non-deuterated ADH10 product (bottom). 124
Figure 95: Optimisation screen using condition 1 and 2 from table 13. 125
Figure 96: First crystallisation optimisation screen using condition 3 from table 13. 125
xiii
Figure 97: Second crystallisation optimisation screen using condition 3 from table 13. 125
Figure 98: PsSalR reduction reaction on salutaridine. 126
Figure 99: Overview of crystal structure of ADH10. 127
Figure 100: Electron density in the active site of ADH10. 128
Figure 101: Network of ADH10 residues holding the NADP(H) cofactor in place. 129
Figure 102: Electrostatic potential map of the surface of ADH10. 130
Figure 103: Alignment of ADH10 and PsSalR with secondary structures annotated. 131
Figure 104: Comparison of SalR and ADH10 superimposed crystal structures. 132
Figure 105: SDS-PAGE analysis of ADH10 mutants expression. 133
Figure 106: LC-MS trace of ADH10 and its mutants. 134
Figure 107: LC-MS trace of enzyme assays with ADH10 and its mutants compared 
to a HYS reaction. 135
Figure 108: Mechanism proposal for reduction of strictosidine aglycon by ADH10. 136
Figure 109: Spectra of absorbance at 340 nm of THAS1 and ADH10 reaction at pH 7 with 
strictosidine aglycon at 100 μM. 137
Figure 111: Vitrosamine compared to the MIA vallesiachotamine and antirhine. 138
Figure 112: Proposed generation of vallesiachotamine from geissoschizine. 139
Figure 113: Backbone rearrangement of strictosidine aglycon. 141
Figure 114: Hypothetical mechanism for generation of the ADH10 product 
from strictosidine. 142
Figure 115: Vallesiachotamine. 142
Figure 116: Reduction parallels between ADH10 reaction (1), the proposed (enzyme not yet 
discovered) 4,21-dehydrogeissoschizine reduction (2), and the HYS reaction (3). 143
Figure 117: Proposed mechanism of salutaridine reduction by PsSalR. 144
Figure 118: Comparison of orientation and position of hydride in ADH10 and (R)-IRED 
products. 145
Figure 119: Reduction catalysed by SanR. 146
Figure 120: Proposed mechanism of SanR. Redrawn from Vogel et al. (2010). 156
Figure 121: Double reduction of dihydrofolate by PTR1. 148
Chapter 5
Figure 122: Strictosidine and SGD have a different subcellular localisation. 159
Figure 123: Abundance of reductases in the MIA biosynthetic pathways of C. roseus. 160
Figure 124: Two proteins are said to be paralogous if they are derived from a duplication 
event and orthologous if they are derived from a speciation event. 161
Figure 125: Example section of MDR ClustalOmega alignment. 168
Figure 126: Bayesian phylogenetic tree of MDRs. 171
Figure 127: Maximum Likelihood phylogenetic tree of MDRs. 172
Figure 128: Phylogenetic tree of MDRs in C. roseus in radiating representation. 173
Figure 129: Phylogenetic tree of the SDR superfamily in C. roseus. 175
Figure 130: MDR cluster arrangement on WGC 126. 176
Figure 131: Syntenic regions between A. thaliana and other plant genomes at the Cr2141 
homolog locus on chromosome 4. 178
Figure 132: Phylogenetic tree of cluster MDRs from plant genomes. 180
Chapter 6





7-DLGT  7-deoxyloganetic acid-O-glucosyl transferase





AS  Anthranilate synthase
BIA Benzylisoquinoline alkaloid
BPF  box P-binding factor
CAD Cinnamyl alcohol dehydrogenase
COSY Homonuclear correlation spectroscopy
CPR  Cytochrome P450 reductase
D4H  Desacetoxyvindoline 4-hydroxylase
DAT  Deacetylvindoline acetyltransferase
DMAPP  Dimethylallyl pyrophosphate
DXR  1-deoxy-D-xylulose-5-phosphate reductoisomerase
DXS  1-deoxy-D-xylulose-5-phosphate synthase
EDTA  Ethylenediaminetetraacetic acid
EtOAc Ethyl acetate
FA Formic acid
G10H  Geraniol 10-hydroxylase
GBF  G-box binding factor 
H2BC Heteronuclear multiple-bond correlation over two bonds spectroscopy
HMBC Heteronuclear multiple-bond correlation spectroscopy
HSQC Heteronuclear single quantum correlation
HYS  Heteroyohimbine Synthase
IO  Iridoid oxidase
IPP  Isopentenyl pyrophosphate
IPTG Isopropyl β-D-1-thiogalactopyranoside
xvi
ISY  Iridoid synthase
LAMT  Loganic acid methyltrasferase
MAT  Minovincine 19-hydroxy-O-acetyltransferase 
MDR Medium chain Dehydrogenase/Reductase
MeJa  Methyl Jasmonate
MeOH Methanol
MEP  2-C-Methyl-D-erythritol 4-phosphate 
MIA  Monoterpene Indole Alkaloid
MYC2  MYC2 transcription factor
NMR Nuclear magnetic resonance
NMT N-methyltransferase
ORCA3  octadecanoid responsive Catharanthus AP2-domain protein
P450  Cytochrome P450
PAGE  Polyacrylamide Gel Electrophoresis
Prx1  peroxidase
ROESY Rotatin frame nuclear Overhauser effect spectroscopy
SAD Sinapyl alcohol dehydrogenase
SDR Short-chain dehydrogenase/reductase
SDS  Sodium Dodecyl Sulfate
SGD  Strictosidine beta-glucosidase
SLS  Secologanin synthase
STR  Strictosidine synthase
T16H  Tabersonine 16-hydroxylase
T16OMT 16-hydroxytabersonine-O-methyltransferase










TIA  Terpene indole alkaloid
TLC Thin-layer chromatography
WGC Whole genome contig
WRKY1  WRKY transcription factor 1








1.1 Chemical diversity of medicinal plants
Plants, as sedentary beings preyed upon by many herbivores, have had to evolve methods of 
defence. Often this defence can come in the form of the plant’s secondary metabolism. A well-
studied example is found in the brassicas, which produce glucosinolates that are unpalatable to 
many animals (Giamoustaris and Mithen, 1995, Hopkins et al., 2009). Another large group of 
plant secondary metabolites are the alkaloids. These compounds are characterised by a bitter 
taste and therefore can serve as a deterrent or antifeedant. Many alkaloids have been linked to 
animal toxicity. Many also have neurological effects, acting as antagonists to neurotransmitters; 
most alkaloids are derived from amino acids and are structurally similar to neurotransmitters, 
which are also made from amino acids (Wink and Schimmer, 2010, Strauss et al., 2002). Plants 
have been extensively studied for centuries to isolate, identify and understand these bioactive 
components that are the products of secondary metabolism. 
Contrary to primary metabolism, which is shared among large groups of living organisms, 
secondary metabolism can be delimited to only one or a small group of related organisms 
(Dewick, 2011). Studying the secondary metabolome of plants has led to the discovery of 
different compounds with novel structural components, some of which have been used in the 
clinic (Saklani and Kutty, 2008, Cushnie et al., 2014). Many fundamental studies of plant extracts 
have been published and show that the field is very active and prolific (for example Google 
Scholar lists 30 000+ publications between 2006 and 2016 under the search term “medicinal 
plant antimicrobial screening”). Despite all these efforts, most plant species on earth have never 
been analysed for their chemical constituents and even fewer have been tested for biological 
activity (Mahesh and Satish, 2008). The potential of discovery of new compounds with medical 
benefits to humans from plants is certain. 
However, discovery of bioactive compounds alone is not enough to translate to efficient use in 
the clinic. These natural products are often present in only trace amounts in the host tissues 
and chemical synthesis can be prohibitively long and expensive. A deeper understanding of the 
biosynthesis of those compounds will provide the scientific community with the knowledge 
necessary to engineer production of those beneficial compounds in large amounts. This could 
come about through many different ways: 1) improved breeding of plants using marker assisted 
selection for varieties expressing the biosynthetic genes at higher levels; 2) genetically modified 
plants, for example expression of the pathway in a tissue that is faster growing or more easily 
harvested; 3) genetic engineering of microorganisms such as baker’s yeast (Saccharomyces 
cerevisiae) which can attain higher mass faster and is compatible with current fermenter 
technologies. Furthermore, a better understanding of the enzyme mechanisms and the enzymatic 
specificity can facilitate enzyme engineering for production of unnatural natural products.
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Some plant families present extraordinary richness in their secondary metabolism. Of notable 
mention is the Ranunculales clade which comprises many species with medicinally important 
secondary metabolites. Perhaps the best known example in this clade is the opium poppy 
(Papaver somniferum), which has been used by humans throughout history for its medicinal 
properties. The order Gentianales (of the Asterid clade) also comprises many species rich in 
secondary metabolites used by humans throughout history. The Gentianales family Apocynaceae 
has been well studied in large part due to two economically-important medicinal plants: Rauvolfia 
serpentina and Catharanthus roseus. The bioactive components of these plants are alkaloids, 
a class of natural products that contain at least one atom of nitrogen in a heterocycle. This 
thesis will focus on these tryptophan-derived indole alkaloids and how their chemical diversity 
is generated in C. roseus.
1.2 Indole alkaloids
The Indole alkaloids are a very large and diverse family of more than 2000 natural products 
(O’Connor and Maresh, 2006). The structural diversity of the indole alkaloids is mirrored in their 
wide clinical use from anti-tumour to antimalarial agents (fig. 1). 
Figure 1: Selected indole alkaloids with medicinal uses. Indole alkaloids currently used as 
treatments in the clinic, including the plant from which they were first identified.
A major subclass of indole alkaloids, the monoterpene indole alkaloids (MIA), are derived from 
tryptamine (produced by decarboxylation of the amino acid tryptophan) and one molecule 
of terpene in the form of secologanin (fig. 2) (Szabó, 2008). Tryptamine and secologanin are 
condensed to form the central intermediate of the pathway. During chemical condensation of 
these two moieties, two isomers are produced with opposite stereochemistry at C-3: vincoside 
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(3-R) and strictosidine (3-S) (Battersby et al., 1969)(fig. 2). However when these compounds 
are condensed enzymatically only the strictosidine isomer is produced (fig. 3). Initial confusion 
about the precursor of the terpene indole alkaloids was dispelled by Stöckigt and Zenk (1977) 
who showed that proteins crudely purified from indole alkaloid-producing plants produce only 
the strictosidine diastereomer, with 3-(S) configuration. Feeding with [3-3H]-labelled strictosidine 
indicated that the 3-(S) diastereomer is the precursor to all monoterpene indole alkaloids, 
including those with 3-(R) configuration (Rueffer et al., 1978)(fig. 3). Therefore strictosidine is 
the universal precursor to thousands of monoterpene indole alkaloids found in numerous plant 
species.
Figure 2: Chemical condensation of tryptamine and secologanin. This reaction yields vincoside 
and strictosidine, the two diastereomers at C-3. Only strictosidine is produced enzymatically.
1.3 Strictosidine Synthase
The enzyme responsible for this stereoselective condensation is Strictosidine Synthase (STR, EC 
4.3.3.2). It was first discovered in C. roseus in 1977 (Stöckigt and Zenk, 1977, Treimer and Zenk, 
1979) and was cloned for the first time from Rauvolfia serpentina in 1988 (Kutchan et al., 1988). 
STR produces strictosidine through a Pictet-Spengler condensation (Stöckigt et al., 2011) of 
secologanin and tryptamine. This enzyme catalyses the first committed step in MIA biosynthesis 
and has been extensively studied.
Figure 3: Strictosidine biosynthesis from tryptamine and secologanin.
4
STR has strict product stereospecificity; it only produces the 3-(S) diastereomer. It also has 
limited substrate specificity and it does not accept other amines such as histamine, tyramine or 
tryptophan and it does not tolerate substitutions to the C-5 and C-6 positions of the tryptamine 
indole ring (McCoy et al., 2006). Furthermore, the catalytic efficiency of the enzyme is not 
affected by the presence of downstream alkaloids such as ajmalicine (AJM), catharanthine, or 
vindoline (Mizukami et al., 1979), which signifies that these downstream alkaloids do not bind 
to the enzyme active site. Possibly negative feedback loops occur at other points in the pathway 
but are not necessary at the step of strictosidine formation. 
Crystal structures of STR were used to understand the mechanism of this enzymatic 
transformation and to design mutations to broaden its substrate specificity (Loris et al., 2007, 
Chen et al., 2006). The broad-specificity engineered STR with the point mutation in the active 
site cavity (V214M) was transformed into C. roseus hairy root lines (Runguphan and O’Connor, 
2009). These lines were fed commercially available tryptamine analogs and the resulting alkaloids 
were purified and characterised. It was found that the substituted tryptamines were accepted 
by the mutated STR and a variety of MIAs was found to have incorporated the analog. AJM and 
serpentine had incorporated all three analogs tested (chlorinated, methylated or brominated 
at position 10 of tryptamine) whereas tabersonine and catharanthine had not incorporated the 
brominated analog. This demonstrates how crystallisation of an enzyme can point to the amino 
acids which help control substrate specificity. Furthermore, these experiments illustrate the 
potential flexibility of the biosynthetic enzymes of this pathway and highlight there is room for 
manipulation of the substrate specificity in order to expand the chemical diversity. 
1.4 Deglycosylation of strictosidine
Strictosidine β-D-glycosidase (SGD) is a key enzyme in the biosynthetic pathways of plants that 
produce monoterpene indole alkaloids. SGD cleaves the glucose moiety of strictosidine, thus 
releasing a reactive intermediate which can rearrange to form the precursor to the downstream 
alkaloids such as AJM, catharanthine and vindoline (fig. 5). This reactive intermediate however 
also has another role, that of defence. The dialdehyde form of the intermediate is able to react 
with free amines, such as those found on proteins, and is also able to crosslink DNA, making 
strictosidine aglycon a formidable defence compound (Guirimand et al., 2010). Interestingly, 
strictosidine is stored in the vacuole of the cell and SGD is present in the nucleus (Guirimand 
et al., 2010). The spatial segregation of these two signifies that strictosidine can be classified 
as a phytoanticipin molecule (Morant et al., 2008). This segregation has been reported before 
for many combinations of β-glucosidases and their substrates in plants (Morant et al., 2008). 
An example of this is the dhurrin cyanogenic glycoside from Sorghum bicolor which is used as a 
defence compound (Tattersall et al., 2001)(fig. 4).
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Figure 4: Aglycon formation from strictosidine, dhurrin, and DIMBOAGlc. Redrawn from Morant 
et al. (2008).
The biological role of strictosidine in the plant is not well understood. Efforts to elucidate the effect 
on pathogens and insects have been few. A study conducted recently found that compounds 
with tetrahydro-beta-carboline moieties (such as strictosidine) have a slight retardant effect on 
the growth of the generalist herbivore Spodoptera littoralis (Sudžuković et al., 2016), but that 
did not affect the lifecycle of this insect. Strictosidine had an inhibitory effect on the growth of 
fungal plant pathogens such as Fusarium oxysporum and Cladosporium cucumerinum. But when 
strictosidine was incubated in the presence of SGD, the inhibitory effect was stronger (Luijendijk 
et al., 1996). This suggests strictosidine could be involved in plant defence, particularly when 
coupled with SGD which can release the reactive intermediate. Wounded leaves would release 
the reactive intermediate thus preventing more fungal growth or acting as an antifeedant for 
insect herbivores (Guirimand et al., 2010). 
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Figure 5: C. roseus general MIA pathway. The upstream part of the pathway that generates the 
monoterpene precursor is shown in lilac; tryptophan decarboxylation in green; generation of 
strictosidine and the central intermediate strictosidine aglycon in red; vindoline biosynthesis 
in gray; catharanthine in blue; AJM biosynthesis in orange. The star represents the central 
intermediate strictosidine aglycon, and question marks indicate pathway steps not characterised 
at the onset of this thesis. Enzymes: G10H: geraniol-10-hydroxylase; 10HGO: 10-hydroxygeraniol-
oxidoreductase; ISY: iridoid synthase; IO: iridoid oxidase; 7-DLGT: 7-deoxyloganetic acid glucosyl 
transferase; 7-DLH: 7-deoxyloganic acid hydroxylase; LAMT: loganic acid O-methyltransferase; 
SLS: secologanin synthase; TDC: tryptophan decarboxylase; STR: strictosidine synthase; SGD: 
strictosidine glucosidase; T16H: tabersonine-16-hydroxylase; T16OMT: 16-hydroxytabersonine-
O-methyltransferase; T3O: tabersonine-3-oxygenase; T3R: tabersonine-3-reductase; NMT:
N-methyltransferase; D4H: desacetoxyvindoline-4-hydroxylase; DAT: deacetylvindoline-4-O-
acetlytransferase.
Contrary to the limited substrate promiscuity of STR, SGD tolerates a wide range of substitutions 
to the indole moiety of strictosidine, but is not very active against strictosidine analogs with 
substitutions on the secologanin moiety (Yerkes et al., 2008). C. roseus SGD also deglycosylates 
the strictosidine isomer vincoside. Therefore, SGD appears to be more permissive of unnatural 
substrates.
1.5 Spatiotemporal localisation
As with many plant processes, secondary metabolic pathways can be induced upon elicitation. 
Adaptive responses to the environment or to an aggressor can help the plant regulate its use 
of resources. For that reason secondary metabolites can fluctuate in concentration both in 
response to the seasons, and in response to pathogen or herbivore attack. Targeted induction 
can also provide a way to produce a secondary metabolite only in the tissues where it is needed, 
for example the roots, the bark, or the leaves. 
The plant hormone methyl jasmonate (MeJa) has an elicitation effect on the expression of some 
parts of the pathway, but appears to act in different ways for upstream (tryptophan decarboxylase, 
TDC) or downstream enzymes (desacetoxyvindoline-4-hydroxylase, D4H) (Vázquez-Flotaand and 
De Luca, 1998). The metabolic flux through the early part of the pathway seems to be very 
tightly regulated. During efforts to engineer the production of ‘unnatural’ natural products in 
C. roseus hairy root lines, Glenn et al. (2011) attempted to overexpress TDC to increase the flux
from the indole pathway of primary metabolism into the indole alkaloid secondary metabolism.
The authors attempted to overexpress TDC in a constitutive manner in hairy roots which
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unfortunately was lethal, even when the hairy roots were grown on media supplemented 
with 500 μM of L-tryptophan. The tight regulation by MeJa of the upstream pathway is further 
evidenced by the successful use of transcriptomes of MeJa-elicited C. roseus tissues for discovery 
of genes in that part of the pathway (Miettinen et al., 2014, Geu-Flores et al., 2012).
Further studies were focused on discovering the transcription factors of the pathway in C. 
roseus. This is of importance as genetically engineered plants or cell cultures overexpressing 
the pathway biosynthetic enzymes could produce more downstream metabolites, thus 
reducing the cost of the valuable end-product, such as the anti-cancer agents vinblastine and 
vincristine. Hairy root lines were developed by Sun and Peebles (2015) to overexpress the ORCA3 
transcription factor which has been shown to control the expression of multiple pathway genes 
(van der Fits and Memelink, 2000). They discovered that in this line, compared to the same 
line without induction of ORCA3 expression, many genes in the pathway (both upstream and 
downstream) were upregulated, but this did not produce a statistically significant increase in any 
strictosidine-derived alkaloid they measured (serpentine, AJM, catharanthine, hörhammericine) 
with the exception of lochnericine (56% increase, p<0.05). However, the authors noticed a 
statistically significant decrease in tabersonine (-97%, p<0.05) and also a slight decrease in SGD 
mRNA levels based on RT-qPCR. Interestingly, in this ORCA3 overexpressing line, they noted that 
many negative transcription factors (ZCT1, ZCT2, ZCT3, GBF1, GBF2, GBF3) were upregulated. 
To counter the SGD downregulation, Sun and Peebles (2015) developed another hairy root line 
which overexpressed both ORCA3 and SGD under the control of an inducible promoter. In this 
line they achieved a ten-fold overexpression of SGD and they observed a statistically significant 
increase in all the alkaloids they measured. These results indicate that the regulation of the 
pathway is not controlled by a single transcription factor, but is instead more complex and 
involves multiple positive and negative regulators. SGD is not under the control of the ORCA3 
transcription factor, and is in fact downregulated when ORCA3 is upregulated. SGD appears to 
be a rate limiting step at this part of the pathway, at least in hairy roots, based on the increase of 
MIAs observed when SGD is upregulated. 
The MIA biosynthetic pathway in C. roseus has been the subject of many studies relating to its 
spatiotemporal localisation. The various MIA it produces can be found in different tissues (van 
der Heijden et al., 2004, McCoy and O’Connor, 2006, Laflamme et al., 2001). This clearly suggests 
one of two scenarios are possible; either the enzymes responsible for the different products 
are expressed differentially in different tissues, or the different MIA are actively transported for 
sequestration in different tissues. There is strong evidence that the first scenario is more likely, 
based on the expression of the pathway biosynthetic enzymes in different tissues and cell types 
(Guirimand et al., 2011b, Verma et al., 2012, Murata et al., 2008). However, these results also 
point to the fact that there must be transport of metabolic intermediates between cell types in 
order for the final products to be produced (St-Pierre et al., 1999). 
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Furthermore, it was discovered that even when parts of the pathway are all expressed in the 
same tissue (leaves for example) certain enzymes are expressed in different cell types. The 
pathway involves at least 4 different cell types in the leaves (Courdavault et al., 2014). The 
internal phloem associated parenchyma cells are the location of the upstream part of the 
pathway, from geraniol to loganic acid biosynthesis (fig. 9). The latter is transported, through an 
unknown transporter, to the leaf epidermis cells where the central part of the biosynthesis takes 
place, namely the synthesis of secologanin, strictosidine, and downstream to catharanthine and 
16-methoxytabersonine (fig. 9 and 10). Finally, vindoline biosynthesis occurs in the laticifers and 
idioblasts (Courdavault et al., 2014, De Luca et al., 2014). 
Adding an additional layer of complexity, many enzymes of the pathway are localised to 
intracellular compartments. The upstream part of the pathway occurs in the plastid until 
geraniol is released to the cytosol. Many enzymes downstream from geraniol are soluble in the 
cytosol or are anchored to the ER membrane (cytochrome P450 enzymes) (Courdavault et al., 
2014, Guirimand et al., 2011a, Guirimand et al., 2011b). Interestingly though, STR, along with 
its product strictosidine, is localised to the vacuole and the next biosynthetic enzyme, SGD, is 
localised to the nucleus (Guirimand et al., 2010). This spatial separation of STR from the cytosol 
and of SGD from the strictosidine pool has implications on the substrate availability for each of 
the enzymes. It is apparent that transport of secologanin and tryptamine, the substrates of STR, 
must occur in order for strictosidine to be produced. Similarly, transport of strictosidine out of 
the vacuole must be controlled by a transporter in order for SGD to access its substrate and 
produce substrates for the downstream parts of the pathway. The flow of strictosidine out of the 
vacuole is could be one of the bottlenecks in this pathway and understanding how it is controlled 
will be a breakthrough in engineering higher vinblastine-producing plants.
1.6 Structural rearrangements unlock chemical diversity in MIA
When strictosidine is deglycosylated it produces a reactive and unstable intermediate (Brown and 
Chapple, 1974, Husson et al., 1977, Kan-Fan and Husson, 1979). Early studies using 14C-labelled 
tryptophan feeding with C. roseus seedlings helped establish the sequence of reactions leading 
to the downstream alkaloids from strictosidine onwards (fig. 6)(Scott et al., 1971). It is clear from 
these early experiments that the deglycosylation of strictosidine unlocks its potential to rearrange 
and form new carbon skeletons. It was also noted that strictosidine can non-enzymatically lose 
its glucose moiety which then can lead to the rearrangement of the backbone through reaction 
of the N4 with a free aldehyde (Smith, 1968).
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Figure 6: Strictosidine aglycon numbering. 
Rearrangement of strictosidine aglycon occurs due to the reactive aldehyde groups on carbon 
17 and 21. As illustrated in fig. 7 either of these aldehydes can attack the nitrogen to produce 
a cyclised molecule. This occurs after rotation of the molecule around either the C-14-C-15 
bond or the C-15-C-20 bond (blue or pink arrow). Rotation around the C-14-C-15 bond results in 
cyclisation through the C-17 whereas rotation around the C-15-C-20 bond results in cyclisation 
through the C-21. In the first case this leads to generation of the vallesiachotaman skeleton, and 
the second to the corynanthean skeleton. The second scenario further leads to the generation 
of chemical diversity which arises through equilibration and/or cyclisation of the final ring. This 
cyclisation can either occur through attack of the C-18 onto C-17 (which leads to the yohimbine 
alkaloids) or through attack of the hydroxyl of C-17 onto C-19 (which leads to cathenamine 
and the heteroyohimbine alkaloids). Finally, if reduction of the C-21-N bond occurs before 
cyclisation then a different mode cyclisation can take place. This involves the intermediate 
geissoschizine which can undergo rearrangements to produce preakuammicine. This undergoes 
further rearrangements (through enzymatic catalysis on dehydrosecodine) to yield the products 
catharanthine and tabersonine. 
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Figure 7: Strictosidine aglycon and its structural rearrangements. Steps illustrated with blue 
arrows must occur through enzymatic catalysis. Pink and blue arrows indicate the rotation of the 
molecule around the C-15 and C-20 bond and the C-14 and C-15 bond. 
During experiments using cell-free crude enzyme assays Stöckigt et al. (1977) identified a 
compound that accumulated when tryptamine and secologanin were supplied as substrates. 
This compound was identified as 20,21-didehydroajmalicine which was given the trivial name 
cathenamine (fig. 7). The authors then went on to demonstrate that it is the direct precursor 
to the ajmalicine-type alkaloids, the heteroyohimbines (fig. 8). Cathenamine was also purified 
from leaves of Guettarda eximia (Rubiaceae) by Husson et al. (1977) and it was noted that 
the compound was not stable and was confirmed to be a precursor to the heteroyohimbine 
tetrahydroalstonine (THA) by reduction with NaBH4. Therefore, it was clear the precursor 
molecule to the heteroyohimbines was an unstable intermediate. 
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Figure 8: Heteroyohimbine alkaloids of C. roseus. The alkaloids ajmalicine (AJM), 19-epiajmalicine 
(19-EA), and tetrahydroalstonine (THA) differ by the conformation at carbons 20 and 19.
Assays involving crude protein extracts from C. roseus (callus, leaves, and stems) indicated 
that soluble proteins were able to convert tryptamine and secologanin into primarily AJM and 
geissoschizine (Scott and Lee, 1975). Early studies involving reduction of cathenamine with C. 
roseus cell suspension culture crude cell protein extract indicated that some cell lines of C. roseus 
produced different ratios of the three heteroyohimbines (AJM:19-epiajmalicine (19-EA):THA)
(Zenk, 1980). It was also demonstrated that the heteroyohimbine synthases are reductases 
which utilise NADPH to reduce the aglycon. The existence of some cell lines which could produce 
only one (or different ratios) of the three heteroyohimbines points to the existence, in C. roseus, 

















































































































































































































































































































































































































































































































































































Dehydrogenases are able to remove two hydrogen atoms from one substrate and pass them 
onto another substrate, thus oxidizing the donor and reducing the acceptor (fig. 11)(Dewick, 
2011, Persson et al., 2008). A pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) 
or nicotinamide adenine dinucleotide phosphate (NADP+) is often used as one substrate as 
cofactor. Usually NAD+ is used in oxidation reactions and NADPH in reduction reactions. One 
of the hydrogens involved either originates from or is passed onto the cofactor, and the other 
hydrogen (a proton) is from the solvent or an acidic amino acid residue.
Figure 11: Oxidation and reduction reactions. A: general reaction scheme for reduction of a carbon-
oxygen double bond (top row), and a general reaction scheme for oxidation of a carbon-nitrogen 
bond (bottom row). B: a general reaction scheme for oxidation-reduction reaction involving the 
cofactor NADP(H) with the R group representing the adenine dinucleotide phosphate moiety of 
the cofactor. Reactions redrawn from Dewick (2011).
The Rossmann protein fold is responsible for the NAD(P) cofactor binding in dehydrogenases 
(Rossmann et al., 1974). It is made up of a twisted parallel β-sheet core flanked on either side 
by α-helices. The Rossmann fold has been found to be one of the most common protein folds 
due to the functional versatility of reductase enzymes (Kavanagh et al., 2008, Kallberg and 
Persson, 2006). Enzymes with a Rossmann fold are present in every kingdom of life and carry 
out a large variety of oxidoreductions (Jörnvall et al., 2010). These enzymes appear to share a 
common ancestor which, after duplications and diversification over the course of evolution, still 
retain the same basic Rossmann fold but have evolved modified structures and extra domains 
(Jörnvall et al., 2010, Kavanagh et al., 2008, Riveros-Rosas et al., 2003). The major families 
within the Rossmann-fold enzyme superfamily are the Short-chain (SDR) and the Medium-chain 
dehydrogenase/reductases (MDR) (Kavanagh et al., 2008, Jörnvall et al., 1999).
1.8 The Medium-Chain Dehydrogenase/Reductase family
The MDR enzymes typically consist of a Rossmann fold/nucleotide binding domain, and a 
substrate binding domain. These enzymes usually are about 350 amino acids long which 
differentiate them from the SDRs which are usually about 250 amino acids long. The Alcohol 
Dehydrogenases (ADH) were first discovered from yeast and were the subject of many detailed 
kinetic analyses. The classic liver alcohol dehydrogenase can reduce or oxidise carbon-oxygen 
bonds of various alcohols (Dalziel and Dickinson, 1966). These enzymes usually catalyse the 
transfer of the pro-R-hydride of the NAD(P)H cofactor to the substrate (fig. 12).
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Figure 12: Reduced nicotinamide adenine dinucleotide phosphate (NADPH). The pro-S and pro-R 
hydrides are illustrated.
The MDRs in plants have undergone a large expansion, especially in the cinnamyl alcohol 
dehydrogenase (CAD) family (Riveros-Rosas et al., 2003). A plant-specific branch of the CADs has 
evolved in plants, the elicitor-inducible defense-related proteins (ELI3, Logemann et al. (1997)). 
These are specifically upregulated by pathogen elicitors and wounds (Riveros-Rosas et al., 2003).
The CAD enzyme group is one of the better studied group of plant MDRs. CAD and its closely 
related paralog Sinapyl alcohol dehydrogenase (SAD) have been purified and studied from many 
different plant species (Knight et al., 1992, O’Malley et al., 1992, Sarni et al., 1984, Wyrambik 
and Grisebach, 1979, Wyrambik and Grisebach, 1975, Mansell et al., 1974). These enzymes are 
of direct importance to the pulping and paper industry as well as forage crop agriculture as they 
are critical players in the lignification of plant tissues (fig. 13, (Halpin et al., 1994)). 
Figure 13: Reaction catalysed by Sinapyl and Cinnamyl alcohol dehydrogenases. The monolignol 
units coniferyl alcohol and sinapyl alcohol are polymerised to yield guaiacyl-syringyl lignin.
In C. roseus two MDRs have been discovered, outside of this thesis work, to participate in the MIA 
biosynthetic pathway. Upstream, the 10-hydroxygeraniol oxidoreductase (10HGO, (Miettinen et 
al., 2014)) oxidises both hydroxyl groups of 10-hydroxygeraniol to give rise to the dialdehyde 
9,10-dioxogeranial (fig. 9). The second MDR member in the C. roseus MIA biosynthetic pathway 
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is the recently discovered tabersonine-3-reductase (T3R, Qu et al. (2015)) which acts in concert 
with a P450 enzyme (T3O) to hydroxylate a late-stage biosynthetic intermediate to produce 
16-methoxy-2,3-dihydro-3-hydroxytabersonine (fig. 10). 
A similar MDR was recently discovered in the related medicinal plant Rauvolfia serpentina, which 
also produces MIAs. This enzyme, vomilenine reductase (RsVR2, Geissler et al. (2015)) reduces the 
carbon-carbon double bond of the substrate vomilenine and produces 19,20-dihydrovomilenine 
(fig. 14). Based on homology to CAD and SAD enzymes, RsVR2 probably originated from evolution 
from a duplication of a CAD or SAD enzyme in R. serpentina (Geissler et al., 2015). 
Figure 14: Reduction of vomilenine by RsVR2. Reduction occurs at the 19-20 double bond.
1.9 The Short-Chain Dehydrogenase/Reductase family
The SDRs are functionally and structurally very diverse (Jörnvall et al., 1995). One of the first SDRs 
to be characterised as such was the Drosophila melanogaster alcohol dehydrogenase (Winberg 
and McKinleymckee, 1994, Winberg and McKinleymckee, 1988) which was originally thought to 
be similar to liver alcohol dehydrogenase, an MDR. Soon though it was understood that the two 
enzymes differ structurally (SDRs do not contain Zinc ions as most MDRs) and they catalyse the 
transfer of the pro-S hydride of NAD(P)H to the substrate. SDRs are usually characterised by a 
conserved motif in the active site (YxxxK), which is part of the typical catalytic triad Ser-Tyr-Lys 
(Filling et al., 2002). 
The SDRs have been reported to be present in very high numbers in the genomes of plants 
compared to animals, fungi, and prokaryotes (Moummou et al., 2012). It was found that in plants 
this family has undergone significant diversification, with some SDR subfamilies emerging after 
the separation of vascular plants from Bryophytes. Interestingly, the more diverged subfamilies 
are involved in the plant secondary metabolism or in developmental processes, and not so much 
in primary metabolism which claims more conserved SDRs (Moummou et al., 2012).
Many examples of SDRs in secondary plant metabolism exist. A well-known pathway is that 
of the benzylisoquinoline alkaloids (BIA), which are based on the amino acid tyrosine as 
opposed to tryptophan that is used for MIA production. The lengthy BIA pathway contains 
many branch pathways found in different plants. One SDR of great pharmaceutical importance 
is salutaridine reductase (SalR) from opium poppy (Papaver somnifeum, (Ziegler et al., 2006)) 
which acts upstream during the biosynthesis of morphine, a widely used analgesic (fig. 15 
left). Another example of an SDR from BIA biosynthesis is sanguinarine reductase (SanR) from 
17
the California poppy (Eschscholzia californica) (Weiss et al., 2006) which is implicated in the 
benzophenanthridine alkaloid branch of BIA (fig. 15 right).
Figure 15: Reactions catalysed by SalR and SanR, SDR enzymes of the BIA pathway. The reduction 
carried out by SalR (left) and the reduction carried out by SanR (right).
In C. roseus one critical step of iridoid biosynthesis is known to be carried out by a member 
of the SDR family. The iridoid synthase (ISY, Geu-Flores et al. (2012)) reduces the substrate, 
10-oxogeranial, which then undergoes cyclisation to yield the cyclised product nepetalactol 
(iridodial, fig. 9). This enzyme is critical for the formation of MIA as it produces the first cyclised 
intermediate in the pathway towards the monoterpene secologanin (fig. 9). It is expected that 
similar enzymes carrying out the same reaction exist in all plants which produce iridoids, and in 
fact a similar enzyme has been discovered in Olive (Olea europaea) (Alagna et al., 2016).
1.10 Stereoselectivity of Dehydrogenases/Reductases
Reductions carried out by dehydrogenases with NADPH are often stereoselective (Dewick, 2011). 
However, there exist examples of enzymes which can reduce two different isomers (substrate 
promiscuity) or produce two isomers (product promiscuity). An example of both can be found 
in the biosynthetic pathway of menthol. The eight-step biosynthetic pathway for menthol 
production from the well-studied and economically important plant Mentha x piperita contains 
multiple dehydrogenation steps (Croteau et al., 2005). Three of the steps are carried out by 
members of the SDR family, and one by a member of the MDR family (fig. 16). This last enzyme 
is not stereoselective and produces both (-)-menthone and (+)-isomenthone (fig. 16).
Figure 16: Menthol biosynthesis pathway from the cyclised terpene limonene. The enzymes 
responsible are indicated as well as the family each enzyme belongs to. In order they are: L3OH: 
limonene-3-hydroxylase (a P450 family member); iPD: trans-isopoperitenol dehydrogenase 
(an SDR); iPR: isopiperitenone reductase (SDR); iPI: isopiperitenone isomerase (a Ketosteroid 
Isomerase, KSI); PR: pulegone reductase (an MDR); MMR: menthone-to-menthol reductase 
(SDR).
18
Interestingly, the reduction carried out by iPR is stereoselective and produces only (+)-pulegone. 
The reduction mechanism and an explanation for this stereoselectivity were given by Lygidakis 
et al. (2016) after crystallisation of the enzyme in presence of the cofactor. The mechanism 
proposed includes an important amino acid in the active site of this enzyme which is an acidic 
glutamate rather than the usual tyrosine of the catalytic tetrad of SDRs. Lygidakis et al. (2016) 
argue that this causes the substrate to bind in a different manner which allows the alkene to 
be the acceptor of the cofactor hydride rather than the carbonyl (fig. 17). When the glutamate 
was mutated to a tyrosine iPR lost its isopiperitenone reductase ability and instead became a 
ketoreductase. This confirms the plasticity of the active site amino acids and demonstrates the 
chemical flexibility that is possible given even a single mutation to a biosynthetic enzyme.
Figure 17: Stereoselective reduction of ( ̶ )-isopiperitenone to produce (+)-cis-isopulegone. 
Proposed reduction mechanism of Isopiperitenone Reductase (IPR), redrawn from (Lygidakis et 
al., 2016). The cofactor is illustrated in green, water molecules in blue, enzyme residues in red 
and the substrate and product in black. The generated stereocentre is indicated with an asterisk.
From a biocatalytic perspective, the stereoselectivity of these reductases is very interesting. 
Efforts have been made to produce enzymes with the opposite stereoselectivity for the product. 
Such optically-pure compounds can form the building blocks for further chemical synthesis. 
Mutations to the active site of a stereospecific MDR from Candida parapsilosis were attempted 
in order to switch the stereoselectivity (Wang et al., 2014). These mutations were able to cause 
the substrate (an aryl ketone) to flip orientation in the active site, resulting in a product with the 
opposite stereochemistry. Remarkably the product was changed from primarily (R) to mostly 
(S) (>99.9 enantioselectivity in both cases). This work highlighted how the variable active site
residues, which might not be taking part in catalysis, can have a large effect on the binding
orientation of the substrate and therefore the stereoselectivity of the enzyme.
The study of these biosynthetic enzymes can enrich our understanding of the enzymatic 
mechanisms governing the chemical diversity found in the natural world. This added knowledge 
can be applied to enzyme engineering to improve existing enzyme catalytic functions or for 
enzymatic synthesis of valuable compounds.
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1.11 Scope of this thesis
The large chemical diversity found in the MIA biosynthetic pathways is generated from the 
unstable intermediate strictosidine aglycon. Despite many years of effort, and a reasonable 
understanding of the enzymatic steps involved in the pathway, no biosynthetic gene immediately 
following deglycosylation of strictosidine had been elucidated at the onset of this project. 
To elucidate the genes responsible for the enzymatic reactions, we relied on data generated 
previously by Zenk (1980) and the newly sequenced C. roseus transcriptome (Góngora-Castillo et 
al., 2012). A screen of candidate clones from C. roseus was carried out by functional expression 
in E. coli followed by in vitro assay, as described in Chapter 2. During the course of this thesis, 
a number of MDRs displaying activity against deglycosylated strictosidine were characterised in 
further detail, particularly to determine the mechanism of reduction. These enzymes have been 
named heteroyohimbine synthases.
As reported in Chapter 3, the discovery of the heteroyohimbine synthases with different product 
profiles provides a unique system to study the structure-function relationship controlling the 
product specificity among this family of enzymes. In addition, as described in Chapter 4, the 
discovery of an enzyme (ADH10) from a different family of reductases, the SDR family, with a 
very different product but a similar reduction mechanism has allowed us to probe the dynamics 
of the unstable strictosidine aglycon substrate. This comparison has given us an unprecedented 
first look into why the chemical diversity of the MIA is so large. 
Finally, an in-depth comparison of the identified enzyme families (Chapter 5) indicated that the 
HYSs discovered are probably derived from primary metabolism enzymes of plants and more 
specifically from CAD enzymes. The origins of ADH10 however are murkier, in part because of the 
complexity of the SDR family in plants. Gene duplications appear to be the driving force behind 
the expansion of the chemical diversity as they provide the primary material for diversification 
and neofunctionalisation.
The discovery of the HYS and ADH10 in C. roseus constitutes the first discovery of enzymes acting 
directly downstream of SGD. This is an important step forwards in the elucidation of biosynthetic 
pathways in many plants which rely on strictosidine aglycon to produce the chemical diversity 
of their secondary metabolism. Understanding the dynamics of this complicated system at a 
more detailed level can provide insight to the evolution and the generation of chemical diversity, 
not only for plant but also for any organism with a rich secondary metabolism. The enzymes 
discovered here can give clues to the nature of the enzymes implicated in similar steps in other 
plants and can also expand the enzymatic toolbox for biocatalysis applications.
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Chapter 2




The heteroyohimbine alkaloids belong to the group of corynanthean MIAs. They differ at the 
configuration of the hydrogens and methyl of carbons 3, 20, and 19 (fig. 18). Some members of this 
group display biological activity and have been used in the clinic. For example, 19-epiajmalicine 
(19-EA) can bind to benzodiazepine receptors in the brain of rats (Ai et al., 1997) and ajmalicine 
(AJM) is an α1-adrenergic receptor antagonist (Roquebert and Demichel, 1984, Li et al., 2004). 
Furthermore, alstonine, an oxidised form of tetrahydroalstonine (THA) displays anxiolytic and 
antipsychotic activity (Costa-Campos et al., 2004, Elisabetsky and Costa-Campos, 2006).
Figure 18: The eight heteroyohimbines. The top row (with (S) stereochemistry at C-3) are derived 
from strictosidine, and the bottom row (with (R) stereochemistry at C-3) are derived from the 
strictosidine isomer, vincoside. The three heteroyohimbines marked with an asterisk have been 
reported to be found in C. roseus. All molecules are stereoisomers and have the same predicted 
mass, 352.178.
2.1.2 Heteroyohimbine biosynthesis in C. roseus 
C. roseus produces three heteroyohombine diastereomers,1 AJM, 19-EA, and THA, with AJM
being the most abundant. Heteroyohimbine alkaloids are derived from strictosidine after
1 The fourth strictosidine-derived heteroyohimbine, rauniticine, is mentioned to be found in C. roseus 
only by Stöckigt et al. (1976) but the authors do not provide a reference to the claim. Whole alkaloid 
extracts of the leaves or roots of C. roseus performed in our lab contain multiple peaks with m/z of 353, 
the largest of which co-elutes with an authentic standard of AJM. As no other reference can be found for 
the presence of this alkaloid in C. roseus other than the passing mention made by Stöckigt et al. (1976), 
and the absence of an authentic standard to compare to our plant extracts, for the remainder of this 
thesis I will assume it is not found in this plant.
26
it is deglycosylated by SGD. Studies done by Stöckigt et al. (1980) using deuterated solvent 
and cofactors illustrated how AJM, 19-EA, and THA can be formed directly from an isomer 
of strictosidine aglycon, dehydrogeissoschizine, when supplied to a C. roseus cell suspension 
culture protein extract. These workers illustrated that dehydrogeissoschizine can isomerise in 
solution into cathenamine and 19-epicathenamine, which can then both isomerise into the 
iminium tautomers (fig. 19). They proposed that these iminium forms are then acted upon by 
NADPH-dependent reductases which produce AJM, 19-EA, and THA (fig. 19). 
Figure 19: Proposed mechanism of biosynthesis of heteroyohimbines from dehydrogeissoschizine. 
Adapted from Stöckigt et al. (1980). Dehydrogeissoschizine equilibrates in solution to the two 
isomers 19(R)-cathenamine and 19(S)-cathenamine. This in turn can equilibrate into the iminium 
form by protonation at C-20. 
During efforts to elucidate how the MIA pathway progresses through secologanin and tryptamine 
Stöckigt et al. (1976) showed that AJM, 19-EA, and THA can all be produced simultaneously in 
vitro using crude protein extracts of C. roseus. The authors prepared a crude protein extract from 
cell suspension cultures of C. roseus and incubated it with tryptamine, secologanin and various 
cofactors. The resulting alkaloid mixture was subjected to purification by TLC and it was shown 
that in presence of NADPH or NADH, three heteroyohimbines are formed, AJM, 19-EA, and THA. 
In absence of a suitable reduced cofactor another alkaloid accumulated, which if purified and 
incubated with the crude enzyme preparation and NADPH, was converted into AJM and 19-
EA. The authors identified this compound as the intermediate in the reaction but could not 
identify its structure. Given the knowledge we now have about the pathway, the authors were 
generating strictosidine from secologanin and tryptamine with STR present in the crude protein 
mixture, and subsequently deglycosylating strictosidine with SGD also present in the crude 
enzyme preparation. When Stöckigt et al. (1976) repeated this in vitro experiment with [2-14C]-
labelled tryptamine they calculated that 26% of the labelled tryptamine was converted into 
these heteroyohimbines. Furthermore, they mention that although rauniticine (see footnote 1) 
and geissoschizine (fig. 20) are found in C. roseus plants, these compounds were not produced 
in these in vitro experiments.
Figure 20: The MIA geissoschizine.
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Later experiments attempted to purify the enzyme or enzymes responsible for these reactions. 
An enzyme displaying tetrahydroalstonine synthase activity was purified from cell suspension 
cultures of different Apocynaceae plants including C. roseus, C. ovalis, Picralima nitida, Rhazya 
stricta and Vinca herbacea (probably Vinca minor), all of which are known THA producers 
(Hemscheidt and Zenk, 1985). The C. roseus cell suspension culture that was used is an unpublished 
cell-line the authors claimed produced only THA and no other heteroyohimbine alkaloids. This 
fact indicates that there exist some enzymes which specifically produce one heteroyohimbine 
and not the others. The presence of tetrahydroalstonine synthase (THAS) activity was compared 
between these plants and also with enzymes purified from control tissues from Beta vulgaris 
(Chenopodiaceae), Malus domestica (Rosaceae), and Solanum marginatum (Solanaceae), plants 
that do not produce heteroyohimbine alkaloids. The authors found that the tissue of the cell 
suspension line of C. roseus had the most active enzyme (0.98 pkat/mg protein), and the second-
best producer was R. stricta (0.64 pkat/mg protein). Different levels of activity were recorded for 
the enzymes purified from the heteroyohimbine-producing plants but no activity was recorded 
in the reactions using the control plants.
To characterise the enzyme purified from C. roseus the authors determined its molecular weight 
based on a gel filtration column against commercially available protein standards and found 
that it was 81 ± 2.4 KDa. They observed that the enzyme could only turnover the strictosidine 
aglycon isomer cathenamine when supplied with NADPH and not with NADH. Kinetic studies 
found that the enzyme had a Km for cathenamine of 62 μM (pH 6.6, 30 ˚C). Hemscheidt and Zenk 
(1985) also purified similar enzymes from another cell suspension line of C. roseus. The purified 
enzymes from this line could turnover cathenamine and produce AJM and 19-EA, which 
led these researchers to hypothesise that there exist different enzymes in Catharanthus which 
are responsible for the production of different ratios of heteroyohimbines found in C. roseus. 
Given this information, it is clear that multiple enzymes in C. roseus must be able to produce 
heteroyohimbines with different stereocentres. The heteroyohimbine biosynthetic enzymes 
appear to be soluble, NADPH-dependent reductases, and approximately 80 KDa. C. roseus 
expresses multiple NADPH-dependent reductases, both short-chain and medium-chain.
2.1.3 Known reduction steps in MIA biosynthesis
Medium-chain Dehydrogenase/Reductases (MDRs) are a type of Alcohol Dehydrogenase (ADH) 
enzyme. They are a very ancient and diverse protein superfamily which was already found in 
the last universal common ancestor of all life on earth (Riveros-Rosas et al., 2003). An in-depth 
study of the diversity and evolution of this superfamily (Riveros-Rosas et al., 2003) revealed that 
there are three macrofamilies of MDRs, each further split into separate Clusters of Orthologous 
Groups (COGs) (Tatusov et al., 1997). 
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According to macrofamily delimitation the authors suggested Cinnamyl Alcohol Dehydrogenases 
(CAD) and Elicitor-inducible defence-related proteins (ELI3) belong to the COG1064 along with 
Yeast-ADHs (Y-ADH) (Riveros-Rosas et al., 2003). CAD are found in plants, fungi, protista, and 
bacteria. Conversely, ELI3 are only found in plants. Y-ADHs are not found in plants, but can be 
found in fungi, animals, archaea, and bacteria. An unrooted tree produced by Riveros-Rosas et 
al. (2003) placed the CAD and ELI3 families as sister groups, and it seems apparent that the ELI3s 
evolved from an ancient duplication of a CAD specifically in plants.
The MIA biosynthetic pathways are predicted to contain numerous reduction steps. Recent work 
on the elucidation of these pathways has revealed roles for both short-chain dehydrogenases and 
medium-chain dehydrogenases. An MDR has been discovered to act upstream in the pathway, 
at the oxidation of 10-hydroxygeraniol to 10-oxogeranial. This involves a two-step oxidation 
of the substrate involving NAD⁺ as cofactor. This reaction is catalysed by 10-hydroxygeraniol-
oxidoreductase (10HGO, fig. 21, (Miettinen et al., 2014)). 
Figure 21: Reaction catalysed by 10-Hydroxygeraniol-Oxidoreductase (10HGO). 
Additionally, an MDR from C. roseus was recently demonstrated to have activity further 
downstream at the tabersonine-to-vindoline branch of the vinblastine biosynthetic pathway (Qu 
et al., 2015). This enzyme, in concert with a cytochrome P450, is capable of reducing tabersonine 
into 3-hydroxy-2,3-dihydrotabersonine (fig. 22). This enzyme was named T3R and is referenced 
as such throughout this thesis.
Figure 22: Conversion of the C. roseus MIA tabersonine into 3-hydroxy-2,3-dihydrotabersonine 
by the action of a cytochrome P450 followed by reduction by T3R.
2.1.4 Discovery of the heteroyohimbine synthases
Synthesis of heteroyohimbines also constitutes a reduction step in the MIA pathway, though 
at the start of this work, the identity of the enzymes that catalysed the formation of these 
structures was not known. In this chapter, I describe the discovery of the genes that encode 
heteroyohimbine synthases. Based on the preliminary work of Zenk and Stockigt described 
above, the most obvious candidate for the heteroyohimbine synthases would be an MDR. The 
transcriptome of C. roseus was indispensable for querying which MDRs could be responsible 
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for heteroyohimbine biosynthesis. During a screening of MDRs from C. roseus which are highly 
induced by application of MeJa at the seedling stage, an MDR was identified which could 
reduce cathenamine and produce primarily THA. This enzyme was named Tetrahydroalstonine 
Synthase 1 (THAS1). This initial success was further used to identify more candidates from 
the transcriptome based on sequence similarity to THAS1. This approach was successful and 
resulted in the identification of multiple heteroyohimbine synthases (HYSs), most of which are 
specific for THA production (THAS2-4), and one of which was capable of producing all 3 C. roseus 
heteroyohimbines (HYS). The enzymes discovered are described as hetetroyohimbine synthases 
(HYSs) to simplify discussion.
Discovery of these HYSs concludes the biosynthetic pathway from geraniol to the 
heteroyohimbines of C. roseus. This is the first report of genes that encode enzymes that act 
on the reactive intermediate strictosidine aglycon. These results provide insights into how the 
chemical diversity of the alkaloids is generated at this crucial branchpoint in MIA biosynthesis.
2.2 Results
2.2.1 Identification and sequence analysis of THAS1
Seedlings of C. roseus have been shown to actively synthesize the MIA whereas shoots, and 
in general older plant material, does not present such active biosynthesis (Scott et al., 1971). 
Therefore, expression profiles of biosynthetic enzymes at different plant growth stages are 
critical to the discovery of new enzymes taking part in this pathway. The transcriptomic dataset 
generated by Góngora-Castillo et al. (2012) was used as the basis for the work described in this 
chapter.
Hierarchical clustering analysis performed previously on this transcriptomic database (Geu-Flores 
et al., 2012) revealed multiple gene candidates that seemed to be co-regulated with other genes 
in the monoterpene indole alkaloid pathway. One of these genes (Cr024553), named THAS1 
for reasons detailed later in this chapter, was of particular interest as it is physically present 
on the genome (WG contig v.2.A 371, Buell and Kim, in preparation) in close proximity to an 
SLS homolog (Cr024556). This gene is expressed in sterile seedlings and induced approximately 
two-fold at both five and twelve hours after the application of methyl-jasmonate (fig. 23). It is 
also expressed in immature and mature leaves (6.5 and 2.2 fpkm respectively) and also highly 
expressed in stem tissue (58.3 fpkm). Together, the expression profile and genome location 
pointed to a role in MIA biosynthesis.
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Figure 23: Expression profile of THAS1 in C. roseus tissues. The expression level (fpkm) is plotted 
against the various tissues including flowers, sterile seedlings, sterile seedlings 5 days after metyl-
jasmonate application, sterile seedlings 12 days after MeJa application, mature and immature 
leaf, primary stem, and roots. 
The gene cloned from cDNA was 1071 bp in length and coded for a member of the ADH family, 
specifically the Medium-chain Dehydrogenase/Reductase (MDR) subfamily (Appendix 1 for 
cDNA and protein sequences). When submitted to BLAST against the NCBI protein database the 
closest characterised homolog was a Sinapyl Alcohol Dehydrogenase (SAD (Bomati and Noel, 
2005)) from the economically important tree species Populus tremuloides (PDB accession code: 
1YQD). The two sequences have 64% identity at the amino acid level. THAS1 was also found to 
share 63% amino acid identity with the C. roseus biosynthetic enzyme Cr10HGO, which catalyses 
the conversion of 10-hydroxygeraniol to 10-oxogeranial early in the alkaloid pathway (fig. 9, NCBI 
accession code: Q6V4H0, (Miettinen et al., 2014)). 
PtSAD, which is implicated in lignin biosynthesis (Li et al., 2001), catalyses the reduction of the 
aldehyde group on sinapaldehyde to an alcohol group, and has been crystallised to 2 Å resolution 
(Bomati and Noel, 2005). PtSAD has been shown to be active as a homodimer, utilises NADPH as 
cofactor, and binds two Zn2+ ions per subunit (Bomati and Noel, 2005). Initial characterisations of 
a similar enzyme CAD isolated from plant material indicated that zinc was necessary for catalysis 
(Wyrambik and Grisebach, 1979). Many MDRs contain two zinc ions, one coordinated in the 
enzyme active site (catalytic zinc) and one positioned near the surface of the protein (structural 
zinc).
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Figure 24: Reduction of sinapaldehyde to sinapyl alcohol, catalysed by Sinapyl Alcohol 
Dehydrogenase (SAD).
The protein product of the cloned THAS1 gene was predicted to be a dimeric zinc-binding 
metalloprotein, consistent with other MDRs which usually contain two zinc ions, one near 
the active site, termed “catalytic zinc” and one in a lobe at the surface of the enzyme, termed 
“structural zinc”. When analysed with zinc-prediction software (PredZinc (Shu et al., 2008), and 
ZincExplorer (Chen et al., 2013)) the residues C54, H76, C107 ,C110 , and C113 were predicted 
to form a zinc coordination sphere in both servers (table 1).  Some predicted Zinc coordinating 
residues were not predicted in both servers.
Table 1: results of Zinc coordinating amino acids prediction of THAS1 residues using ZincExplorer 
online server. The score reflects the confidence of the prediction (most confident prediction 
gives a score of 1)
Zinc atom Residue Score
Zinc atom 1 Cysteine 54 0.889883
Histidine 76 0.739041
Cysteine 162 0.700843




These cysteines of THAS1 align to cysteines on the amino acid sequence of PtSAD. However, not 
all these cysteines take part in Zn2+ binding, as shown by the crystal structure of SAD (Bomati 
and Noel, 2005) in which it was shown that the catalytic Zn2+ binding residues are Cys50, His72, 
Cys166 and a water molecule which is coordinated with Ser52 (fig. 25). The crystal structure of 
PtSAD indicates that Ser52 is implicated in the catalysis of sinapaldehyde reduction and His55 
is coordinated to the ribose of the cofactor (Bomati and Noel, 2005). Alignment of PtSAD with 
THAS1 indicates that a glutamate (Glu59) is equivalent to His55 of SAD and a tyrosine (Tyr56) 
is equivalent to Ser52. Tyrosine is not easily ionisable and glutamate has an opposite charge to 
histidine; this raises some interesting questions about the active site of THAS1 and the catalysis 
mechanism.
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Figure 25: SAD reduction mechanism. Sinapaldehyde (substrate, in black) is reduced through 
hydride attack from the cofactor, NADPH (in red). The catalytic Zn2+ ion activates the carbon-
oxygen bond. The active site serine provides the second hydrogen during the reduction and an 
electron transport chain is achieved through the hydrogen-binding network, via the cofactor 
ribose, and the coordinating histidine and finally into the bulk solvent.
Interestingly, the THAS1 protein sequence was found to contain a Class 5 nuclear localisation 
signal which is plant-specific (Kosugi et al., 2009). The amino acids 214-KKKR-217 are likely 
responsible for transport of this protein into the nucleus. 
2.2.2 Initial functional characterisation of THAS1
The THAS1 gene was cloned into the E. coli IPTG-inducible expression vector pOPINF which 
contains an N-terminal His6-tag for purification with a nickel column. Expression was better and 
higher protein yields were achieved when a richer medium was used, such as Terrific Broth or 
2x YT media, and high amounts of protein (4 mg/L of culture) was achieved when IPTG between 
1 mM and 0.01 mM were used. Concentration of the protein was possible up to approximately 
20 mg/mL but beyond that it precipitated out of solution. The purified protein was aliquoted 
in 5 – 10 μL aliquots in sterile Eppendorf tubes. It was discovered that THAS1 lost activity after 
freezing and thawing and therefore was stored in small single-use aliquots. Inclusion of glycerol 
in the storage buffer did not improve the stability after thawing. Freezing of the aliquots in liquid 
nitrogen before storage at – 20 ˚C was necessary to retain activity; aliquots placed at – 20 ˚C 
without snap freezing were found to be inactive upon thawing. All purified ADH proteins reported 
in this thesis were snap frozen and stored in the same manner after discovering this fact.
Gel filtration chromatography revealed that in a typical preparation the enzyme was usually 
present in two isoforms, a monomer and a dimer (fig. 26, left panel). This has been observed for 
similar enzymes in the past (Wyrambik and Grisebach, 1975). Both isoforms were active (fig. 26, 
right panel), but only the fractions containing the dimer was stored for future use as the dimer 
forms of ADH are reported to keep their activity longer (Wyrambik and Grisebach, 1975).
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Figure 26: Gel filtration trace and LC-MS assays of THAS1 with dimer isozyme and monomer 
isozyme labelled. Left panel: Gel filtration trace of eluate from nickel column purification, the 
early bump constitutes high-molecular weight contaminants. The largest peak corresponds to 
the dimer form of THAS1 (approx. 65 KDa) and the last peak corresponds to the monomer form 
of THAS1 (approx. 42 KDa). Right panel: LC-MS chromatogram traces of the product of THAS1 
assays in presence of strictosidine aglycon and NADPH.
Enzyme reactions were initially monitored by LC-MS. LC-MS measurements of the enzyme 
reactions were performed using targeted methods (Multiple Reaction Monitoring- MRM). Such 
targeted techniques allow better resolution of peaks as the detector selectively monitors the 
ions for the specified parent mass and also the specified fragmentation pattern. Thus each 
trace for the specified ion is free of all other contaminating ions. This method allows use of low 
concentrations of substrate and product and can also distinguish between ions which co-elute. 
Here, an MRM specifically developed from a heteroyohimbine authentic standard was used with 
reactions using purified strictosidine and also using a fresh enzymatic reaction of strictosidine 
aglycon. 
Purified THAS1 was tested with deglycosylated strictosidine in vitro. The enzyme was able 
to reduce this substrate in the presence of the cofactor NADPH and produced a compound 
of mass 353 m/z (fig. 27 trace a). In absence of SGD, THAS1, substrate or reduced cofactor 
no product was formed (fig. 27, traces c to g). THAS1 was able to utilise NADH as well but 
produced lower amounts of product compared to the reaction utilising NADPH after 30 minutes 
incubation. The assays were also done in the presence or absence of the metal chelating agent 
ethylenediaminetetraacetic acid (EDTA, fig. 27, inset). There did not appear to be any significant 
reduction in activity of THAS1 with 5 mM of EDTA. While this suggests that metal is not required 
for THAS activity, the complete removal of the metal was not verified spectroscopically.
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Figure 27: Chromatograms of THAS1 reaction along with controls. Enzyme reactions were 
performed at 25 ̊ C for 30 minutes. Total ion chromatogram for heteroyohimbines m/z 353. Trace 
a: THAS1 (50 nM), SGD (6 nM), strictosidine (200 μM), NADPH (200 μM); b: NADPH replaced with 
NADH; c: boiled THAS1; d: no THAS1; e: no strictosidine; f: no SGD; g: no SGD, no THAS1. Inset: 
Assay with EDTA (black, 5 mM) and without EDTA (red). 
THAS1 was also tested for activity in the reverse reaction, by supplying 300 μM THA as substrate 
together with NADP+ as cofactor. This reaction did not yield significant amounts of cathenamine 
(fig. 28). The trace of 351 is of low intensity signal, and most probably corresponds to the normal 
variation in sensitivity of the MS detector or contamination of the authentic standard of THA. 
However, it is not possible to rule out the possibility that THAS1 does oxidise THA in the reverse 
reaction, but it is clear that the Km is very low compared to its Km for the normal reduction.
Figure 28: LC-MS trace of THAS1 reaction with THA and NADP+ as substrate. The substrate (top 
panel, 353 m/z), and the product trace (bottom panel, 351 m/z).
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2.2.3 Characterisation of THAS1 product
There are multiple alkaloids reported to be found in C. roseus which have a mass of 353 m/z 
and it was not possible to determine the identity of the product based on mass alone. Authentic 
standards for AJM and THA were available, but unfortunately when tested using standard LC-
MS conditions (“fast method” described in the Materials and Methods section below) these 
stereoisomers co-eluted. Even after development of LC conditions that could effectively 
separate these stereoisomers (“separation method”), as one of the potential heteroyohimbine 
diastereomers (rauniticine) is unavailable commercially, it is not possible to rule out the possibility 
it could co-elute with one of the others. To unambiguously identify which product(s) THAS1 
produced, an NMR characterisation was necessary. A large-scale reaction using the purified 
enzyme and deglycosylated strictosidine was separated using silica thin layer chromatography 
(TLC) (fig. 29). 
Figure 29: TLC of THAS1 large scale reaction. The loading areas of the various extracts are 
indicated on the figure; Ethyl acetate: the ethyl acetate extract of the water fraction after the 
MeOH extraction; Methanol: the methanol fraction; H2O fraction: what was left over after both 
MeOH and ethyl acetate extraction. The authentic standards were loaded to the right of the 
plate in the order AJM, serpentine (SER), and THA. M indicates the migration front; P indicates 
the migration of the major product; B indicates the unknown by-products of the reaction. 
Extraction of the dried reaction by MeOH appears to have extracted most constituents; only 
trace amounts of the major product and the lowest by-product can be seen in the lane with 
the ethyl acetate extract (fig. 29). The water fraction does not appear to contain any visible 
traces of heteroyohimbines. AJM and THA migrated and separated very well on silica and the 
THA standard migrated higher than the AJM and corresponded to the major product of the 
reaction. The serpentine authentic standard did not migrate in these conditions and appeared 
bluish under this UV illumination. There appears to be a slight band of product visible at the 
same Rf as AJM in the MeOH extract but 1H NMR of this product was not of high enough signal 
to allow identification of that alkaloid. However, LC-MS measurement of the extract from that 
band confirmed that it is a heteroyohimbine (fig. 30). Other minor products were visible on 
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the TLC but unfortunately were not in high enough amounts for NMR. TLC purification of the 
major product yielded approximately 500 μg of material which was enough to obtain an NMR 
measurement in deuterated chloroform. Comparison of the proton shifts with published shifts 
of the heteroyohimbine alkaloids (Lounasmaa and Kan, 1980) indicated that the major purified 
product is THA (fig. 31).
Figure 30: LC-MS trace of the TLC band corresponding to AJM. Targeted MRM trace of the 
heteroyohimbine isolated from the AJM band from the large-scale TLC purification of THAS1 
reaction. 
Figure 31: NMR traces of an authentic standard of THA and the purified major product of the 
large-scale THAS1 reaction. The structure of THA is included for reference.
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2.2.4 Screening for similar enzymes with THAS activity
The discovery of an MDR from C. roseus which produces a heteroyohimbine alkaloid allowed 
a first positive hit from which to continue the search for other MDRs which could reduce 
deglycosylated strictosidine. The DNA sequence of THAS1 was BLASTed against the C. roseus 
transcriptome and resulted in only a few hits. However, BLASTing of the protein sequence with 
tblastn gave more results. Most hits had a predicted 45-55% identity with the THAS1 amino 
acid sequence, but there were some transcripts which showed higher identity, above 65%. The 
hits selected are Cr021691 (THAS2), Cr010119 (THAS3), Cr032583 (THAS4 and HYS, see section 
below), Cr017994, Cr021541 (T3R), and Cr027234 (amino acid sequence percent identities are 
displayed in table 2).
SAD from P. tremuloides was also BLASTed against the same database in order to provide negative 
controls as the hits from THAS1 BLAST search are biased towards high identity with THAS1. 
Various hits were retrieved when PtSAD was BLASTed and seven of them were picked due to 
the predicted presence of a serine or a threonine in the active site at the equivalent position 
to the catalytic serine of PtSAD. These hits selected were the transcripts Cr011702, Cr030442, 
Cr006840, Cr022770, Cr033537, Cr033062, and Cr2141 (amino acid sequence percent identities 
are displayed in table 2).
Figure 32: Expression level of the MDRs cloned in the initial HYS screen plotted against various 
tissues (HYS and THAS4 are not displayed, see below and Chapter 5 for discussion of this). 
The MDRs which were similar to CAD and SAD enzymes (i.e. with Ser or Thr in the active 
site) are illustrated in shades of blue. The MDRs with other residues in the predicted active 
site are illustrated in shades of orange and brown. THAS1 is displayed in red. For clarity the 
highest expression points (Cr2141 in the two MeJa application conditions, 1042 and 886 fpkm 
respectively, and T3R in immature leaf, 889 fpkm) are not displayed. 
All the MDRs cloned display some expression in leaf tissues (fig. 32). By far the most highly 
expressed transcript is that of T3R, which contrary to almost all other transcripts is not expressed 
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in the stem. Cr2141 is the highest expressed MDR overall, including leaf tissue, where it is 
surpassed only by T3R. Cr2141 is also very highly induced by MeJa application at the seedling 
stage, which indicates it could be under the control of a MeJa-responsive promoter. 
Sequencing of two Cr032583 (THAS4 and HYS) clones revealed that at least two very similar 
(96.2% identity) MDR genes were cloned. Interestingly, the differences were mostly present in the 
substrate binding domain of the enzyme, with the cofactor binding domain largely unchanged. 
The two clones have 14 synonymous (dS) substitutions between them and 20 non-synonymous 
(dN) substitutions. This results in a dN/dS ratio of 1.42 which suggests positive selection has 
been acting at this locus, however it is not possible to determine which gene the selection 
is acting on with only two sequences for comparison. These genes have likely arisen from a 
duplication, but which gene is experiencing the positive selection cannot be investigated without 
more information about the duplication, or sequencing of other examples of this duplication. 
The evolutionary origin of the MDR duplications will be discussed in detail in Chapter 5.
Alignment of the candidate MDR sequences revealed that most of each protein is similar in 
sequence (fig. 33). This is in agreement with the pairwise identities (table 2). However there 
appears to be a relatively large gap in the alignment that does not have identity in any of the 
proteins. The region between position 140 and 170 appears to have low identity in all these 
candidates. Most importantly there appear to be numerous indels in this section of the sequences. 
THAS2 and THAS3 have more amino acids in this section of the protein than all the others (24 
and 21 more amino acids for THAS3 and THAS2 respectively compared to the THAS1 sequence). 
The sequence of candidate Cr017994 does not align well up to position 93 and this suggests the 
cloning of this candidate might not have been correct. This candidate also did not express when 
heterologously expressed in E. coli. The enzymes most similar to each other are THAS4 and HYS 
which share almost 94% identity at the amino acid level (fig. 33). The lowest identity (38.1%) is 














































































































































































































































































































































































































































































































































































































































Figure 33: Protein alignment of candidate 
MDRs. Identical sites are coloured red 
and sites with more than 65% identity are 
coloured orange. The predicted active site 
equivalent amino acid to the SAD/CAD 
serine or threonine is at position 73 and is 
not conserved among these enzymes. The 
Rossman fold GXGXXG motif is conserved 
among all the candidates and starts at 
position 231. 
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After heterologous expression in E. coli, all candidates were tested in triplicate for production of 
heteroyohimbines. Cr017994 could not be expressed in E. coli and was not tested. Quantification 
of products was done using the “separation method” by LC-MS (fig. 34). THAS2, 3, and 4 all 
produce primarily THA, with THAS2 being the most promiscuous of all the THAS. HYS produced 
the three heteroyohimbines and is named Heteroyohimbine Synthase to reflect this promiscuity.
Figure 34: LC-MS traces of product formed after reaction of strictosidine aglycon with the HYSs. 
The trace in black is a mixture of the authentic standards for AJM, 19-EA, and THA. THAS1 is 
illustrated in red. 
All other MDRs tested converted less than 1% of the initial strictosidine substrate into a 
heteroyohimbine, with Cr033062 being the best producer among them with 0.45% conversion. 
This enzyme is not very specific but the extremely low activity strongly suggests it is not a HYS. 
T3R and Cr033537 were initially chosen because they lack the serine or threonine active site 
amino acid that the classic SAD/CAD enzymes have (position 73 in alignment fig. 33), but did not 
show any significant HYS activity (table 3). A detailed mutational study of the active site will be 
described in Chapter 3.
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Table 3: Results of enzyme assay analysis by LC-MS of MDRs that were screened for 
heteroyohimbine synthase activity. The total conversion refers to the yield compared to the 
starting concentration of strictosidine aglycon. The measured concentrations of the three 
identified heteroroyohimbines (AJM, 19-EA, THA) define the product ratio; values are rounded 




Product ratio Conversion 
compared to 
THAS1Ajmalicine 19-epiajmalicine Tetrahydroalstonine
THAS1 19% 2% 2% 97% 100%
THAS3 23% 0.5% 12% 88% 123%
THAS2 19% 2% 12% 87% 29%
THAS4 11% 1% 10% 89% 57%
HYS 22% 35% 15% 50% 115%
Cr011072 0% 0% 0% 100% 0%
Cr030442 0% 0% 0% 100% 0%
Cr006840 0% 0% 0% 100% 0%
Cr022770 0% 0% 0% 100% 0%
Cr033537 0% 0% 0% 100% 0%
Cr033062 0.5% 17% 5% 78% 2%
Cr2141 0% 0% 0% 100% 0%
T3R 0% 0% 0% 100% 0%
Cr027234 0% 0% 0% 100% 0%
2.2.5 pH and temperature optima
Analysis of the pH optimum of THAS1 was done by calculating the rate of the reaction by taking 
three timepoints for a single pH into account. All regressions had a high correlation, the minimum 
was R2=0.97. The rate of each replicate was averaged and the standard deviation calculated. 
Results are displayed in figure 35.
Figure 35: pH optimum of THAS1. The rate of product formation of THA (red) is plotted against 
the pH of the reaction. Error bars represent the standard deviation of the triplicate. 
It appears the rate of product formation increases with decreasing pH, and THAS1 performed 
better at the lowest pH assayed, pH 5.5. The average of pH 5.5 is higher than that at pH 6.0 
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but the difference is not statistically significant (Student’s one-tailed t-test t-statistic = 1.35). 
However there was a significant difference between the rate at pH 5.5 and at 6.5 (Student’s one-
tailed t-test t-statistic = 3.52).
The temperature optimum was assayed by varying the temperature of the assay by increments of 
5 ˚C. The rate of reaction was calculated and plotted for the two replicates; results are displayed 
in figure 36. The data suggest that higher temperatures increase the rate of THA formation for 
THAS1. After these first results were obtained (fig. 36 left panel) another assay was done with a 
temperature range between 40 and 65 ˚C but unfortunately the variation among the replicates 
did not allow for any meaningful analysis of the data. Nevertheless, the temperatures above 
55 ˚C showed low product formation at 3 minutes (fig. 36, right panel). Product formation seems 
to not be possible above 55 ̊ C, which indicates the enzyme is not stable above that temperature.
Figure 36: Temperature optimum of THAS1. Left panel: Rate of product formation is plotted 
according to temperature, triangles and dots represent two replicates. Right panel: Mean 
product formed in assay conditions after 3 minutes incubation at each temperature (mean of 3 
replicates). Error bars represent the standard deviation. 
The product formation with HYS at different pH values was assessed after running the samples 
on the LC-MS using the “fast method”. The reaction in HEPES pH 7.5 produced a large amount of 
product at timepoint 1 minute. HYS appears to be very active and therefore comparison between 
the 1 and the 2-minute timepoints was not meaningful. This was exaggerated by the appearance 
of double peaks, which are perhaps the stereoisomers presenting some separation in some of 
the runs. Integration of the response area was done for both peaks where they were separated 
and the values were combined (table 4). It appears HEPES buffer at pH 7.5 resulted in the largest 
amount of product formed. It is not clear why the response area for the 2 minute timepoints is 
lower than that at 1 minute. Comparisons between 1 minute and 2 minutes are therefore not 
meaningful, especially because at 1 minute the products in the high-activity assays were close to 
saturation of the detector (above 1.0 e8).
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Table 4: pH assay of HYS product formation. 
Buffer used
Peak response area
1 min 2 min
MES pH 5.5 635443 850858
Phosphate pH 6.0 2860224 2399075
Citrate pH 6.0 2183272 1097576
MES pH 6.5 1713416 900544
HEPES pH 7.0 3973651 1970816
Phosphate pH 7.0 18810523 15516128
HEPES pH 7.5 22848140 21184542
Phosphate pH 7.5 18346649 14730331
2.2.6 Kinetics of THAS1 with strictosidine aglycon
To determine the steady state kinetic constants of THAS1 for strictosidine aglycon and NADPH, 
kinetics were attempted by monitoring the rate of product formation at different initial 
concentrations of strictosidine aglycon by LC-MS. Monitoring the consumption of the substrate 
is not possible because strictosidine aglycon is present in solution in multiple forms and can 
interconvert between the forms. It is not known which isomers of strictosidine aglycon are 
available to THAS1 for reduction. 
After optimisation of THAS1 concentration and the assay timepoints the results were analysed 
using the software SigmaPlot. The data were plotted in a Michaelis-Menten plot (fig. 37 and 38) 
and the Km was calculated both for strictosidine aglycon and for the cofactor, NADPH. 
Figure 37: Michaelis-Menten plot of THAS1 with varying concentrations of strictosidine aglycon. 
Product formation rate (μmol/min) is plotted against the initial concentration of strictosidine 
aglycon (μM). The concentration of NADPH was kept constant at 500 μM.
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Assays with varying amounts of strictosidine aglycon were not straightforward; the product 
precipitates in the assay conditions above approximately 50 μM and this is reflected in the 
errors associated with the different measurements by LC-MS (fig. 37). For reasons that are not 
clear the kinetics done with strictosidine aglycon seem to follow a sigmoidal pattern at low 
concentrations. This would suggest a threshold of substrate concentration needs to be passed 
before THAS1 can achieve a certain rate of product formation. However, given that the substrate 
can equilibrate into multiple isoforms this phenomenon could also be produced if at low 
concentrations the equilibration into the accepted substrate isoform is smaller than at higher 
concentrations. Because of the doubt surrounding the actual THAS1 substrate concentration the 
sigmoidal character of the measured product formation rate is not taken into account. Despite 
these caveats the THAS1 Km for strictosidine aglycon was calculated to be 58.29 ± 20.7 μM. 
Figure 38: Michaelis-Menten plot of THAS1 with varying concentrations of NADPH. Product 
formation rate (μmol/min) is plotted against the initial concentration of NADPH (μM). The 
concentration of strictosidine aglycon was kept constant at 300 μM.
Kinetics done with varying NADPH concentration also displayed large error. The Km for NADPH is 
calculated to be 4.84 ± 2.5 μM.
2.2.7 ITC
Isothermic titration calorimetry of THAS1 with NADPH and deglycosylated strictosidine was 
carried out at constant temperature to determine the order of substrate binding and dissociation 
constants (kd). It was discovered that the NADPH cofactor binds first with a kd of 1.5 ± 0.1 μM (ΔH 
(cal/mol) 2310 ± 123.2; ΔS (cal/mol/deg) 34.2 ± 0.3, fig. 39) which is consistent with reported 
values for other MDRs (Lee et al., 2013). Titration assays with deglycosylated strictosidine and 
THAS1 in the absence of any cofactor did not give any signal, indicating that deglycosylated 
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strictosidine does not bind to the active site in the absence of NADPH. Titration with deglycosylated 
strictosidine was also attempted on THAS1-NADPH complex in order to measure the kd for the 
second substrate. However, when the substrate concentration reached approximately 50 μM 
precipitation was observed and this caused aberrant signals which could not be processed.
Figure 39: Isothermic titration calorimetry for NADPH binding to THAS1. Titration with NADPH 
indicates that binding of the cofactor to the enzyme is an exothermic process and THAS1 has a kd 
of 1.5 ± 0.1 μM. Bottom panel illustrates the molar ratio between the injectant (NADPH) and the 
target (THAS1) is 2.0, i.e. approx. 2 moles of NADPH bind per dimer of THAS1.
2.2.8 Pull-down of THAS1 with SGD
Collaborators have demonstrated that THAS1 localises to the same compartment as SGD (the 
nucleus) suggesting there might be a biological role for this common localisation (Stavrinides et 
al., 2015). To test if there is a protein-protein interaction between SGD and THAS1, SGD was used 
as bait in a pull-down assay of THAS1. His6-tagged SGD was loaded onto a nickel-column and an 
untagged preparation of THAS1 (fig. 40 A) was loaded onto the column. Aliquots of the different 
steps were analysed by SDS-PAGE (fig. 40). Although most of the loaded THAS1 appears to have 
not been retained by the column (fig 40 B lanes 8 to 12) a small amount was retained and eluted 
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together with SGD (fig 40 B lanes 14 to 16). These results were suggestive of an interaction 
between SGD and THAS1, but not conclusive. However, BiMFC experiments performed by a 
collaborator confirmed the interaction in vivo.
Figure 40: Cleavage of His6-tag of THAS1 and pull down with SGD. A: SDS-PAGE analysis of His6-
tag cleavage by 3C protease, lane 1: Protein ladder; lane 2: Un-cleaved His6-THAS1; lane 3: His6-
tag cleaved THAS1 and 3C protease. B: Pull down of THAS1 with SGD. Lane 1: Protein ladded; 
lane 2-3: SGD loading onto nickel column; lane 4-7: washes; lane 8-9: THAS1 loading onto nickel 
column; lane 10-11: washes; lane 14-16: elution of bound SGD and THAS1. 
2.3 Discussion
2.3.1 Heteroyohimbines in C. roseus
Tetrahydroalstonine (fig. 41) is a heteroyohimbine alkaloid derived from the reduction of 
deglycosylated strictosidine. Deglycosylated strictosidine is a reactive compound which can 
undergo multiple rearrangements to generate different backbones (see fig. 7, Chapter 1). There 
are four possible heteroyohimbine stereoisomers that can be produced from deglycosylated 
strictosidine, three of which have been reported to be found in C. roseus. These heteroyohimbines 
differ at the stereochemistry at the C-20 and at C-19. When the ring D closes to form the five 
member ring system of deglycosylated strictosidine, the methyl group (C-18) can be either in (R) or 
(S) configuration to yield cathenamine and epi-cathenamine, respectively (fig. 19). Cathenamine
can give rise to THA or AJM, presumably resulting from the stereochemistry of the iminium
tautomer at C-20. It is hypothesized that this iminium is then reduced to form either THA or
AJM. Ring closure of the strictosidine aglycon to yield 19-epicathenamine analogously gives rise
to the heteroyohimbines 19-EA and rauniticine (which is not reported to be found in C. roseus).
It is unclear why there is not an equal distribution of all four heteroyohimbines in C. roseus. The
enzymatic redundancy described here indicates there could be more undiscovered HYSs that
could account for the product distribution observed in the plant. There could also be enzymes
of different eductase enzyme families acting as HYSs. The function of the heteroyohimbines
in planta is not understood, and without a better understanding it is not possible to draw
conclusions about the significance of these product ratios. The mechanism of reduction will be
detailed in Chapter 3.
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Figure 41: Tetrahydroalstonine
2.3.2 THAS1 discovery and characterisation
Previously reported hierarchical clustering of the transcriptome of C. roseus identified several 
genes annotated as ADHs which appeared to be co-regulated with previously characterised 
upstream pathway genes. An MDR from this list was cloned from leaf cDNA of C. roseus and 
expressed heterologously in E. coli. This enzyme, when incubated in the presence of NADPH 
and strictosidine aglycon, produces primarily THA, as verified by NMR, with small amounts of 
AJM and 19-EA also produced. THAS1 is also able to utilise NADH, though at rates too low to be 
accurately quantified. 
An attempt was made to determine the Km of THAS1 for the strictosidine aglycon/cathenamine 
and NADPH substrate. Efforts to accurately measure the steady-state kinetics of this enzyme 
were complicated by several factors. First, strictosidine aglycon reacts with nucleophiles, opening 
the possibility that the substrate, especially at higher concentrations, reacts with components 
in the reaction or with amines present on the surface of the enzyme. Furthermore, strictosidine 
aglycon exists as several isomers that presumably interconvert. If only one of these isomers is 
the correct substrate for the ADH, then estimating the concentration of the actual substrate in 
the reaction will be a challenge. Measuring equilibration rates in vitro would likely have limited 
relevance in vivo. Nevertheless, given these caveats, we obtained estimated Km and kcat values. 
Unfortunately the measurement error was very large for strictosidine at concentrations above 
50 μM and therefore the final Km calculation has a large error associated with it. Despite these 
complications the Km for strictosidine aglycon was calculated to be 58.29 ± 20.7 μM. Interestingly, 
for concentrations of strictosidine below 50 μM the rate of product formation appears to follow 
a sigmoidal pattern. It is not clear why this phenomenon is observed, but sigmoidal curves are 
usually interpreted as representing an allosteric enzymatic activity. This behaviour in the case of 
strictosidine aglycon could be due to the substrate interconversion between different forms; at 
low concentrations of strictosidine aglycon the substrate of THAS1, cathenamine, might not be 
present at high enough concentrations. THAS1 was calculated to have a Km for NADPH of 4.84 ± 
2.5 μM. The binding constant was also calculated for the cofactor, NADPH, using ITC (kd of 1.5 ± 
0.1 μM), and was discovered that two molecules of NADPH can bind to the THAS1 dimer. These 
values for NADPH are comparable to values obtained for similar characterised enzymes (Lee et 
al., 2013). 
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Assays to determine the pH optimum of the enzyme revealed that THAS1 has a faster rate at 
lower pH values. Assays to determine the temperature optimum were not as straightforward 
as the pH optimum assays and the results are not as reproducible, but the enzyme appears to 
perform best between 45 and 55 ˚C; this is in line with results found for other similar MDRs 
(Mansell et al., 1974). It is not clear if this increase in catalytic efficiency is only due to facilitation 
of the enzymatic catalysis or whether substrate equilibration or solubility plays a large part in 
this effect. Similarly, it is not clear if the increase in activity at lower pH is solely due to the 
enzyme catalysis becoming more efficient or rather the solubility or equilibration of the substrate 
speeding up. For these reasons and because of limited substrate availability temperature and pH 
optima were not determined for all the HYSs. 
2.3.3 Discovery of other HYS
The initial discovery of THAS1 prompted a more in-depth study of other C. roseus MDRs. By 
submitting the protein sequence of THAS1 to a BLAST against the C. roseus transcriptome it 
was possible to identify similar MDRs. The genes for these other candidates were cloned and 
expressed in E. coli in the same way as THAS1. Surprisingly one transcript, Cr032583, when cloned 
resulted in two distinct genes with identity at the cDNA level of 96%. This level of variation is 
too high to be explained by allelic variation and therefore the two versions of the gene were 
considered as two independent but similar genes. It is not clear why the transcriptome assembly 
was not able to differentiate between the two genes. 
Four other MDRs were identified which produce primarily THA, based on LC-MS assays and co-
elution with authentic standards. They yield varying amounts of product ratios with THA: AJM: 
19-EA from 50:35:15 (HYS) to 96:2:2 (THAS1 table 3). These other HYSs, although of the same
enzyme family as THAS1, are quite diverged. Pairwise alignment between the protein sequences
reveals the highest homology is between THAS4 and HYS, which appear to be recently-diverged
copies. Interestingly, these two clones were found to have strikingly different product profiles,
with THAS4 being selective for THA production and HYS presenting a more promiscuous product
profile. The next highest homologies are between THAS2, HYS, and THAS1. Perhaps more
interesting is the fact that THAS2 and THAS3 share only approx. 53% identity with THAS1 but
are still tetrahydroalstonine synthases. This reveals the large flexibility of the enzyme scaffold for
production of heteroyohimbines.
All the MDRs cloned code for proteins of approximately 350 amino acids. The HYS discovered 
converted varying amounts of the initial strictosidine aglycon substrate, but none converted 
more than 23.2% (fig. 34). This is a comparable conversion to the 26% conversion described by 
Stöckigt et al. (1976) and it is possible one of the enzymes described here was the one purified 
by Hemscheidt and Zenk (1985). The enzymes are of similar size and catalyse the same reaction, 
but it is not possible to say with certainty which enzyme(s) Hemscheidt and Zenk (1985) had 
purified.
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2.3.4 Interaction with upstream enzymes
A class 5 nuclear localisation signal (Kosugi et al., 2009) was discovered in the protein sequence 
of THAS1. Strictosidine biosynthesis is carried out in the vacuole of C. roseus cells (McKnight 
et al., 1990), and the following step, deglycosylation by SGD is done in the nucleus (Guirimand et 
al., 2010). The spatial organisation of the pathway is of great importance and the possibility that 
THAS1 is also present in the nucleus in close proximity to SGD is very intriguing. To test whether 
THAS1 and SGD have a protein-protein interaction between them a pull-down was done using 
His-tagged SGD and non-tagged THAS1. 
The results of the pull-down of THAS1 with SGD suggests that these two successive enzymes have 
protein-protein interactions but the interaction seems to be weak given the small amount of 
THAS1 that co-eluted with SGD. It is not possible to comment on the specificity of the interactions 
from this experiment. The nuclear localisation signal is present in the closest paralogs of THAS1, 
THAS4 and HYS, and this suggests these enzymes might too interact with SGD in the nucleus. 
Indeed, fluorescently-tagged THAS1 and HYS are localised to the nucleus of transformed C. 
roseus protoplasts as demonstrated by collaborators (Stavrinides et al., 2015, Stavrinides et al., 
2016). These collaborators have also been able to show that these enzymes interact with SGD in 
the nucleus of transformed C. roseus protoplasts which suggests the localisation serves a role. 
2.4 Conclusion
The discovery of these heteroyohimbine synthases in C. roseus completes the biosynthetic 
pathway of the heteroyohimbines. Much of the MIA structural diversity is thought to be 
generated in the first few steps after the deglycosylation of strictosidine. Discovery of the 
HYSs is the culmination of many decades of research and constitutes an important step of the 
branching of the pathway after strictosidine deglycosylation by SGD. The HYSs discovered allow 
an unprecedented opportunity to study how enzymes achieve stereochemical control of reactive 
intermediates. 
Equilibration of strictosidine aglycon in solution in theory could lead to AJM, 19-EA, THA, and 
rauniticine. THAS1 could potentially be selectively reducing only the pro-THA iminium form 
of the substrate pool in solution, or could actively be catalysing the cathenamine-to-pro-THA 
iminium equilibration in its active site. Likewise, HYS could be promiscuous and could accept all 
three iminum precursors into the active site for catalysis. In order to answer these questions and 
to better understand the reduction mechanism a more detailed investigation of the structure/
function relationship of the enzymes and the catalysis mechanism is necessary. This is discussed 
in Chapter 3.
Most of the results described in this chapter are published in Stavrinides et al. (2015) (Annex 1).
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2.5 Materials and Methods
2.5.1 RNA extraction from C. roseus and cDNA synthesis
Young leaf material (40 mg) of C. roseus cv. SunStorm® Apricot was ground in a mortar and pestle 
and RNA was extracted using the RNEasy plant mini kit (Qiagen, UK) according to manufacturer’s 
instructions. The genomic DNA was degraded using RNase-free DNase (Roche Diagnostics, UK) 
according to manufacturer’s instructions. The RNA quality was verified by running an aliquot on 
a 1% agarose gel at 100 V for 30 min and checking for presence of the Ribosomal RNA bands 
and absence of a smear that would indicated carry-over of genomic DNA. Good-quality RNA was 
subjected to reverse-transcription for synthesis of the first cDNA strand using the SuperScript III 
Reverse Transcriptase (Thermo-Fisher Scientific, UK), according to manufacturer’s instructions 
using poly-A primers to specifically amplify expressed gene transcripts. The produced cDNA was 
used fresh or aliquoted in 4 μL volumes and stored at -20 ˚C until use. 
2.5.2 Identification of candidate gene
The C. roseus transcriptome (Góngora-Castillo et al., 2012) was analysed for highly-expressed 
Alcohol Dehydrogenase/Reductase genes that were expressed at non-negligible levels (>1 
fragments per kilobase of transcript per million mapped reads, fpkm) in young and fully 
developed leaves and were also upregulated by Methyl-jasmonate at the seedling stage.
In parallel the ADHs identified from the transcriptome were located in the whole genome 
assembly of C. roseus (Kellner et al., 2015) in order to determine their genomic context. THAS1 
(transcript Cr024553) was found in close genomic proximity to a paralog of the Secologanin 
Synthase gene (SLS3, Cr024556).
2.5.3 Polymerase chain reaction
Cloning from cDNA was routinely performed using 1 μL of cDNA, 0.5 μM of each primer and the 
high-fidelity DNA polymerase KOD Hot Start (Merck Millipore, Herfordshire, UK) according to 
the manufacturer’s instructions for 30 cycles. The annealing temperature was set at 2-3 ˚C lower 
than the lowest melting temperature of the primer pair used. Screening of positive colonies was 
done as follows: Four to eight colonies were picked using a sterile toothpick and placed in single 
wells of a 96-well sterile plate containing 150 μL of LB media supplemented with appropriate 
antibiotics. The cultures were placed at 37 ˚C for 3-4 hours, or until they became cloudy. PCR 
was done using 1 μL of the culture, 0.5 μM of each primer, and the HotStart Taq polymerase 
according to manufacturer’s instructions (Qiagen, UK). The first step of the colony PCR was a 
minimum of 5 min at 92 ˚C to break open the E. coli cells, and the annealing temperature was set 
to at least 2-3 ˚C lower than the lowest melting temperature of the primer pair used. 
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2.5.4 Vectors
For expression of proteins the InFusion system was used; mainly the vectors pOPINF (high-copy, 
AmpR, N-terminal His6-tag), and pOPINA (low-copy, KanR, C-terminal His6-tag). These vectors 
are designed for directional cloning and possess a T7 promoter and a T7 terminator. For simple 
cloning of PCR fragments the vector system pJET (high-copy, AmpR, CloneJet PCR cloning kit, 
Thermo Fisher Scientific) was used. This does not have directional cloning and does not require 
the manufacturer’s kit but rather any T4 ligase can be used. 
2.5.5 Cloning THAS1
The gene coding THAS1 was amplified from C. roseus leaf cDNA using primers designed based 
on the expression sequence reads alignment. The open reading frame of the gene was amplified 
using the primer pair detailed in table 5 which contain overhangs for directional InFusion cloning 
(Berrow et al., 2007). PCR was performed as detailed above and the amplified gene fragment 
was gel-purified from 1% agarose gel (Promega, UK)  and cloned into the E. coli expression vector 
pOPINF (Berrow et al., 2007) following the manufacturer’s instructions for ligation. Vectors 
were transformed into chemically competent E. coli Top10 cells by heat shock at 42˚C for 30 
seconds and then spread-plated onto LB+agar plates supplemented with carbenicillin (100 μg/
mL). After a night of growth at 37 ˚C positive clones were identified by PCR using the gene-
specific primers above and the HotStart Taq polymerase (Qiagen, UK). Positive colonies were 
grown overnight in 4 mL of LB media supplemented with the appropriate antibiotics at 37 ̊ C. The 
following day plasmids were isolated from the cultures using a miniprep kit (Qiagen) according to 
manufacturer’s instructions. Vectors were verified visually by running on a 1% agarose gel at 100 
V and the identity of the inserted sequence was confirmed by Sanger sequencing.
2.5.6 Cloning of other candidate MDRs showing homology to THAS1
The protein sequence of THAS1 was blasted against the transcriptome of C. roseus (Góngora-
Castillo et al., 2012). The hits which were represented by a full-length gene were considered as 
good candidates only if their expression levels were acceptable (>1fpkm) in leaves. In order to 
have representative MDRs which were not likely to function as heteroyohimbine synthases the 
protein sequence of Populus tremuloides SAD was also blasted against the C. roseus transcriptome 
and the top 5 hits of this search were also included in the screen. Furthermore, some C. roseus 
MDR candidates which had been uploaded to NCBI but had not been functionally characterised 
were also included in this screen. 
Primers were designed based on the open reading frame of transcripts after manually verifying 
that the predicted ORF was full length by submitting the predicted amino acid sequence to BLAST 
against the NCBI protein database using blastp and checking that the protein was not truncated 
on either end. Primers used are detailed in table 5. PCR was carried out as described above and 
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the resulting PCR product was gel purified and cloned into pJET according to manufacturer’s 
instructions (Thermo Fisher Scientific). The resulting vector was transformed into E. coli Top10 
competent cells by heat shock at 42 ˚C for 30 seconds. Cells were spread plated onto LB plates 
containing carbenicillin (100 μg/mL) and grown overnight at 37 ̊ C. Multiple colonies were verified 
by colony PCR and two positive clones were verified by sequencing. After verification that the 
PCR fragment cloned coded for a full-length MDR (by Sanger sequencing) the PCR fragment with 
the InFusion overhangs was cloned into pOPINF for expression. Positive inserts were verified 
in two ways, first by miniprep and analysis of the purified plasmid by gel electrophoresis, and 
secondly by PCR by using the vector specific T7 forward primer and the gene-specific reverse 
primer. 
Table 5: Primers used for cloning the MDR candidates into the expression vector pOPINF
Medium Chain 
Reductases Forward primer Reverse primer





























































2.5.7 THAS1 protein expression and purification
The THAS1 gene was expressed in Rosetta 2 pLysS E. coli cells (Novagen®, Merck Millipore, 
Massachusetts, USA). A starter culture was grown overnight at 37 ˚C with 200 rpm shaking in 20 
mL of LB media supplemented with carbenicillin and chloramphenicol (100 μg/mL and 34 μg/
mL respectively). The culture was diluted 1:100 in fresh LB media supplemented with antibiotics 
and was grown at 37 ˚C until an OD600 of 0.6. The cultures were cooled on ice and then induced 
by addition of 0.1 mM of IPTG and placed at 18 ˚C with 200 rpm shaking and allowed to express 
the protein for 16 h. The cells were then collected by centrifugation and resuspended in 50 mL 
of Buffer A (50mM Tris-HCl pH 8, 50 mM glycine, 500 mM NaCl, 5% glycerol, 20 mM imidazole) 
containing a tablet of protease inhibitor cocktail (Roche Diagnostics Ltd) and lysozyme (0.2 mg/
mL). Cells were lysed by sonication on ice with an effective sonication time of 3 minutes with 2 
seconds ON and 3 seconds OFF.  The cell debris was pelleted by centrifugation at 17 x 1000g at 
4 ˚C. All purification steps were performed at 4 ˚C on an ӒKTAxpress purifier (GE Healthcare).  A 
HisTrap FF 5 mL column (GE Healthcare) column was equilibrated with Buffer A and the lysate 
was loaded at a flow rate of 4 mL/min and step-eluted with Buffer B (50 mM Tris-HCl pH 8, 
50 mM glycine, 500 mM NaCl, 5% glycerol, 500mM imidazole). The eluate was further purified 
on a Superdex Hiload 26/60 S75 gel filtration column (GE Healthcare) at a flow rate of 3.2 mL/min 
using Buffer C (20 mM Hepes pH 7.5, 150 mM NaCl). The fractions were analysed by SDS-PAGE 
and those containing only THAS1 were pooled and concentrated in a 10 KDa cutoff Millipore 
filter (Merck Millipore) and the concentration was measured using a BCA assay (Thermo Fisher 
Scientific Inc., USA). 
2.5.8 Small scale protein expression and purification
The pOPINF vectors harbouring the WT genes were transformed into SoluBL21 E. coli cells for 
expression (Novagen®, Merck Millipore, Massachusetts, USA). Positive clones were identified 
by PCR using the gene specific primers (Table 5). A starter culture was grown overnight at 37˚C 
in 50 mL of LB media supplemented with the antibiotic carbenicillin (100 μg/mL), and was then 
diluted 1:100 in 100 mL of fresh 2x YT media supplemented with carbenicillin and allowed to 
grow to an OD600 of 0.6 before induction of expression with 0.1 mM IPTG. The cultures were 
grown at 18 ˚C for 16 h, with 200rpm shaking. Cells were collected by centrifugation and 
resuspended in 10 mL Buffer A (50 mM Tris-HCl pH 8, 50 mM glycine, 500 mM NaCl, 5% glycerol, 
20 mM imidazole) containing a tablet of protease inhibitor (Roche Diagnostics Ltd) and lysozyme 
(0.2 mg/mL). Cells were lysed on ice using sonication for an effective time of 1.5 minutes with 
2s pulse ON and 3s pulse OFF. Cell debris was pelleted by centrifugation at 17 x 1000g and 
the supernatant was incubated for 1 h at 4 ˚C with 200 μL of Ni-NTA agarose beads (Qiagen 
GmbH, Germany) pre-equilibrated with Buffer A. The total was centrifuged at 1000 rpm for 1 
minute to pellet the Ni-NTA agarose and the supernatant was discarded. The Ni-NTA agarose 
was washed three times with 500 μL of Buffer A to remove non-specifically bound proteins, 
each time centrifuging for 1 min at 1000 rpm to pellet the Ni-NTA agarose. Elution was done 
by incubating the Ni-NTA with two volumes of 300 μL of Buffer B (50 mM Tris-HCl pH 8, 50 mM 
glycine, 500 mM NaCl, 5% glycerol, 500 mM imidazole) and centrifuging for 1 min at 1000 rpm. 
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The eluates were transferred to a Durapore centrifugal filter (PVDF 0.1μm, Merck Millipore) to 
remove any residual Ni-NTA agarose. An aliquot of eluates was analysed by SDS-PAGE to verify 
the purity and the molecular weight of the purified proteins. Protein-containing eluates were 
concentrated to approximately 250 μL and buffer exchanged to Buffer D (50 mM Phosphate 
pH 7.6, 100 mM NaCl) in a 30 KDa cutoff membrane filter Millipore filter (Merck Millipore). 
Protein concentration was measured with Bradford reagent (Sigma-Aldrich) according to the 
manufacturer’s instructions. Purified proteins were aliquoted in 20 μL aliquots and snap-frozen 
in liquid nitrogen before being stored at -20 ˚C.
2.5.9 Enzyme assays
Purified candidate proteins and purified SGD were used in all assays. Strictosidine aglycon was 
generated in situ prior to addition of reductases by incubation of strictosidine (production is 
described below in section 2.5.14) and SGD at room temperature in the appropriate solution for 
ten minutes, at which time strictosidine was completely converted to the aglycon. Strictosidine 
was routinely used at 300 μM and NADPH at 500 μM. During initial screening the candidate 
MDRs were used at a concentration of 1 μM. For ease of pipetting and to minimise error all 
constituents of the reaction, including strictosidine, were mixed as a Master Mix and allowed to 
incubate at room temperature for at least 10 minutes before aliquoting the appropriate volume 
and adding the reductases and NADPH. SGD has been shown to have a pH optimum between 
6 and 8.5 (Luijendijk et al., 1998), therefore in enzyme assays with a pH between these values 
strictosidine was deglycosylated by SGD in the buffer used. In reactions where the pH was below 
6 then strictosidine was deglycosylated by SGD before addition of the buffer to ensure SGD was 
functional. 
2.5.10 Steady state kinetics for THAS1
Purified THAS1, SGD, and strictosidine were used for all enzymatic assays. Strictosidine was 
deglycosylated in situ prior to the addition of the reductase enzyme by incubating strictosidine 
with SGD  as described above. Steady state kinetics were performed in 50 mM phosphate buffer 
(pH 7.5), with 6 nM SGD, 50 nM of THAS1, 200 μM NADPH (Sigma Aldrich), and 50 μM of the 
internal standard (caffeine). 
The kinetics were done as follows: varying concentrations of strictosidine was placed in the wells 
of a 96-well plate with 50 mM of phosphate buffer, followed by addition of 6 nM of SGD and the 
necessary volume of MilliQ water to standardize the volume and caffeine (50 μM) was added to 
this mix as an internal standard. Another set of wells were prepared which contained pre-mixed 
solutions of 50 nM of THAS and 200 μM of NADPH. At ten minutes the strictosidine mix was 
added to the THAS+NADPH mix and mixed by pipetting several times. At 0.5 minutes, one minute 
and two minutes, a 10 μL aliquot of the reaction was placed in 80 μL of H2O + 0.1% formic acid 
premixed with 10 μL of methanol, for a 10-fold final dilution of the sample. The presence of 10% 
methanol was required to keep the THAS product soluble. The 96-well plate was centrifuged at 
4000 rpm for 10 minutes to pellet the enzymes and then analysed by LC-MS. A similar setup was 
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used for determination of the Km for NADPH, using 300 μM strictosidine and varying the NADPH 
concentration. The initial rate of the reaction (V0) was calculated by fitting a linear regression 
through the points of product formation plotted against time. Michaelis-Menten plots were 
done using SigmaPlot (Systat Software Inc.).
2.5.11 Isothermic Titration Calorimetry
Isothermic titration calorimetry on a MicroCal iTC200 System (GE Healthcare Life Sciences) was 
used to determine the binding constant (Kd) for the cofactor, NADPH. For determination of the 
dissociation constant of THAS1 and NADPH, the purified THAS1 was dialysed overnight against 
2 L of Buffer C (20 mM Hepes pH 6.8, 100 mM NaCl). The protein concentration was adjusted 
with dialysis buffer before the experiment to 40 μM of dimer (80 μM of monomer). Titration was 
carried out by injecting 2 μL of titrant (1 mM NADPH, dissolved in dialysis buffer) at 750 rpm with 
a propeller stirrer at intervals of 110 seconds. The first injection was 0.5 μL and was not used for 
data analysis. Titrations were carried out in triplicate and a control titration was carried out in 
which Buffer C was injected into the cell containing THAS1 in order to determine the background 
dilution and mixing heat. This background was then subtracted from the analysis of the NADPH 
titrations. Data analysis was done using Origin 7.0 software (MicroCal) by fitting a single site 
model to the data obtained. The dissociation constant (Kd), binding enthalpy (ΔH), and entropy 
(ΔS) were determined for each replicate.
Titration was also attempted in triplicate for determination of the Kd for cathenamine. THAS1 
was premixed with 1 mM of NADPH and prepared cathenamine reaction (1 mM, prepared 
in Buffer C) was injected using same conditions as above for NADPH injection. Unfortunately 
substrate or product precipitation interfered with the calorimetry and therefore did not yield any 
meaningful data. Titration was attempted with cathenamine only (no NADPH cofactor) but did 
not give any significant binding heat. 
2.5.12 Secologanin purification from Symphoricarpos albus
Berries of S. albus were picked in the autumn when ripe and frozen at -20 ˚C until use. One 
kilogram of berries was ground using a mortar and pestle in liquid nitrogen until a fine powder. 
The powder was transferred to a 1 L bottle and 500 mL of MeOH was added and the solution was 
sonicated for 15 minutes in a water bath and then filtered into a round bottom flask. The berry 
debris was replaced in the bottle and another 500 mL of MeOH was added and sonication and 
filtration was repeated twice. The combined methanolic solution was concentrated on a rotary 
evaporator until reduced to a volume of approximately 10 mL. 
The resulting syrupy concentrate was diluted 1:1 in MeOH and injected on a prep-HPLC for 
secologanin purification. This was performed on a Dionex Ultimate 3000 (Thermo Scientific) 
preparative HPLC coupled to a multiwavelenth UV-vis detector. Separation was performed on a 
Phenomenex Luna C18 column (250 x 30 mm) with 5 μm particles. The flowrate was set to 24 mL/
minute and started with 99 % Solvent A (H2O + 0.1 % TFA) and 1 % Solvent B (100% ACN). Solvent 
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B gradually increased to 40 % at 12 minutes, followed by a rapid increase to 100% at 14 minutes, 
holding there for 2 minutes and then decreasing to 1 % again at 17 minutes. Column equlibration 
was done for a further 6 minutes, until 23 minutes, at 1 % Solvent B. The fractions containing 
secologanin were verified by LC-MS as described above and were combined and concentrated 
on a rotary evaporator. The concentrate was rediluted in a small volume of H2O (2-5 mL) and 
freeze dried overnight and the dry powder was stored at -20 ˚C. The purified secologanin was 
also verified by 1H-NMR on a Bruker Avance III 400 NMR spectrometer, operating at 400 MHz for 
1H and 100 MHz for 13C.
2.5.13 Strictosidine synthase production
The gene coding Strictosidine synthase (STR) was cloned from C. roseus  leaf cDNA 
into the expression vector pOPINA (Berrow et al., 2007) using the primers forward 
5’AGGAGATATACCATGTCACCAATTTTGAAAAAGATTTTTATTGAAAGCCC and reverse 
5’-GTGGTGGTGGTGTTTGCTAGAAACATAAGAATTTCCC. Primers were designed in order to exclude 
the first 93 bp of the STR gene which constitute a signal peptide for vacuolar localisation of the 
WT CrSTR. Vectors were transformed into competent E. coli Top10 cells by heat shock at 42 ̊ C for 
30 seconds and then incubated in SOC media for 1h before spread-plating onto LB+agar plates 
containing Kanamycin (kan) and placing them at 37 ˚C overnight. Colonies were screened by 
colony PCR using the gene-specific primer pair detailed above. Vectors were verified for correct 
insertion by sequencing. For expression, the pOPINA construct harbouring STR was transformed 
into E. coli SoluBL21 cells by heat shock as described above. An LB overnight starter culture of 50 
mL, supplemented with Kan was placed at 37 ˚C with 200 rpm shaking. This culture was diluted 
1:100 in fresh 2x YT media supplemented with Kan and was grown with shaking and allowed to 
grow to an OD600 of 0.6 before induction of expression with 0.1 mM IPTG. Purification of STR was 
done as described above for THAS1. 
2.5.14 Production and purification of strictosidine
Purified secologanin (2 mM) was incubated with tryptamine (2.5mM, Sigma Aldrich) in 50mM 
Phosphate Buffer (pH 7) and purified STR (the precise amount of STR was not determined). 
The reaction was placed in a conical flask and placed on a rotary shaker overnight at 30 ˚C. 
The reaction was stopped by addition of 1 volume of MeOH and the total was concentrated 
on a rotary evaporator to a syrupy consistency. After filtration through a 0.2 μm pore filter the 
sample was injected in 2 mL volumes on a preparative HP-LC and purified as described above for 
secologanin, but collecting the strictosidine elution fractions.
2.5.15 Determination of pH optimum of THAS1
To determine the pH optimum for THAS1 the rate of the reaction in presence of different pH 
was measured. Phosphate buffer (100 mM) was varied from 5.5 to 8.0 in 1/2 pH increments. 
All assays were done in triplicate and to minimise the error due to pipetting Master Mixes were 
used everywhere possible. To stabilise the ionic charge 200 mM NaCl was also included in all 
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assays. Purified SGD (12 nM) was incubated with strictosidine (200 μM final concentration) in a 
50 mM pH 7 buffer solution to deglycosylated strictosidine before the addition of THAS1. This 
was incubated at 25 ˚C for 30 minutes before aliquoting into clean tubes. The new buffer was 
added to each (100 mM of the new pH buffer to counter the pH 7 buffer in the SGD incubation 
pre-mix), as well as the NaCl solution, and the NADPH (200 μM). Purified THAS1 (10 nM) was 
added and mixed immediately by pipetting. Aliquots were taken at 1, 2, and 3 minutes and 
prepared for LC-MS measurement as described above. 
2.5.16 Determination of temperature optimum of THAS1
Rate of product formation was done using a thermocycler (AB Applied Biosystems Verity 96-
well Thermal Cycler) with the capability to adjust to different temperatures across the heating 
block. The strips were used at 25, 30, 35, 40, 45, and 50 ˚C.  Strictosidine (50 μM) was incubated 
with purified SGD (6 nM) in Phosphate buffer (pH 7.5, 50 mM) at 37 ˚C for 10 minutes, and 
then was aliquoted into sterile tubes for assaying. Purified THAS1 (10 nM) was pre-mixed in 
another set of tubes with NADPH (200 μM). After the 10 minutes incubation of the substrate 
the thermocycler was adjusted at 15 ˚C for 30 sec and the enzyme/cofactor mix was added and 
mixed. The thermocycler was then brought to the necessary temperature and incubated for 
5 minutes. An aliquot of each assay was taken at 2 and at 3 minutes and prepared for LC-MS 
measurement as described above. This assay was done in duplicate.
As the 50 ̊ C assay had a higher rate of activity than the others. Therefore the assay was repeated 
another day in triplicate with the temperature range set from 40 to 65 ˚C with 5 ˚C increments. 
LC-MS analysis and quantification was done as described in the section “LC-MS measurement”.
2.5.17 Analysis of pH and temperature optima experiments
To determine the best condition for THAS1 activity the assays in which pH or temperature was 
varied were analysed in Microsoft Excel. The quantified THA concentrations were corrected for 
dilution (multiplied by the dilution factor, 10). For the temperature optimum the rate of the 
reaction was calculated by comparing the product formed at 2 minutes with that measured for 
3 minutes. The equation used is 
(y2-y1) 
(x2-x1)
where y1 and y2 are the amounts of THA measured for timepoints 2 and 3 minutes respectively, 
and x1 and x2 correspond to the timepoints 2 and 3 minutes respectively. 
For the pH optimum the rate of the reaction was calculated by plotting all three measurements 
(timepoints 1, 2, and 3 minutes) and calculating a linear regression through the three points 
using the equation 
y=ax-b
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where y is the THA produced, a is the slope of the correlation, x is the timepoint, and b is a 
constant.
The rates were plotted against pH or temperature to determine the best conditions for THAS1.
Student’s t-test was used to determine if two measurement means were statistically different 
from each other. 
2.5.18 Determination of pH optimum of HYS
To determine the optimum pH/buffer combination for use during HYS reactions, a small panel of 
buffers was assayed. Strictosidine (500 μM) was incubated with purified SGD in deionised water 
for 15 minutes at room temperature. Then the reaction was split into eight tubes containing 
different buffers. The buffers used are (in order of increasing pH): MES pH 5.5, Phosphate pH 
6.0, Citrate pH 6.0, MES pH 6.5, Phosphate pH 7.0, HEPES pH 7.0, Phosphate pH 7.5, and HEPES 
pH 7.5. All buffers were used at a concentration of 50 mM. NADPH (1 mM) was added, followed 
by 50 nM of purified His-tag cleaved HYS. The reactions were mixed and an aliquot was taken at 
1 minutes and at 2 minutes and prepared as usual for analysis by LC-MS. 
2.5.19 LC-MS measurements
All measurements were done on an AQUITY UPLC with a Xevo TQ-S Mass-spec equipped with a 
BEH Sheild RP18 1.7 μm column (Waters). Two different methods were employed for analysis of 
the samples. The first was a quick method (5 minutes) which allowed separation of strictosidine, 
strictosidine aglycon and heteroyohimbines, but did not provide separation of the different 
heteroyohimbine diastereomers. The second LC-MS method was developed to separate the 
diastereomers but was only used for assays where it was necessary to determine the ratios of 
the products as this method was substantially longer (23 minutes). 
For the first “fast method” the solvents used were Water + 0.1% Formic Acid as solvent A1 and 
100% Acetonitrile as solvent B1, with a flow rate of 0.6 mL/minute and the column was held at 
35 ˚C. Two μL of the sample was injected on a gradient starting with 5% solvent B1 increasing to 
35% for 3.5 minutes, changing to 100% at 3.75 minutes, held for 1 minute to wash the column, 
then back to 5% solvent B1 for 1 minute to re-equilibrate the column. 
For the second “separation method”, developed based on the method in Sun et al. (2011), the 
solvent A2 was Water + 0.1% NH4OH and solvent B2 was 0.1% NH4OH in acetonitrile. A linear 
gradient from 0% to 65% B2 in 17.5 minutes was applied for separation of the compounds 
followed by an increase to 100% B2 at 18 minutes, a 2-minute wash step and a re-equilibration 
at 0% B2 for 3 minutes before the next injection. The column was held at 60 °C throughout the 
analysis and the flow rate was 0.6 ml/minute.
All MS detections were done in positive ESI mode. Capillary voltage was 3.0 kV; the source was 
kept at 150 °C; desolvation temperature was 500 °C; cone gas flow, 50 L h-1 and desolvation 
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gas flow, 800 L h-1. Unit resolution was applied to each quadrupole. Targeted methods for each 
compound were developed using commercial standards (caffeine, AJM (Sigma-Aldrich Co Ltd, 
Dorset, UK)) or enzymatically produced compounds (strictosidine and strictosidine aglycon, 
Table 6). Multiple Reaction Monitoring (MRM) signals were used for detection and quantification 
of the heteroyohimbine alkaloids (table 6).
Table 6: Multiple Reactions Monitoring conditions 
Molecule Parent ion Daughter ion Cone Voltage Collision Voltage
Strictosidine 
aglycone
351 170.22 28 22
351 144.16 28 24
Strictosidine 531 352.25 32 24
Heteroyohimbines
353 117.19 50 40
353 144.16 50 26
For each compound the parent ion was surveyed and fragmented using cone voltages and 
collision voltages optimised for the standards. Quantification of product formed was done using 
TargetLynx software by integrating the detected peak after two iterations of Savitzky-Golay 
smoothing (MassLynx™, Waters).
2.5.20 Large-scale THAS1 reaction and product purification 
For NMR characterisation of the THAS1 product a large scale reaction was setup to produce 
enough purified product. Strictosidine (4.3 mg) was diluted in 20 mL of distilled water to give 
a final concentration of 400 μM and the pH was adjusted to 7.5 with 50 mM phosphate buffer. 
Purified SGD (3 nM), 500 μM of NADPH, and 100 nM of THAS1 were added to the solution. 
An NADPH regeneration system was employed by addition of 20 units of Glucose-6-Phosphate 
Dehydrogenase (Roche Diagnostics) together with 1 mM of glucose-6-phosphate. The reaction 
was incubated with gentle shaking at room temperature and the reaction progress was followed 
by subjecting aliquots to LC-MS analysis in order to verify strictosidine aglycon was consumed. 
The reaction was deemed complete after 5 hours and was quenched by addition of two volumes 
of MeOH. The total was concentrated by evaporating to dryness under vacuum with the help 
of a rotary evaporator. The dry precipitate was extracted with MeOH and the supernatant 
was transferred to a clean round-bottom flask. This was repeated multiple times to yield an 
approximate volume of MeOH of 15 mL. The remaining precipitate was re-extracted by addition 
of 2 mL of distilled water, followed by addition of 2 mL of ethyl acetate (HPLC grade). The two 
phases were mixed gently and then allowed to separate. The organic fraction was transferred 
to a clean round-bottom flask and the extraction of the water phase was repeated 5 times with 
ethyl acetate. The ethyl acetate and MeOH fractions were dried under vacuum and were each 
resuspended in 50 μL of ethyl acetate. A preparative silica TLC plate (UNIPLATE, Analtech™) was 
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pre-soaked with trimethylamine (TEA). The extracts were loaded onto the TLC plate and the 
plate was developed in ethyl acetate : hexanes : TEA (24 : 75 : 1), twice, allowing the plate to 
air dry between runs. The bands were visualised using UV (254 nm). Aliquots of commercially 
available standards of AJM, THA, and serpentine were also loaded on the TLC as reference. 
The major product of the reaction was excised from the TLC plate using a scalpel and the silica was 
extracted by crushing in ethyl acetate multiple times (for a total volume of approx. 20 mL). The 
ethyl acetate was filtered into a clean round-bottom flask through a millipore filter to remove the 
silica. The extract was evaporated to dryness under vacuum and the product was resuspended 
in 200 μL of fresh ethyl acetate and passed through an SPE column that was pre-equilibrated 
with hexanes (HPLC grade). The product was eluted using increasing amounts of ethyl acetate 
in hexanes and the first three elution fractions (corresponding to 25 – 75 % ethyl acetate) were 
pooled and dried under vacuum. The product was dried overnight on a high-vacuum pump and 
was resuspended in 300 μL of CDCl3 (Sigma) and transferred to a Shigemi tube. NMR spectra (
1H 
NMR, 13C NMR) were acquired using a Bruker Avance III 400 NMR spectrometer, operating at 400 
MHz for 1H and 100 MHz for 13C. The residual 1H- and 13C NMR signals of CD3Cl (δ 7.26 for 
1H and 
δ 77.36 for 13C) were used as internal chemical shift references. 
The minor products were purified in the same manner as detailed above, but there was not 
sufficient signal in the 1H NMR spectra to determine the nature of the isolated compounds. 
2.5.21 Pull down of THAS1 with SGD
Purified THAS1 was prepared for pull-down assay by cleaving the His-tag using 3C protease. 
THAS1 (200 μg) was incubated with 3C protease (1 μg) overnight at 4 ˚C, then with an additional 
1 μg of fresh 3C protease was added and the reaction was allowed to progress for another thirty 
minutes at room temperature. 
To purify the cleaved THAS1 the reaction was passed through a 0.5 mL Ni-NTi Agarose slurry 
(Qiagen Ltd., Manchester, UK) pre-equilibrated with Buffer E (20 mM Hepes, pH 7.5, 150 mM 
NaCl). The flow-through was collected and an aliquot was analysed by SDS-page gel to verify 
the shift in molecular weight. This cleaved THAS1 was concentrated using a Millipore filter unit 
with a 10 KDa cutoff and its concentration measured using a BCA assay (Thermo-Fisher). A glass 
chromatography column (0.5 cm x 10 cm) was loaded with 0.5 mL of Ni-NTi Agarose slurry 
(Qiagen) which was washed and equilibrated with 15 mL of Buffer E. His-tagged SGD (380 μg) 
was loaded onto the column and 1 mL fractions were collected. The column was then washed 
with 5 mL of Buffer C, followed by loading of 100 μg of THAS1 which was premixed with 0.5 mM 
of NADPH. The column was washed with 5 mL of Buffer E, and then elution was carried out 
with 3 mL of Buffer F (20 mM Hepes pH 7.5, 150 mM NaCl, 250 mM imidazole). A 20 μL aliquot 
of each fraction was analysed by SDS-page gel and stained using InstantBlue (Expedeon Ltd, 
Cambridgeshire, UK). 
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2.5.22 Alignment of protein sequences
The amino acid sequence of the cloned candidates were aligned using the program Seaview 
(PRABI-Doua, (Gouy et al., 2010)) using the ClustalOmega algorithm (Sievers et al., 2011). The 
alignment was visualised using BioEdit software (Hall, 2011).
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Chapter 3
Achieving Stereoselectivity in Heteroyohimbine Synthases
3.1 Introduction
The remarkable chemical diversity found in many Apocynaceae plant species, including C. roseus, 
is due to the reactivity and instability of strictosidine aglycon, a key biosynthetic intermediate 
for many alkaloid natural products. The heteroyohimbine family of these alkaloids can form after 
the ring E closure (fig. 42) and reduction of the double bond of ring D. Although theoretically 
all sixteen stereoisomers (derived both from strictosidine with 3-(S) and vincoside with 3-(R)) 
are possible, only three have been reported to be found in the plant C. roseus, all derived 
from strictosidine: ajmalicine [AJM, 19(S), 20(R)], tetrahydroalstonine [THA, 19(S), 20(S)], and 
19-epiajmalicine [19-EA, 19(R), 20(R)].
Figure 42: Deglycosylation of strictosidine and equilibration into cathenamine (and its isomer 
19-epicathenamine) and generation of the iminium form through tautomerization. The rings 
formed are indicated in red A-E.
In Chapter 2 I described the discovery of 5 HYSs. Some of the enzymes (THAS1-4) displayed 
a specific THA-producing profile, but one enzyme, HYS, appeared to be promiscuous and was 
capable of producing all three heteroyohimbines found in C. roseus. Although the enzymes 
were found by similarity to THAS1 they are quite diverged, except for THAS4 and HYS that share 
approximately 94 % identity at the amino acid level. The mechanism of reduction would in theory 
be similar for all five, but the numerous differences in the active site and the loop sections near 
the predicted active site complicate interpretation of the protein alignment. 
The discovery of the heteroyohimbine synthases described in Chapter 2 has demonstrated that 
the MDR family of ADH enzymes is capable of evolving an imine-reducing activity. However, it is 
not yet clear if these enzymes are truly imine reducing or if they reduce the carbon-carbon double 
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bond of the enamine (cathenamine) (fig. 43), but we believe the iminium would be the most 
likely substrate. Furthermore, the mechanism by which the enzymes control this stereoselective 
reduction remains unclear. 
Figure 43: Equilibration of cathenamine and the iminium form of cathenamine in water.
A better understanding of the mechanism of enzymatic stereoselectivity at this key biosynthetic 
pathway branchpoint is necessary to understand how the other scaffolds stemming from 
strictosidine might be generated. To this end mechanistic studies have been carried out using 
deuterium labelling, and mutations to the active site of THAS1 and HYS. Crystal structures of 
these two enzymes, as well as of THAS2 (done by collaborators) were also obtained to aid in 
understanding the active site of the enzymes and for in silico docking of the substrate.
3.2 Results
3.2.1 Crystallisation of THAS1
THAS1 protein for crystallisation was purified by nickel resin and by gel-filtration chromatography 
(see fig. 40 A for representative SDS-PAGE gel). Crystallisation screens were initially set up using 
commercially available screens (PEG, JCSG+, and PACT) using both apo protein and protein pre-
mixed with the cofactor NADP+. Initial screening resulted in crystals forming under a number of 
different conditions, many of which were sent for X-ray crystallography to the Diamond Light 
Source synchrotron. The best quality holo crystal was obtained from a solution containing 0.2 M 
potassium/sodium tartrate with 20 % w/v PEG 3350. THAS1 apo crystals lacking the NADP+ 
cofactor did not diffract to below 2 Å resolution, and therefore an optimisation screen was set 
up using the best conditions identified in the initial screens. THAS1 without the His6-tag was 
also crystallised in case this produced better quality crystals. THAS1 apo crystals were obtained 
from protein in which the His6-tag was removed. A high quality apo crystal was obtained from a 
condition containing 0.1 M MES buffer, pH 6.5, with 15 % w/v PEG 2000.
3.2.2 Crystallisation of HYS
Heterologous expression of HYS produced a dimer enzyme with approximately 38 kDa molecular 
weight for each subunit (as analysed on SDS-PAGE). Purification only on His-trap was not sufficient 
to produce protein of high enough purity for crystallisation assays (fig. 44, left). Therefore further 
purification by size exclusion gel filtration was needed, and resulted in a higher purity protein 
(fig. 44, right). However, some contaminants are still visible by SDS-PAGE. To remove these last 
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contaminants anion exchange was attempted, but was largely unsuccessful due to the neutral PI 
of HYS (7.38) and therefore was not attempted again. 
Figure 44: Images of a typical SDS-PAGE gel analysis of purified HYS after only His-trap purification 
(left) and after both His-trap and size exclusion gel-filtration (right).
The His6-tag was removed before crystallisation and the protein was further cleaned by passing 
through a nickel column once again, resulting in a higher purity protein. Crystallisation of HYS 
was attempted as done for THAS1, using commercially available screens in 96-well sitting drop 
format but crystallisation of this enzyme proved challenging. Multiple attempts resulted in 
low quality crystal structures lacking the resolution necessary to clearly define some flexible 
loop sections, in particular the loop (loop2) over the active site. Crystallisation of the protein in 
presence of NADP+ was difficult; the few crystals that did form had very low resolution and did 
not result in any useful dataset. A condition in one of the screens which gave apo crystals was 
selected for optimisation (fig. 45-48). The MMT Buffer is not available commercially and was 
prepared according to the recipe used by Molecular Dimensions.
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Figure 45: Optimisation screen for HYS apo crystals with 0.2 mM MMT Buffer (pH 5.0) with 
varying PEG sizes and concentrations. Asterisks mark the wells with the best crystals. 
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Figure 46: Optimisation screen for HYS apo crystals with 0.2 mM Sodium Nitrate with varying 
PEG sizes and concentrations. No usable crystals formed on this plate.
PLATE 3

















Figure 47: Optimisation screen for HYS apo crystals with 0.1 mM MMT Buffer with varying pH 
and PEG concentrations. No usable crystals formed on this plate.
PLATE 4



















Figure 48: Optimisation screen for HYS apo crystals with 0.1 mM MMT Buffer (pH 5.0) with 
varying PEG sizes and concentrations. Asterisks mark the wells with the best crystals. 
The crystals that resulted from this optimisation were analysed at Diamond Light Source and 
the best dataset was obtained from a crystal grown in plate 4 (fig. 48) 0.1 M MMT buffer, pH 5, 
with 15% PEG 3350. No crystals of good quality were obtained in conditions with NADP+. Due to 
the low quality of the crystal nucleation, seeding was attempted using crystals from conditions 
which crystallised more readily. Drops containing NADP+ microcrystals and also drops with left 
over high-quality apo crystals were used. Optimisation screens were setup using seeds from a 
total of 6 different conditions using the best condition as precipitant (0.1 mM MMT buffer pH 




















Figure 49: Optimisation seeding screen for HYS holo crystals with 0.1 mM MMT Buffer (pH 5.0) 
with varying PEG concentrations. Asterisks mark the wells with the best crystals. 
The seeding optimisation for HYS holo crystals (fig. 49) appeared to be successful, generating 
multiple drops with crystals in presence of NADP+. Unfortunately, these crystals were revealed 
to be made up of apo HYS after solving the X-ray diffraction and none of the datasets obtained 
showed any density for the cofactor in the active site. It appears although the crystals formed, 
they did not form with the cofactor bound. Therefore attempting to crystallise HYS in presence 
of the cofactor was not re-attempted. 
After multiple failed attempts to improve the resolution, an aliquot of HYS was sent for analysis 
by thermofluor. This technique uses the temperature-mediated unfolding of the protein to 
quantify its stability in various buffers or in presence of different additives or ligands. 
HYS was tested against a panel of additives, buffers, pH conditions, detergents, and also 
cofactors. All results of the screens are found in Appendices 2-4. Dissociating reagents, such 
as UREA and DMSO, appear to destabilise the protein in a concentration-dependent manner. 
Addition of salts, such as Na2SO4, did not have an effect on the protein stability. However, the 
addition of multivalent and metal ions had a destabilising effect, most notably the addition of 
1 mM ZnCl2 which caused the Tm to shift from 61 ˚C to 45 ˚C. Reducing agents, such as DTT and 
TCEP had a destabilising effect which was concentration dependent. Various crowding agents 
had a stabilising effect on the protein, notably the addition of glycerol (5-20% w/v) increased 
the Tm to 64 ˚C (fig. 50). PEG addition did not have the same effect. Interestingly, the addition of 
imidazole had a detrimental effect on the Tm of HYS in a concentration-dependent manner. The 
same concentration of imidazole (500 mM) used in Buffer B for protein elution from the Ni-NTA 
column reduced the Tm by nearly 30 ˚C reducing it to just under 35 ˚C. Some amino acids (L-Arg 
and L-His) destabilised the protein to some degree, but detergents such as CHAPS did not have 
an effect. Some cofactors (ATP, NADH, cAMP, etc) were also tested for their effect on HYS but 
none showed any significant effect on the Tm. 
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Figure 50: Thermofluor assay of HYS with addition of ethylene glycol, glycerol, or PEG at differing 
concentrations. 
The cofactors included in the general screen did not include NADPH or NADP+ and for that reason 
an extra screen was requested in order to understand the effect of the cofactor. HYS appeared 
to have a melting temperature of 60.3 ˚C in 50 mM HEPES buffer pH 7.5 in the absence of any 
cofactor (fig. 51). After the addition of NADP+ (2 or 5 mM) the melting temperature increased 
slightly to about 63 ˚C. However, after addition of NADPH (2 or 5 mM) the melting temperature 
increased by almost 10 ˚C to 70 ˚C. Therefore it is evident this enzyme is greatly stabilised by the 
addition of NADPH but not by NADP+. This effect probably reflects the effect the cofactor binding 
has on the tertiary structure of the enzyme.
Figure 51: Thermofluor result with HYS and cofactor at varying concentrations. Protein was used 
at approximately 25 μM. 
HYS showed slight variation of stability at different pH values, when tested against a range 
of different pH buffers (succinic acid/phosphate/glycine 2:7:7) it appeared to be unfolded at 
pH below 5.0 and above 9.0 (Appendix 2). At pH between 5.6 and 9.0 its Tm was between 57 
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and 62 ˚C. The concentration of the buffers HEPES, NaPO4, and Tris were tested between 10 to 
250 mM at pH 7.5 (8.0 for Tris) but did not seem to have any effect, negative or positive on the 
stability of the protein. The addition of NaCl however seemed to increase the stability of the 
protein in HEPES buffer (50 mM, pH 7.5) and in Tris buffer (50 mM, pH 8.0); this increase was 
seen even at concentrations of 1000 mM NaCl. 
Based on the results of the thermofluor assay HYS was stored in a buffer designed for maximum 
stability (HEPES 50 mM, NaCl 150 mM, glycerol 10%, TCEP 0.5 mM, pH 7.06).  The crystallisation 
was reattempted with HYS purified in optimal conditions with included TCEP, but no crystals 
could be grown of better quality than the ones identified in the previous screen.
3.2.3 Comparison of crystal structures
The crystal structure for the THAS1-holo enzyme was solved using the strong anomalous signal 
of the four Zn2+ ions contained in each enzyme dimer. After data collection a structure solution 
was automatically obtained by single wavelength anomalous dispersion phasing and the initial 
density map obtained was already of sufficient quality (fig. 52) and completeness to contain 94% 
of the residues expected in the dimer enzyme. The refined structure of THAS1-holo was used 
to solve the corresponding apo structure and also the apo structure of HYS. THAS1-holo was 
solved to a resolution of 1.05 Å and the apo structure was solved at 2.25 Å; HYS-apo was solved 
at 2.25 Å (fig. 53 and 58).
All structures have a similar tertiary organisation, with 13 α-helices and 18 β-sheets. The enzyme 
is an elongated homodimer with two sections to each monomer: a substrate-binding and a 
cofactor-binding domain. The dimerization is achieved through the β-sheets 15 and 16 in the 
cofactor-binding domain (fig. 57). RMSD values between apo and holo THAS1 structures are 
1.21 Å and 1.54 Å for the monomer and dimer respectively. Between HYS apo and THAS1 apo 
the RMSD are 0.72 Å and 1.48 Å for the monomer and dimer respectively. These structures 
are similar to the crystal structure of the similar MDRs PtSAD (PDB accession codes 1YQX and 
1YQD) and also to AtCAD (PDB accession codes 2CF5 and 2CF6) (Bomati and Noel, 2005, Youn 
et al., 2006). These enzymes are implicated in the lignin biosynthesis of poplar and Arabidopsis 
respectively (see Chapter 1 for a more detailed description). 
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Figure 52: NADP+ depicted in the electron density (turquoise mesh) which was experimentally 
phased after solving the structure and before any further refinement. Surrounding water 
molecules are illustrated as red spheres and the THAS1 chain A and B backbones are illustrated 
in light blue and lilac cartoon representation (Chain B and A respectively).
Figure 53: Crystal structure of THAS1 holo (top) and apo (bottom). Views from the side and from 
the front (left and right respectively). Each chain is coloured differently; zinc atoms are illustrated 
as dark blue spheres. The NADP+ is illustrated with green carbons in the holo structure. 
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Figure 54: Overview of THAS1 active site. A: Electrostatic map of THAS1, focused on the active 
site; B: Zoomed in section of area in grey box of panel A, with the right, left, and bottom walls of 
the active site cavity illustrated; C: Same section as B in cartoon representation with loop1 and 
loop2 drawn in dark and light blue respectively. The NADP+ is illustrated with green carbons and 
the Zn2+ ion is illustrated as a blue sphere in panel C.
The active site cavity of THAS1 is framed on the left wall by the helix α2, the “catalytic” zinc 
coordination sphere towards the back, and loop 1 towards the entrance and loop 2 above the 
active site (fig. 54). The bottom of the active site is responsible for the co-factor binding and the 
right wall of the active site consists mainly of turns between α-helices and β-sheets. 
The NADP+ is held in position by a network of hydrogen bonds with water molecules and residue 
side chains and backbone amide and carbonyl groups (fig. 55 and 56). Residues from both the 
catalytic domain of the protein (Met1 residue to Leu152 and Ala299 to Asn356) and the nucleotide 
binding domain (Pro153 residue to Thr298) take part in this network. The nicotinamide ring of 
NADP+ is positioned towards the floor of the central cavity which forms the active site of the 
enzyme. Above this ring there is space which in this crystal structure is occupied by multiple water 
molecules (3) with more water molecules towards the entrance of the active site. The Tyr56 of 
THAS1 is positioned above the nicotinamide ring with approximately 6 Å distance between the 
side chain ring and the cofactor. The ribose hydroxyl groups interact with the carboxylic acid of 
Glu59 in THAS1-holo; this amino acid is conserved in HYS. Glu59 probably plays a similar role to 
that played by His55 in PtSAD although in PtSAD His55 interacts with the 3’ OH of the NADPH 
cofactor only. 
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Figure 55: 2-D figure of coordination of NADP+ in THAS1 chain A. Black dashed lines represent 
hydrogen bonds; green lines represent hydrophobic interactions. Image produced with the 
software PoseView (Stierand and Rarey, 2010).
75
Figure 56: Interactions between NADP+ and THAS1. NADP+ is illustrated as cylinders with green 
carbons; THAS1 chain B is illustrated in cartoon with gray carbons and chain A is coloured lilac. 
The residues interacting with NADP+ are illustrated either only as the backbone if the interaction 
is achieved through the backbone oxygen or nitrogen, or illustrated only with the side chain if 
the interaction is only achieved through the side chain functional groups. The “active site” zinc 
ion is illustrated as a blue sphere and water molecules within 4 Å of NADP+ are illustrated as red 
spheres.
Figure 57: Sequence alignment of C. roseus THAS1, THAS2, HYS, and P. tremuloides SAD. 
Numbering corresponds to HYS. Identical and similar amino acids are highlighted in red and 
yellow, respectively. Secondary structure elements of the HYS apo crystal structure are displayed. 
THAS1- and HYS-active site amino acids (Tyr56/53 and Glu59/56) are indicated by blue dots, 
and THAS2 active site amino acids (Tyr120 and Asp49) are indicated by green dots. Ligands for 
catalytic and structural zinc ions are highlighted by black and grey dots, respectively. The nuclear 
localization signal of (THAS1 and HYS) and loops 1 and 2, respectively, are indicated in red. A 
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non-proline cis-peptide bond that is observed in THAS1 holo, in one subunit of THAS1 apo, in HYS 
apo, and not at all in THAS2 is indicated with an orange dot. The substrate-binding domain and 
the cofactor-binding domain are indicated by blue and purple bars, respectively.
The HYS active site cavity is in general very similar to that of THAS1 (fig. 56) with the exception of 
some amino acid differences on loop1 and the extended loop2 which drapes over the active site. 
Loop1 in THAS1 has two phenylalanines which project into the active site in the crystal structure, 
one of which does not have enough electron density to model confidently. These phenylalanines 
(Phe65 and Phe67) could be involved in substrate binding by interacting with its indole moiety. 
HYS also has a phenylalanine at the equivalent position to Phe65 (Phe62) but has a methionine 
rather than a phenylalanine at the second position (Met64). Like in the THAS1 structure this 
residue does not have enough electron density to model confidently. 
HYS and THAS1 present a very similar tertiary structure (fig. 58). Alignment of the apo HYS with 
apo THAS1 gave an RMSD value of just 1.48. However, HYS has many active site differences to 
THAS1, most notably the loop2 over the active site is extended in HYS (D125-GHFGNN-F132) 
compared to THAS1 (D128-SN-Y131). This loop2 in the crystal structure of HYS appears to dip 
down and frame the active site from above, but the loop in THAS1 is shorter and therefore does 
not drape down into the active site.
AJM is a minor byproduct of the THAS enzymes discovered thus far. Extensive mutagenesis 
has not been attempted on any THAS homolog with the exception of THAS1. Mutations to the 
active site of THAS1 did not result in a significant AJM production with the exception of the E59 
mutants (see section 3.2.7). Mutation of the E59 could result in the cofactor binding in a slightly 
different orientation in the active site resulting in more flexibility in the iminium formed (fig. 67). 
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Figure 58: Overview of THAS1 (top) and HYS (bottom) crystal structures. 
Two Zn2+ ions are found in each subunit of the enzymes, one above the active site termed “active 
site” zinc, and one more distal to the active site that is a “structural” zinc (fig. 59). In both THAS1 
and HYS the active site zinc is coordinated by two cysteines, one histidine, and one glutamate. 
The structural zinc is coordinated in both structures by four cysteine residues. 
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Figure 59: Zinc coordination spheres of THAS1 (upper panels) and HYS (lower panels). The amino 
acids coordination the “active site” and the “structural” zinc ions are illustrated as cylinders and 
labelled. Zinc ions are illustrated in blue for THAS1 and in coral for HYS.
3.2.4 Enzymatic labelling of products with 2H
To investigate the mechanism of THAS1 and HYS, a pro-R-NADPD (deuterated NADPH) was used 
in large-scale reactions with the strictosidine aglycon substrate. The reaction products (AJM, THA, 
and 19-EA from the HYS reaction and THA from the THAS1 reaction) were purified by preparative 
TLC and analysed by 1H-NMR and compared to the spectra obtained for authentic standards (fig. 
60-62). In all cases one hydrogen atom was replaced by a deuterium and the effect was evident 
on both the spectra of H-21β and on the spectra of H-20. All the purified products lacked a signal 
for the H-21α consistent with this being deuterated (fig. 63).
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Figure 60: 1H-NMR spectra of [21α-2H]-THAS1 and HYS products. H-21 and H-20 are boxed in pink 
and green, respectively, for clarity. 
Figure 61: 1H-NMR spectra of [21α-2H]-ajmalicine from large-scale HYS reaction. H-21 and H-20 
are boxed in pink and green, respectively, for clarity. 
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Figure 62: 1H-NMR spectra of [21α-2H]-19-epiajmalicine from large-scale HYS reaction. H-21 and 
H-20 are boxed in pink and green, respectively, for clarity. 
Figure 63: Heteroyohimbines with deuterium at α-position on carbon 21. 
Deuterium labelling has shown that the hydrogen from NADPH is transferred to the α-position 
of all the substrates’ C-21. This is in agreement with the hydride transfer described using crude 
enzyme purifications from C. roseus (Stoeckigt et al., 1983). Therefore the substrate must orient 
itself in the same general manner in the active site of both enzymes. 
3.2.5 pH effect on product profile
A small panel of different pH buffers was used to test whether it is possible to modify the product 
profile of HYS and THAS1 in a pH-dependent manner. The enzyme profiles were compared to 
the product profile of chemical reduction with NaBH4 (fig. 64). Enzyme profiles were monitored 
by a highly optimised LCMS method that separated all diastereomers. The results indicate 
that chemical reduction at all four pH values produces primarily THA, and only trace amounts 
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(< 0.5 μg) of AJM and 19-EA (fig. 64, panels A, B, C, F). THAS1 has a product profile similar to that 
of chemical reduction. Both THAS1 and chemical reduction were able to produce larger amounts 
of THA at the lower pH values. HYS however was able to produce more AJM at all the pH values 
tested and produced a maximum of 2.5 μg of AJM at pH 6. HYS was also able to produce larger 
amounts of 19-EA than the other methods but the 19-EA amounts produced were lower than 
for the other compounds. 
Figure 64: Product profile of THAS1, HYS, and NaBH4 dependence on pH from 5 to 8. Top row: 
Ajmalicine (A), 19-epiajmalicine (B), and tetrahydroalstonine (C) produced by THAS1 (red), HYS 
(blue), or NaBH4 (green) per 15.9 μg of strictosidine in 10 min. Bottom row: 3D graph of products 
of THAS1 (D), HYS (E), and NaBH4 (F). Error bars are the standard error of the mean of three 
replicates.
It is interesting that HYS is capable of producing a larger amount of AJM than other compounds 
at pH 6 (fig. 64, panel E). This suggests an amino acid in the active site of HYS is in the catalytically-
active conformation at pH 6. His127 on loop2 has a pKa near the AJM-producing maximum of 
HYS (pH 6), however in the absence of detailed pH dependent kinetics it is not possible to assign 
with certainty that His127 is responsible for the increased AJM activity at this pH.
3.2.6 Docking of cathenamine into THAS1 active site
Co-crystallisation of THAS1 with THA had been attempted, but no crystals were ever obtained in 
those conditions. Soaking of some crystals with deglycosylated strictosidine had been attempted 
but those crystals did not show any density in the active site that would suggest the substrate had 
entered. Therefore, molecular in silico docking was used to visualise the position of strictosidine 
aglycon in THAS1. Cathenamine was used for the docking as collaborators identified that as 
the predominant strictosidine aglycon isomer in solution by using 15N-strictosidine aglycon and 
15N-HMBC NMR as described in Stavrinides et al. (2016). 
Docking was done using the THAS1-holo structure with 100 runs. This resulted in just two distinct 
docking clusters, which constituted 98% and 2% of the resultant poses, respectively. The latter 
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cluster placed the indole moiety such that the N1 atom was closest to the cofactor. This cluster 
was eliminated since it was inconsistent with the results of the deuterium labelling experiments 
(fig. 63). The poses contained within the major cluster were all deemed to be “productive” since 
they placed the indole moiety of cathenamine towards the entrance of the active site and the 
C-20 and C-21 3.3 Å above the nicotinamide C-4 atom (fig. 65). The indole moiety in this second 
cluster was positioned near the entrance to the active site. The top ranked pose had an estimated 
free energy of binding = -8.76 kcal mol-1, and is used in the structures illustrated here. 
Figure 65: Cathenamine docked in the active site of THAS1. THAS1 is illustrated as cartoon 
with the amino acids Y56, E59, and F65 illustrated as cylinders; NADP+ is illustrated as cylinders 
with green carbons; cathenamine is illustrated as cylinders with blue carbons; the Zn2+ ions are 
illustrated as dark blue spheres.
The substrate is positioned in the space between the nicotinamide ring and the active site Tyr56. 
This orientation is consistent with the labelling studies using NADPD which showed that the 
hydride from C-4 of the nicotinamide ring of the cofactor is transferred to the bottom face of the 
C-21 of the substrate to generate the final reduced product. In this orientation of the substrate 
it is reasonable to suggest that Phe65 or Phe67 could interact with the indole moiety of the 
substrate and aid in correct orientation in the active site. In HYS the substrate is expected to dock 
in the same manner, although in silico docking with HYS was not attempted as we were not able 
to obtain a HYS structure with the cofactor bound. Tyr56 and Phe65 are conserved in HYS, while 
Phe67 is replaced by a methionine. The role of this residue is not clear but both methionine and 
phenylalanine are hydrophobic, so this residue may play a similar role in both THAS1 and HYS. 
3.2.7 Mutagenesis of THAS1 and HYS
Mutations to the active site of THAS1 were carried out to probe the role of the residues in 
catalysis of the reduction. Based on sequence homology with PtSAD the equivalent active site 
amino acids Tyr56 and Glu59 were chosen for mutation. Amino acids which were predicted to 
frame the active site, Phe65 and Phe67, were also chosen for mutation due to their possible 
ability of interacting with the hydrophobic indole ring of the substrate. Such an interaction is 
seen in STR where two aromatic residue side chains sandwich the indole and help in the correct 
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orientation in the active site (Loris et al., 2007). The amino acid Ser102 was also mutated due its 
possible equivalence with the PtSAD active site serine. 
Figure 66: Selected representative traces of THAS1 mutants with interesting effect on the product 
profile of the enzyme. 
Mutant THAS1 were compared by LC-MS analysis both with the “fast method” and with 
the “separation method” to determine the product ratio. In the fast method, where the 
heteroyohimbine diastereomers do not separate, the overall activity of the enzyme mutants was 
measured. The separation method was then used to determine whether the ratio of products 
had been altered by the mutation (fig. 66). Most mutations did not abolish activity of THAS1, 
reflecting the resilience and plasticity of the active site (table 7). Some mutations, such as Tyr56 
mutated to Phe, resulted in an increase of AJM and 19-EA, but this mutant showed very little total 
conversion compared to the WT enzyme (0.72%). Mutating Tyr56 to Ser did not impact the total 
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conversion very substantially (21.86% conversion compared to WT) which demonstrates that an 
enzyme with an active site more similar to that of PtSAD which has a Ser in place of Tyr could 
still carry out this reaction. Interestingly, mutating Tyr56 to Ala did not abolish activity though 
mutation of Tyr56 to Phe did (fig. 66); although the two mutations are aliphatic the smaller 
residue was much better supported than the larger, more sterically similar Phe. Mutating Tyr56 
to Glu resulted in a large reduction in conversion which may be the result of the introduction of 
a negative charge in the active site cavity. 
Ser102, which is positioned in the active site and may be implicated in the mechanism (fig. 67), 
was mutated as well. Most mutations to this residue (Ala, Tyr, Thr) did not impact the amount 
of substrate conversion compared to the WT enzyme and did not have any significant effect 
on the product profile either (table 7). However, mutating Ser102 to Asp resulted in a reduced 
conversion (2.84%) and an increased promiscuity for AJM production (13.73% of total product 
formed). Ser102 therefore does not appear to be an important amino acid for the reduction of 
the substrate but the introduction of a negative charge in the active site disrupted the activity. 
Table 7: List of THAS1 mutants that were screened for heteroyohimbine synthase activity 
against strictosidine aglycon. The total conversion refers to the yield of reduction compared to 
the starting concentration of strictosidine aglycon. The measured concentrations of the three 
identified heteroroyohimbines (ajmalicine, 19-epi-ajmalicine, tetrahydroasltonine) define 
the product ratio; values are rounded to the nearest integer. The activity of all enzymes was 









THAS1 Y56A 2% 4% 5% 92% 12%
THAS1 Y56E 0% 0% 29% 71% 0.3%
THAS1 Y56T 1% 8% 8% 84% 5%
THAS1 Y56S 4% 2% 6% 92% 22%
THAS1 Y56F 0% 54% 11% 35% 1%
THAS1 E59A 21% 4% 11% 85% 113%
THAS1 S102A 12% 1% 2% 97% 65%
THAS1 S102Y 6% 2% 2% 96% 29%
THAS1 S102T 13% 2% 1% 97% 68%
THAS1 S102D 1% 14% 4% 82% 3%
THAS1 T166S 1% 13% 5% 82% 3%
THAS1 T166V 0% 24% 7% 69% 2%
THAS1 F67V 19% 6% 6% 87% 100%
85
Mutating the Glu59 (which coordinates with the ribose OH groups of the cofactor, fig. 67) to 
alanine does not abolish activity, but slightly affects it (fig. 66). An increase in 19-EA biosynthesis 
is observed with this mutant compared to WT THAS1.
Figure 67: Mutations to THAS1 active site. Crystal structure of THAS1 with side chains of mutated 
residues illustrated in grey carbons and NADP+ in green carbons. The side chain of Phe67 is not 
resolved well in the crystal structure beyond Cβ. The active site Zn2+ is pictured as a blue sphere 
and the hydrogen bonds of Glu59 illustrated by dashed lines.
Thr166 is positioned towards the back wall of the active site cavity, below the plane of the 
nicotinamide ring (fig. 67). This residue could potentially coordinate a water molecule which 
could serve as a source of protons for protonation of C-20 of cathenamine. This residue was 
mutated to valine and serine to probe its role in the catalysis. Both mutations reduced activity 
and increased the promiscuity. Notably, Thr166 to valine increased the amount of AJM and 
19-EA produced compared to WT, suggesting that this residue could be coordinating a water 
molecule in the right position to carry out the protonation of cathenamine. However, drawing 
firm conclusions would only be possible after thorough investigation of the kinetic properties 
of this mutant, which was not done due to the complexities of this two-enzyme system, as 
described in Chapter 2. 
The phenylalanine residues (Phe65 and Phe67, fig. 67) on loop1 were both mutated to valine. 
Only Phe67 is listed in table 7 as the Phe65 to valine mutant did not express well and precipitated 
during purification. The Phe67Val mutant had poor expression as well but remained soluble 
and was therefore possible to assay. Mutating Phe67 to valine did not have a negative effect on 
activity but did slightly increase the product promiscuity of THAS1. This could be either because 
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of modification of the secondary structure of the loop1, but could also signify that Phe67 may 
play only a minor role in correct orientation of the substrate into the active site.
3.2.8 Loop swaps and mutations to HYS loop2
The major structural difference between THAS1 and HYS is the extended loop over the HYS active 
site, loop2 (fig. 68). Loop1, which is near the active site and frames the entrance to the active 
site on the left side, also exhibits some differences between the two enzymes (THAS1: Lys62-
NKFGFT-Ser69; HYS: Thr59-NKFGMT-Lys66). To investigate whether either of these loops control 
product stereoselectivity, and whether it is possible to switch stereoselectivity between THAS1 
and HYS, the loops 1 and 2 were swapped between these two enzymes.
When THAS1 loop1 was replaced with loop1 from HYS, the resulting mutant was not expressed 
as well as wild type enzymes. The same was observed when Phe67 on loop1 was mutated 
individually in THAS1. This indicates that mutations to this section of THAS1 are not very well 
tolerated. When the loop2 from HYS was inserted into THAS1, the resulting mutant did not show 
an increase in AJM production and neither did the double loop (loop1 + loop2) swap mutant. 
HYS with the THAS1 loop1 swap did not show a difference in product profile, but its activity 
was negatively impacted. Conversely, when the loop2 of HYS was replaced with the short loop2 
found in THAS1, the resulting mutant HYS enzyme produced a product profile resembling that of 
THAS enzymes (fig 68, table 8). 
Figure 68: Product profile of THAS1 and HYS loop swap mutants. A: Crystal structure of THAS1 
chain A illustrated in gold cartoon representation with Y56, E59 and F65 illustrated as sticks for 
reference. THAS1 and HYS loops 1 (blue or red) and loops 2 (light blue or purple) are illustrated 
for clarity. B: UPLC-MS chromatograms of THAS1 loop swap mutants; C: chromatograms of HYS 
loop swap mutants. Legend for colours used is inset in panel B.
The striking result of the loop2 swap in HYS indicates that loop2 is responsible for the increase in 
promiscuity of HYS. Circular dichroism of the WT enzymes and the loop swap mutants was done 
to verify that the swaps did not cause a significant modification of the tertiary structure of the 
enzymes (fig. 69). The CD spectra of all enzymes have a similar profile, however there are some 
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slight modifications to the THAS1 structure, but there do not appear to be major changes to the 
structure as a result of the loop swaps. 
Figure 69: Circular dichroism of THAS1, HYS, and the corresponding loop swap mutants. A. WT 
and loop swap mutants of THAS1. B. WT and loop swap mutants of HYS. Wild-type enzymes 
are plotted in red, loop 1 swap mutants in green, loop 2 swap mutants are in blue and the 
double loop 1 and 2 swap mutants are in yellow. The secondary structure of the mutants is not 
substantially different from that of the wild type proteins.
Table 8: List of THAS1 and HYS loop swap mutants screened for heteroyohimbine synthase activity 
against strictosidine aglycon. The total conversion refers to the yield of reduction compared to 
the starting concentration of strictosidine aglycon. The measured concentrations of the three 
identified heteroroyohimbines (AJM, 19-EA, THA) define the product ratio; values are rounded 








wild typeAJM 19-EA THA
THAS1 loop1 swap 11% 4% 5% 91% 59%
THAS1 loop2 swap 0.5% 19% 9% 72% 2%
THAS1 loop1 + loop2 
swap
1% 12% 8% 80% 3%
HYS loop1 swap 2% 26% 33% 41% 9%
HYS loop2 swap 10% 2% 5% 93% 43%
HYS loop1 + loop2 
swap
1% 20% 58% 22% 3%
3.2.9 Point mutations of HYS
Mutations were made to His127 to investigate its role in reduction of cathenamine, an isomer of 
strictosidine aglycon. Phe128 was also mutated to investigate whether this amino acid could be 
responsible for promoting a different binding mode of the substrate to the active site which would 
give rise to the pro-ajmalicine iminium species. However, this seemed unlikely, since deuterium 
labelling studies described above suggest that the substrate binds in the same position and is 
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labeled at the same carbon regardless of whether the THA or the AJM product is formed. The 
Phe128Ala and Phe128Tyr mutants did not show a modified product profile but rather showed 
a decrease in product formed. The His127Ala and His127Asn mutants both displayed a product 
profile that resembles that of THAS (fig. 70, table 9) which supports the hypothesis that AJM is 
formed due to the presence of this histidine on loop2. 
Figure 70: Results of point mutations on HYS active site amino acids. A: crystal structure of 
HYS chain B, active site cavity with H127 and F128 drawn in stick representation and the active 
site tyrosine (Y53) for reference (green carbons). Loop 2 is illustrated in purple, grey sphere is 
the “active site” zinc. B: UPLC-MS chromatograms of the point mutations of HYS (all traces are 
1.16e8). Ajmalicine elutes at 10.99 min, 19-epi ajmalicine at 11.36, and tetrahydroalstonine at 
12.87.
Table 9: List of HYS point mutants that were screened for heteroyohimbine synthase activity 
against strictosidine aglycon. The total conversion refers to the yield of reduction compared to 
the starting concentration of strictosidine aglycon. The measured concentrations of the three 
identified heteroroyohimbines (ajmalicine, 19-epi-ajmalicine, tetrahydroalstonine) define 
the product ratio; values are rounded to the nearest integer. The activity of all enzymes was 




Product ratio Conversion 
compared to 
wild typeAJM 19-EA THA
HYS H127A 1% 3% 4% 93% 4%
HYS H127N 2% 1% 1% 98% 11%
HYS F128A 0% 34% 8% 57% 0.5%
HYS F128Y 0.5% 48% 6% 46% 3%
3.2.10 Mechanism proposal for tetrahydroalstonine biosynthesis in THAS enzymes
The cathenamine substrate most likely binds into the active site with the indole moiety oriented 
towards the phenylalanine residues on loop1 and above the NADPH nicotinamide ring (fig. 65). 
We propose equilibration to the iminium species is achieved by a proton addition at C-20 from 
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a water molecule positioned behind and below the molecule. This produces an (S) orientation 
at C-20. The crystal structure of THAS1 displays many water molecules in the active site (fig. 
56); therefore it is not unlikely that a water molecule coordinated in the active site could be 
responsible for the iminium generation. The only amino acid residue that is positioned to possibly 
perform this protonation is Thr166, which is positioned towards the back wall of the active site 
cavity, in proximity to the location of the substrate C-20. Mutation of Thr166 to a valine did not 
show any significant reduction effect to the product profile. Therefore it is likely that a water 
molecule and not Thr166 could be responsible for providing the proton. 
Once the pro-THA iminium is formed, the hydride from the pro-R face of NADPH attacks the C-21 
to produce THA. The active site tyrosine can stabilise the transition state through the N-4 (fig. 
71). Mutation of the THAS1 Tyr56 to a phenylalanine resulted in a much reduced activity which 
supports this hypothesis. 
Figure 71: Reduction mechanism of Tetrahydroalstonine Synthases and Heteroyohimbine 
Synthase for production of tetrahydroalstonine. The substrate, cathenamine, is shown with the 
indole moiety truncated for clarity. The cofactor and the hydride originating from it are illustrated 
in red and the hydride originating from water (on C-20) is illustrated in blue.
3.2.11 Mechanism proposal for ajmalicine biosynthesis in HYS
Based on the deuterium labelling results cathenamine binds to HYS with the C-20 to C-21 bond 
in proximity to the NADPH cofactor, in the same orientation as it does for THA production. I 
hypothesize that generation of the pro-AJM iminium form of the substrate is achieved by 
abstraction of an exchangeable proton of the His127 side chain by C-20 at the pro-R position and 
corresponding tautomerisation to the iminium. His127 is coordinated in the crystal structure by 
the active site Tyr53 phenolic group. Once the pro-AJM iminium is formed the reaction proceeds 
in the same fashion as THAS. The NADPH hydride attacks the C-21 at the pro-R position and the 
transition state is stabilised by the Tyr53 hydroxyl (fig. 72).
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Figure 72: Reduction mechanism of Heteroyohimbine Synthase for production of ajmalicine. The 
substrate, cathenamine, is shown with the indole moiety truncated for clarity. The active site 
His127 and the hydride originating from it are illustrated in green. The cofactor is illustrated in 
red and the hydride originating from water (on C-20) is illustrated in blue.
3.2.12 Removal of zinc and functional assays
MDRs usually contain two zinc ions per subunit (Auld and Bergman, 2008), one “structural”, 
found in a flexible loop area near the surface of the MDRs, and one “active site” zinc found near 
the active site cavity. The latter is implicated in the catalytic mechanism in some MDRs and is 
therefore termed “catalytic” in those MDRs. However, in the HYSs there is no evidence that the 
zinc is necessary for catalysis and is therefore termed simply “active site” zinc in this thesis. The 
“structural” zinc is coordinated by four cysteine residues and the “active site” zinc in most MDRs 
is coordinated by two cysteines and one histidine with the fourth position usually occupied by 
a water molecule. In the case of the crystallised heteroyohimbine synthases, THAS1, THAS2 
(performed by a collaborator and not described in this thesis), and HYS, the “active site” zinc is 
positioned further back in the active site and is coordinated in the fourth position by a glutamate 
residue (fig. 59).
To determine whether zinc is required for HYS activity, THAS1 and HYS were subjected to 
treatment with the chelator EDTA. THAS1 and HYS did not degrade after the overnight dialysis 
against EDTA-containing buffer, based on SDS-PAGE analysis which showed the expected 
molecular weight. However, after the second overnight dialysis to remove the EDTA most of 
THAS1 had precipitated. HYS did not show any degradation. The smell of sulfur was noted when 
the dialysis container was opened after the EDTA dialysis, as noticed by Hoagstrom et al. (1969). 
The removal of the zinc was verified visually by reacting an aliquot of Zn-holo and Zn-apo protein 
with a commercial zinc detection kit. The assay did not show any difference when the proteins 
were incubated “as is” and therefore the enzymes were boiled and pelleted before assaying 
again (fig. 73). The results were clearer with the boiled protein; visual inspection showed that 
there were very low levels of Zinc in the Zn-apo conditions, confirming that the EDTA dialysis was 
successful. 
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Figure 73: Photos of zinc detection assay conducted on Zn-apo and Zn-holo THAS1 and HYS. 
The Zinc detection assay was done after boiling of the protein. The pellets of protein in the +Zn 
conditions show strong pink colouring whereas the pellets in the –Zn conditions are not pink. 
Figure 74: Circular dichroism spectra of non-treated (red) and zinc-apo (blue) THAS1 (A) and HYS 
(B). The secondary structure of the Zn-apo proteins is not significantly different from that of the 
Zn-holo proteins.
After recuperating the soluble fraction of each protein an SDS-PAGE gel analysis did not indicate 
degradation in either protein. CD-spectra analysis of both proteins did not suggest the soluble 
proteins had substantially changed in structure (fig 74). This suggests that the zinc ions are not 
necessary for conservation of the tertiary or quaternary structure of these enzymes.
Analysis of protein assays by UPLC-MS using the “fast method” showed that the Zn-apo enzymes 
were able to catalyse the reaction (fig. 75). However, the slight decrease of conversion in the 
THAS1-Zn-apo assays means the result of this experiment is not clear-cut. It is not possible to 
exclude the presence of trace amounts of “active site” zinc left over in some active sites of THAS1. 
It is also not possible to rule out the possibility that the EDTA treatment of THAS1 resulted in a 
slightly misfolded protein (as evidenced by the high protein precipitation after overnight dialysis) 
which possibly was not as catalytically active.
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Figure 75: LC-MS chromatogram traces of THAS1-Zn-apo and HYS-Zn-apo protein assays 
compared to untreated control reactions. 
Although these results strongly suggest that the “active site” zinc does not play a role in the 
mechanism detailed here, the catalytic role of zinc cannot be definitively eliminated. The distance 
of the zinc from the bound cofactor in the active site (NADP+) is not a clear indication of its role 
in catalysis, as indicated by studies done on other members of the MDR family. For example, 
crystallisation of a Glucose Dehydrogenase from an archaeon with different combinations of 
substrates and products revealed that the zinc atom could swap ligands and could be displaced 
by as much as 1.4 Å within the active site cavity (Baker et al., 2009).
3.3 Discussion
3.3.1 Protein crystal structures
Crystallisation of THAS1 and HYS was carried out to gain a better understanding of the structure 
of the proteins and in particular of the active site. THAS1 crystallised well in the holo form and 
quite readily in the apo form. As with many other MDR enzymes, crystals in the holo form were 
of better resolution than the apo crystals, perhaps indicating some inherent instability of the apo 
enzymes, which present a more open structure between the substrate-binding and the cofactor-
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binding domains. This is consistent with the Isothermic Titration Calorimetry (ITC) results for 
THAS1 (Chapter 2, Results 2.2.6) which indicated that the binding of the cofactor to the active 
site of THAS1 is exothermic. 
The crystal structure of the THAS1-holo enzyme was initially going to be solved by using 
molecular replacement with the crystal structure of PtSAD (PDB: 1YQD (Bomati and Noel, 2005)). 
However, due to the very strong signal by the 4 Zn2+ ions contained in each enzyme dimer the 
anomalous signal was used successfully to generate an experimentally phased density map. The 
high resolution of the crystal electron density allowed for a high resolution and high confidence 
protein structure to be built in it. 
Although the thermofluor analysis of HYS showed it was a relatively stable enzyme with a high 
melting temperature, especially in the presence of NADPH, it proved difficult to crystallise. An apo 
structure of HYS was obtained which provided the necessary resolution and details to compare 
it directly to the crystal structures of THAS1, along with another THAS homologue solved by a 
collaborator, THAS2. A holo crystal of HYS with NADP+ could not be obtained. 
The structures of these C. roseus enzymes are similar, and also similar to the structures of other 
MDRs. The most notable differences between them are the loop2 sections above the active sites. 
These loops are variable in length between THAS1 and HYS and other THAS homologues (fig. 76).
Figure 76: Crystal structures of THAS1, THAS2, and HYS with the loop2 sections highlighted. A: 
apo THAS1, THAS2, and HYS displayed in cartoon, with the loop2 section inset in black box.B: 
holo THAS1 and THAS2 displayed in cartoon, with the loop2 section inset in black box.
THAS1 possesses a very short loop2, HYS an intermediate length, and THAS2 a very long 
loop2 which covers the active site entrance. The crystal structures confirmed that a tyrosine is 
positioned in the active site in an equivalent position to the serine or threonine that is necessary 
for SAD or CAD enzymes to catalyse reduction of their substrate. 
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3.3.2 Steric course of hydrogen transfer
Strictosidine aglycon is present as a mixture of isomers in solution due to its reactive nature and 
inherent instability (see fig. 7 in Chapter 1). In solution the predominant species is cathenamine, 
as illustrated by collaborators, which is an enamine containing a double bond between C-20 and 
C-21. Enzymatic labelling of the products of these enzymes was the most reliable technique to 
identify which hydrogen is originating from the cofactor. 
Deuterium labelling with NADPD and subsequent characterisation of the enzymatic products 
showed that in all cases the hydride from NADPH is transferred to C-21 from the bottom face 
of the substrate to yield the product. Labelling studies using NADPD conducted by Stöckigt et 
al. (1980) and Stoeckigt et al. (1983) with crude protein extracts from C. roseus cell suspension 
cultures indicated that the hydride from the cofactor is transferred onto the α-position at C-21 
of the substrate, which is in agreement with the results obtained here. In their experiments, the 
workers used a crude enzyme preparation from an unpublished cell suspension line; therefore 
it is not possible to verify which heteroyohimbine synthases these authors were working with. 
It is also possible that the heteroyohimbine synthases described here were not expressed in the 
cell line that was used. 
This experiment illustrates that the substrate(s) must be oriented in the same manner in both 
THAS1 and HYS and therefore the enzymes must follow a similar catalytic mechanism. The 
increased AJM production of HYS cannot be explained simply as the substrate orienting itself 
differently in the active site. There is no reason to suspect that orientation in other HYSs would 
be any different to the results presented here for these two enzymes. 
In silico docking done using cathenamine and the holo crystal structure of THAS1 were consistent 
with the deuterium labelling experiments. The cathenamine was docked in the active site cavity 
in an orientation that brings the C-20-C-21 bond very close to the cofactor C-4 (which carries 
the hydride used in reduction). Furthermore, cathenamine was docked in an orientation which 
would result in the hydride being added on the bottom face of the substrate resulting in the same 
pattern observed with deuterium labelling. We assume that the cofactor reduces the iminium 
form of the substrate, which is formed by equilibration of cathenamine by addition of a proton 
to the C-20.
3.3.3 Effect of pH on product profile
The pH of a solution can of course have a large effect on the enzymatic reaction (as seen in 
Chapter 2, section 2.2.4). On the other hand, the pH could have an effect on the equilibration of 
strictosidine aglycon to the different isomer heteroyohimbines substrates. Stöckigt et al. (1977) 
chemically reduced strictosidine aglycon with NaBH4 in MeOH and demonstrated that the major 
isomer in solution is cathenamine which then gives rise to THA. These conditions did not lead to 
AJM or 19-EA, suggesting they are not favoured in the non-enzymatic reaction. When, instead, 
the workers reduced the strictosidine aglycon with a crude enzyme preparation from C. roseus 
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they found AJM and 19-EA being produced as well. They propose the synthesis of AJM and 
19-EA is entirely enzyme dependent, perhaps relying on an enzyme-driven isomerisation of 
cathenamine to 19-epicathenamine for generation of the correct stereocentre at C-19 for 19-EA. 
To investigate if the pH has an effect on the product profile of HYSs, THAS1 and HYS were tested 
on a small panel of buffers with different pH values. 
The results of the experiment indicated that in total greater amounts of heteroyohimbines 
can be produced at lower pH (fig. 64). Both the enzyme assays and the control reaction using 
the chemical reducing agent NaBH4 displayed an increase of heteroyohimbines which was pH 
dependent. The product profile of THAS1 and of the chemical reduction looked very similar, with 
predominantly THA being produced. Interestingly, HYS responded differently to the varying pH 
and produced an increasing amount of AJM at lower pH at the expense of THA. The pH at which 
this enzyme produced the maximum amount of AJM was pH 6.0. 
The absence of this effect in the chemical reduction of strictosidine aglycon suggests this increase 
in AJM is not due to a modification of the properties or equilibration of the substrates with the 
change in pH. Instead it suggests that the pH has a significant effect on the enzyme activity and 
allows HYS to carry out the reduction, or equilibration into pro-AJM iminium, more easily. 
3.3.4 Mutations to THAS1
A better understanding of the role of the active site amino acids in THAS1 is needed to propose 
a reduction mechanism for generation of heteroyohimbines. The crystal structures, as well as 
alignments to other characterised MDRs, indicated the likely active site of THAS1. The conserved 
Ser or Thr of most SADs and CADs was not present in the HYSs discovered from C. roseus, and 
instead were replaced by other, often hydrophobic, residues. In THAS1 the active site residue 
in this position is Tyr56. A serine is present in the active site of THAS1 but it is positioned on 
the opposite side of the active site compared to Tyr56 or the SAD and CAD serine or threonine 
catalytic residues. Another notable difference between the SAD/CADs and HYSs is the histidine 
in SAD/CAD that is coordinated to the cofactor ribose and responsible for the electron transfer 
during catalysis. This residue in HYSs is replaced by an acidic amino acid, such as glutamate in 
THAS1 and HYS and aspartate in THAS2. The entrance of the active site also has two hydrophobic 
residues in THAS1 (Phe65 and Phe67) which were intriguing given the hydrophobic nature of the 
substrate and the product. 
Mutating Tyr56 has some effect on THAS1 activity. Mutating it to Phe greatly reduces the activity 
and the stereoselectivity indicating that the hydroxyl group of Tyr could be implicated in the 
reduction mechanism. Introduction of Phe in the active site pocket, assuming the enzyme achieves 
correct folding and adopts the correct tertiary structure, would increase the hydrophobicity of 
the environment which could inhibit or modify the correct orientation of the substrate. Mutation 
of Tyr56 to Ala did not have the same effect on enzyme activity, perhaps due to the less disruptive 
size of Ala. Its small size would not increase the hydrophobicity of the active site as much as Phe 
would. By the same logic Y56T or Y56S would favour a more hydrophilic pocket, thus allowing the 
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substrate to orient and dock correctly, or allowing any water molecules necessary for activity to 
take up their ideal positions. The activity of these latter two mutants is relatively high, thereby 
confirming the important role of the hydroxyl group in the THAS1 active site. Mutating Tyr56 to 
Glu seems to have greatly reduced activity, most probably due to the introduction of a negative 
charge in the active site. This reduction in activity could also be because the α2 helix which 
carries both Tyr56 and Glu59 is not anchored in place (in fact it can move out of place in the 
absence of the cofactor as evidenced by the differences between the holo and apo structures) 
and the mutated residue could be competing with Glu59 for binding of the cofactor. 
Mutating THAS1 Glu59 (which is coordinating with the ribose OH groups of the cofactor, fig. 67) 
to alanine does not abolish activity, but decreases it and also causes the product profile to be 
less specific. This could be because the cofactor does not dock correctly into the structure when 
this is mutated to alanine. A residue further back on the helix, Asp55, might compensate, but in 
so doing this might have an effect on the general structure of the area. 
Mutating Ser102 (which lies on the right wall of the active site pocket) affects the activity slightly 
but does not affect stereoselectivity. Mutating Ser102 to Tyr surprisingly does not have a large 
effect on the enzyme; this could be due to the fact that there is enough space for such a large 
residue to swing out of the way of the active site cavity and not interfere with the reaction. 
Mutations to the loop1 phenylalanines had detrimental effects on protein stability; one mutant 
(Phe65 to valine) was not stable in solution and precipitated over the course of 3-4 hours. This 
residue is conserved in HYS and could be important for the stability of the loop1 section of these 
enzymes. 
Finally, Thr166 is a conserved residue in these HYSs, which is positioned at the bottom of the 
active site cavity. This residue seems ideally situated to coordinate a water molecule which could 
be the source for the proton needed during equilibration of cathenamine to the iminium forms. 
Mutations to this residue did affect the enzyme product profile slightly, but not enough to clearly 
distinguish the role of this amino acid in catalysis. Detailed kinetic studies would be needed to 
determine what its role is, but these are not feasible because of the two-enzyme system and the 
inherent instability and reactivity of strictosidine aglycon. 
Although all mutations to the THAS1 active site had some slight effect on the enzyme’s 
product profile and end-point conversion only Tyr56 appears to have a very significant effect. 
Therefore this residue is proposed to be taking part in the reduction of cathenamine to yield the 
heteroyohimbines as illustrated in figure 71.
3.3.5 Loop swaps between THAS1 and HYS 
Gaining or losing the ability to synthesise one diastereomer is a difficult matter in enzyme 
engineering. THAS1 and HYS presented an excellent opportunity to attempt to switch 
stereoselectivities of two enzymes. THAS1, which has a short loop2 over the active site cavity, 
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produces a simple product profile of primarily THA and only trace amounts of AJM and 19-
EA. HYS, however, is able to produce three heteroyohimbines. HYS and THAS1 are very similar 
enzymes (76.3% identity), but present a large difference in their loop2 sections. To test whether 
this loop could be the key to unlocking the potential of HYS to producing AJM and 19-EA, the loops 
were swapped between the two enzymes. Removal of the loop2 from HYS and its replacement 
with the loop2 of THAS1 resulted in a product profile resembling that of THAS. Unfortunately, 
replacing the short loops of THAS1 with the loop2 from HYS did not allow THAS1 to produce a 
product profile like that of HYS. Nevertheless, from these results it is apparent that the loop2 
section of HYS is promoting the functional promiscuity of HYS.
Point mutations to HYS loop2 were also carried out and tested enzymatically. HYS possesses one 
ionisable amino acid on the loop2, His127. This could be providing a proton during equilibration 
of cathenamine to the pro-AJM or pro-19-EA iminium. Mutating this amino acid, and the 
phenylalanine next to it, confirmed the results obtained with the loop swaps and demonstrated 
that His127 is necessary for HYS to produce AJM and 19-EA.
3.3.6 Reduction mechanism of HYSs
The results obtained with the mutational screening and the deuterium labelling, as well as the in 
silico docking of cathenamine, have allowed us to propose a reduction mechanism for generation 
of heteroyohimbines by C. roseus HYSs. Cathenamine, the most abundant strictosidine aglycon 
isomer present in solution, enters the active site and stacks above the nicotinamide ring with 
the indole moiety pointing outwards towards the solvent. The cathenamine equilibrates into the 
iminium form in one of two ways. The first leads to the pro-THA iminium by protonation of C-20 
from a water molecule to generate a tertiary carbon with S stereochemistry (fig. 77 top row). The 
second way to equilibration involves protonation of C-20 from the other face of the substrate from 
His127 to generate the tertiary carbon with R stereochemistry (fig. 77 bottom row). Depending 
on the orientation of the C-18 methyl group the substrate is either cathenamine (leading to 
AJM and THA) or 19-epicathenamine (leading to 19-EA and rauniticine). There is no evidence 
that any of the HYS produce rauniticine, therefore it is reasonable to hypothesise that these 
enzymes are not capable of protonating 19-epicathenamine from the bottom face. Whether or 
not cathenamine can equilibrate, through ring opening and re-closing, into 19-epicathenamine 
in the active site of the enzyme is still an open question. 
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Figure 77: Mechanism proposal for reduction and production of tetrahydroalstonine (top row) 
and ajmalicine (bottom row). NADPH is illustrated in red; water and the hydrogens originating 
from it are illustrated in blue; the loop2 histidine residue of HYS and the hydrogen originating 
from it are illustrated in green.
After the generation of the iminium with the appropriate stereochemistry at C-20, the two 
reduction mechanisms are carried out in the same manner (fig. 77). The pro-R-hydride from the 
cofactor attacks the C-21 from the bottom face to generate a secondary carbon. The transition 
state during movement of the electron pair onto the N-4 is stabilised by the partial charges 
network facilitate by the active site tyrosine. The product thus formed can exit the active site 
before the enzyme also dissociates with the cofactor.
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Figure 78: Mechanism of cinnamaldehyde reduction by AtCAD, redrawn from Youn et al. (2006). 
The substrate is illustrated in black; NADPH in red; enzyme residues in green; and Zn2+ and water 
molecule in blue. 
The mechanism proposed here for HYSs differs to the mechanism proposed for SAD and CAD 
enzymes during reduction of their aldehyde substrates. The mechanisms proposed for those 
enzymes rely on the presence of the “active site” zinc to activate the carbon-oxygen double bond 
of the substrate (fig. 78). Once the bond is activated the carbon atom can receive the NADPH 
hydride and the oxygen can abstract a proton from the active site threonine (or serine in PtSAD) 
(Youn et al., 2006, Bomati and Noel, 2005). Based on the orientation of the residues in the active 
sites of AtCAD and PtSAD the electron transfer during reduction is proposed to be shuttled to 
the solvent through the active site threonine (or serine in the case of PtSAD) and then onto the 
hydroxyl groups of the NADPH ribose, following transfer onto the active site histidine before 
being transferred to the neighbouring aspartate and finally onto a water molecule (fig. 78).
A major difference is the role of the “active site” zinc in HYSs. Chelation studies suggest that zinc 
is not essential for catalysis, and there may be no need for activation of the carbon-nitrogen 
bond as it is easily reduced. Although the “active site” zinc might not be necessary for catalysis 
in HYSs it could still be carrying out a structural role. The coordinating amino acids are conserved 
among all the HYS from C. roseus. Notably, zinc is absent from certain MDRs and are apparently 
not necessary for their activity. For example, the quinone oxidoreductase (QOR, PDB accession 
code: 1QOR) from E. coli has lost both the structural and the “active site” zinc (Edwards et al., 
1996). The “active site” zinc coordination sphere has been replaced by amino acids incapable of 
coordinating zinc (such as leucine and asparagine) and the loop section which is responsible for 
binding the structural zinc is entirely absent from the sequence. The need to boil THAS1 and HYS 
to successfully carry out a zinc detection assay suggests that the Zn2+ ions are very tightly bound 
to the protein and not easily accessed by other reagents. This raises the question of whether the 
structural zinc has a function in MDRs and could these MDRs evolve or be engineered to lose the 
zinc binding loop without compromising protein stability and function?
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3.4 Conclusions
Crystallisation of these heteroyohimbine synthases has facilitated the study of the mechanism 
of heteroyohimbine synthesis from strictosidine aglycon. Extensive mutagenesis and deuterium 
labelling has allowed the proposal of a catalytic mechanism. Some aspects of the mechanism are 
not entirely clear: for example how cathenamine and 19-epicathenamine equilibrate. However, 
not all mechanistic aspects could be investigated in this enzymatic system. 
These enzymes have revealed the potential of biosynthetic machinery to generate stereochemical 
variation. Even similar enzymes, such as THAS1 and HYS (76.3 % amino acid similarity), can 
display different stereoselectivity. Flexible loop regions can be the key to unlocking chemical 
diversity. As demonstrated here, mutating the extended loop2 over the HYS active site (fig. 68) 
impacts stereochemical outcome. The MDRs discovered from C. roseus show large variability in 
this section of their sequence. This active site loop of the MDRs could potentially be harnessed 
in protein engineering efforts to generate novel catalytic activity.
The existence of four (at least) redundant, and highly diverged, THAS enzymes in C. roseus 
indicates firstly that this branch of the pathway is relatively ancient and secondly that this reaction 
is possible with many different variations of the active site. Whether or not there is selective 
pressure to maintain or eliminate the promiscuous HYS enzyme remains to be determined. The 
function of the various heteroyohimbine stereoisomers in planta still remains cryptic.
The results detailed in the chapter have been published in Stavrinides et al. (2016).
3.5 Materials and Methods
3.5.1 Site directed mutagenesis of THAS1 and HYS
THAS1 mutants were generated by overlap extension PCR. Briefly, the codon to be mutated was 
selected and two primers, one reverse and one forward (table 10), were designed to overlap and 
introduce the mutation. Two PCR steps were necessary to create the mutations. A first PCR was 
carried out using the reverse mutant primer and the 5’ forward gene-specific primer (Chapter 
2 table 5), thus generating the 5’ half of the gene carrying the mutation. In parallel, the 3’ half 
of the mutated gene was generated by PCR using the forward mutant primer and the 3’ reverse 
gene-specific primer (Chapter 2 table 5). The PCR products were gel purified and used for the 
second PCR overlap reaction for generation of the full-length mutated gene. To do this the 5’ 
and 3’ halves of the mutated genes were mixed in a PCR reaction in equimolar amounts (approx. 
100 ng per fragment) and 5 cycles of PCR were carried out without including primers in order 
for the fragments to act as primers for each other. After 5 overlap PCR cycles the forward and 
reverse gene-specific primers were added to the mix and a further 30 cycles were performed 
using the annealing temperature for the primers. Full-length PCR products were gel purified, 
ligated into pOPINF expression vector and transformed into competent E. coli Stellar strain cells 
(Clontech Takara) as described in the Chapter 2 methods section. Due to repeated issues with 
101
generating the HYS point mutants, these were instead obtained as gene fragments (Integrated 
DNA Technologies, Belgium) with the H127 or F128 codons mutated (H127A CAT -> GCA; H127N 
CAT -> AAC; F128A TTT -> GCT; F128Y TTT -> TAC) and the pOPINF overhangs included at the 3’ 
and 5’ extremities. 
3.5.2 Loop swap mutants 
Loop swap forward and reverse primers were designed by removing the codons for the loop 
amino acids and substituting those for the loop of the other enzyme (table 10). First the loop1 
mutants were generated by overlap extension PCR following the same procedure detailed above 
for the point mutants and then the second loop2 swap was introduced. Mutant constructs were 
sequenced by Sanger sequencing to verify the mutant gene sequence and correct insertion.
Table 10: List of primer pairs for mutagenesis of THAS1 and HYS.








































F67V CAAGCTATCCTTATGTTTTAGGGC GCCCTAAAACATAAGGATAGCTTGTAACTCC 
AAATTTGTTTTTGC
THAS1 loop swaps










Mutant Forward primer Reverse primer








The mutated codons are underlined.
3.5.3 Expression of mutant THAS1 and HYS
The pOPINF vectors harbouring the gene constructs were transformed into SoluBL21 (DE3) E. coli 
cells. A starting culture was grown overnight at 37˚C in 50 or 100 mL of LB media supplemented 
with carbenicillin (100 μg/mL) and was then diluted 1:100 in 100mL 2xYT media supplemented 
with carbenicillin (100 μg/mL) and allowed to grow to an OD600 between 0.8 and 1 before 
induction with 0.1 IPTG. The cultures were grown at 18˚C for 16h with 200 rpm shaking. Cells 
were collected by centrifugation and resuspended in 6 mL Buffer A (50 mM Tris-HCl pH 8, 50 mM 
glycine, 500 mM NaCl, 5% glycerol, 20 mM imidazole) along with EDTA-free protease inhibitor 
(Roche Diagnostics Ltd.). Cells were lysed using sonication for 4 minutes on ice using 2 s pulses 
with a 5-minute pause after 2 minutes on ice. Cell debris was pelleted by centrifugation at 
17 x 1000 g and the supernatant was incubated for 1h at 4˚C with 200 μL of Ni-NTA agarose 
beads (Qiagen GmbH, Germany) pre-equilibrated with Buffer A. The total was centrifuged at 
1000rpm for 1minute to pellet the Ni-NTA agarose and the supernatant was discarded. The Ni-
NTA agarose was washed three times with 500 μL of Buffer A to remove non-specifically bound 
proteins, each time centrifuging for 1min at 1000 rpm to pellet the Ni-NTA agarose. Elution was 
done by washing the Ni-NTA with two volumes of 300 μL of Buffer B (50 mM Tris-HCl pH 8, 
50 mM glycine, 500 mM NaCl, 5% glycerol, 500 mM imidazole). The eluates were transferred 
to a Durapore centrifugal filter (PVDF 0.1 μm, Merck Millipore) to remove any residual Ni-NTA 
agarose. An aliquot of eluates was analysed by SDS-PAGE to verify the purity and the molecular 
weight of the purified proteins. Protein containing eluates were concentrated to approximately 
250 μL and buffer exchanged to Buffer C (50 mM Phosphate pH 7.6, 100 mM NaCl) in a 30 KDa 
membrane filter Millipore filter (Merck Millipore). Protein concentration was measured with 
Bradford reagent (Sigma-Aldrich) according to the manufacturer’s instructions. Purified proteins 
were aliquoted in 20 μL aliquots and fast-frozen in liquid nitrogen before being stored at -20˚C. 
3.5.4 SGD expression and purification
SGD expression and purification was done in large scale as described for THAS1 above using the 
expression system as described previously (Yerkes et al., 2008).
3.5.5 Expression and crystallisation of THAS1
Cultures of SoluBL21 E. coli expressing THAS1 (2L of 2xYT) were prepared as described above 
for small-scale purification. The cell pellet was resuspended in 50 mL of Buffer A and sonication 
Table 10 (cont.)
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was done as described above and the cell debris was pelleted by centrifugation at 17 x 1000 g 
for 20 min.  All large-scale purification steps were done at 4˚C on an ÄKTAxpress purifier (GE 
Healthcare). His-tagged THAS1 was purified using a HisTrap FF 5 mL column (GE Healthcare) 
equilibrated with Buffer A. The sample was loaded at a flow rate of 4 mL/min and step-eluted 
using Buffer B. Eluted protein was subjected to further purification on a Superdex Hiload 26/60 
S75 gel filtration column (GE Healthcare) at a flow rate of 3.2 mL/min using Buffer D (20 mM 
Hepes, pH 7.5 150 mM NaCl) and collected by a fractionator into 8 mL fractions. The fractions 
were analysed by SDS-PAGE and those containing no traces of other contaminating proteins were 
pooled and concentrated in a 10 KDa cutoff Millipore filter (Merck Millipore) and concentration 
was measured using a BCA assay (Thermo Fisher Scientific Inc, USA). A fraction of the purified 
THAS1 was subjected to His6-tag cleavage. Purified THAS1 was incubated overnight at 4 ˚C with 
3C protease. The sample was then incubated with 1 mL of pre-equilibrated Ni-NTA column and 
then the total mixture was filtered and the flow-through was checked visually on SDS-PAGE for 
purity.
Crystallization screens were set up with purified protein in sitting-drop vapor diffusion in MRC2 
96-well crystallization plates (Swissci) with a mixture of 0.3 µl well solution from the PEGs 
(Qiagen), PACT (Qiagen) and JCSG (Molecular Dimensions) suites and 0.3 µl protein solution. 
NADP+ (Sigma Aldrich) was added to a final concentration of 1 mM for co-crystallization studies. 
Solutions were dispensed by an OryxNano (Douglas Instruments). THAS1 NADP+ crystals were 
obtained from a solution containing 0.2 M potassium/sodium tartrate with 20% w/v PEG 3350, 
and THAS1 apo crystals were obtained from His6-tag cleaved THAS1 (3C protease) in a solution 
containing 0.1 M MES, pH 6.5, 15% w/v PEG 2000.
3.5.6 Expression and crystallisation of HYS
Protein for crystallisation was expressed and purified as detailed above, but with the addition 
of 1 mM DTT to all purification buffers. The His6-tag was cleaved as described above for THAS1. 
HYS was concentrated using a 30 KDa cutoff filter (Millipore) and was buffer exchanged into 
Buffer E (50 mM HEPES, pH 7.06, 150 mM NaCl, 10% (w/v) glycerol, 0.5 mM TCEP) for storage 
and crystallisation. 
Crystals were grown from a hanging drop containing an optimised condition (0.1 M MMT buffer, 
pH 5 and 15% PEG 3350). Purified HYS (10.75 mg/mL) was mixed in a 1:1 ratio with the precipitant 
and incubated at 19˚C for two weeks before harvesting of crystals. Crystals were cryo-protected 
with well solution containing 25% ethylene glycol for 1 minute and frozen in liquid nitrogen.
Seeding experiments were carried out using droplets containing crystals which were pipetted 
repeatedly to crush up the crystals and then diluted 1:30 in well solution and then briefly 
vortexing the sample. A 48-well plate was setup by mixing protein and seeding solution in a ratio 
of 3:1:2 with the precipitant. NADP+ was premixed with the protein for a final concentration of 
1 mM. To determine the best storage and buffer conditions for HYS a thermofluor assay was 
done at the SPC facility (EMBL, Hamburg, Germany). 
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3.5.7 Data collection
X-ray datasets were recorded on one of three beamlines at the Diamond Light Source 
(Oxfordshire, UK) (5FI3, I04; 5FI5, I03; 5H83, I04-1) at wavelengths of 0.9000-0.976 Å (5FI3, 0.900 
Å; 5FI5, 0.976 Å; 5H83, 0.920 Å) using either a Pilatus 6M or 2M detector (Dectris) with the 
crystals maintained at 100 K by a Cryojet cryocooler (Oxford Instruments). Diffraction data were 
integrated using XDS (Kabsch, 2010) and scaled and merged using AIMLESS (Evans, 2006) via 
the XIA2 expert system (Winter, 2010); data collection statistics are summarized in Stavrinides 
et al. (2016). Initially the THAS1 NADP+ dataset was automatically processed at the beamline by 
fast_dp45 to 1.12 Å resolution and a structure solution was automatically obtained by single 
wavelength anomalous dispersion phasing using the SHELX suite (Sheldrick, 2008) via the 
fast_ep pipeline (Winter, manuscript in preparation). Despite being collected at a wavelength 
somewhat remote from the zinc K X-ray absorption edge (theoretical wavelength 1.284 Å) the 
anomalous signal was sufficient for fast_ep to locate four zinc sites and calculate a very clear 
experimentally phased electron density map (fig. 52). This was available to view at the beamline 
in the ISPyB database (Delagenière et al., 2011) via the SynchWeb interface (Fisher et al., 2015) 
within a few minutes of completing the data collection. The map was of sufficient quality to 
enable 94% of the residues expected for a THAS1 homodimer to be automatically fitted using 
BUCCANEER (Cowtan, 2006). The model was finalised by manual rebuilding in COOT (Emsley et 
al., 2010) and restrained refinement using anisotropic thermal parameters in REFMAC5 (Winn 
et al., 2003) against the same dataset reprocessed to a resolution of 1.05 Å as described above, 
and contained 97% of the expected residues, with one NADP+ molecule and two zinc ions per 
subunit. All the remaining structures were solved by molecular replacement using PHASER 
(McCoy et al., 2007). In each case, the asymmetric unit corresponded to the biological dimer 
and the preliminary models were obtained by searching for two copies of a monomer template. 
For THAS1 apo and HYS apo a THAS1 NADP+ protein only monomer model was used as the basis 
for the template, although in the latter two cases a homology model of the target structure was 
generated from the THAS1 template using the Phyre2 server (Kelley et al., 2015) (http://www.
sbg.bio.ic.ac.uk/~phyre2) before running PHASER. In contrast to THAS1 NADP+, the THAS1 apo 
and HYS structures were refined in REFMAC5 with isotropic thermal parameters and TLS group 
definitions obtained from the TLS-MD server (Painter and Merritt, 2006). Model geometries 
were validated with the MOLPROBITY (Chen et al., 2010) tool before submission to the PDB. The 
statistics of the final models are summarized in Stavrinides et al. (2016) in Annex 2. Additional 
statistics for Rpim: 5FI3, 0.020 (0.517); 5FI5, 0.038 (0.600); 5H83, 0.068 (0.664) and CC½: 5FI3, 
0.999 (0.510); 5FI5, 0.999 (0.523); 5H83, 0.996 (0.510) (where values in parentheses are for 
highest-resolution shell) were also noted. Ramachandran statistics (favored/allowed/outlier 
(%)) are 5FI3, 96.8/3.2/0.0; 5FI5, 96.0/4.0/0.0; 5H83, 96.6/3.1/0.3. All structural figures were 
prepared using CCP4mg (McNicholas et al., 2011).
3.5.8 UPLC-MS and NMR analysis
UPLC-MS analysis was carried out on a UPLC (Waters) equipped with an Acquity BEH C18 1.7 μm 
2.1 x 50 mm column connected to Xevo TQS (Waters). For fast dereplication of active enzymes 
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and mutants, a linear gradient method (“fast method”) was used at a flow rate of 0.6 ml min-1 
using a binary solvent system in which solvent A1 was 0.1% formic acid in water and solvent 
B1 was acetonitrile. The gradient profile was: 0 min, 5% B1; from 0 to 3.5 min, linear gradient 
to 35% B1; from 3.5 to 3.75 min, linear gradient to 100% B1; from 3.75 to 4 min, wash at 100% 
B1; back to the initial conditions of 5% B1 and equilibration for 1 min before the next injection. 
Column temperature was held at 30 °C. The injection volume for both the solutions of standard 
compounds and the samples was 1 μl. Samples were kept at 10 °C during the analysis.
For separation of the different heteroyohimbines, a different chromatographic method was 
applied that was adapted from the work of Sun J. et al. (Sun et al., 2011). In this method (Method 
2) solvent A2 was 0.1% NH4OH and solvent B2 was 0.1% NH4OH in acetonitrile. A linear gradient 
from 0% to 65% B2 in 17.5 min was applied for separation of the compounds followed by an 
increase to 100% B2 at 18 min, a 2 min wash step and a re-equilibration at 0% B2 for 3 min before 
the next injection. The column was kept at 60 °C throughout the analysis and the flow rate was 
0.6 ml min-1.
MS detection was performed in positive ESI. Capillary voltage was 3.0 kV; the source was kept 
at 150 °C; desolvation temperature was 500 °C; cone gas flow, 50 L h-1 and desolvation gas 
flow, 800 L h-1. Unit resolution was applied to each quadrupole. Multiple Reactions Monitoring 
(MRM) signals were used for detection and quantification of the compounds of interest (details 
of conditions in table 11).
Table 11: Multiple Reactions Monitoring conditions
Molecule Parent ion Daughter ion Cone Voltage Collision Voltage
Strictosidine aglycon
351 170.22 28 22
351 144.16 28 24
Strictosidine
531 352.25 32 24
Heteroyohimbines
353 117.19 50 40
353 144.16 50 26
NMR spectra were acquired using a Bruker Advance NMR instrument operating at 400 MHz for 
1H equipped with a BBFO plus 5 mm probe. 
3.5.9 2H labelling experiments
Deuterated pro-R-NADPD was regenerated in solution by Thermoanaerobacter brockii alcohol 
dehydrogenase (50 units, Sigma) using 400 μM NADP+ and 1% v/v [2H6]-isopropanol (CIL). The 
NADPD regeneration was monitored by UV spectroscopy at 340 nm. Strictosidine (19.9 mg) 
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was incubated with 1.27 nM SGD in 94 ml of 50 mM phosphate buffer (pH 6.5). THAS1 enzyme 
was added to the reaction (final concentration of 1.65 μM) and the mixture was incubated at 
35 ˚C with shaking. The reaction was monitored for completeness by LC-MS and after 5 h no 
strictosidine or deglycosylated strictosidine was observed. The reaction was stopped by addition 
of 100 ml of methanol and reaction mixture was concentrated to dryness. The dried reaction 
mixture was resuspended in 15 ml H2O and extracted with 3 x 15 ml of ethyl acetate and the 
EtOAc fraction was dried. [21α-2H1]-THA was isolated by preparative TLC separation on a nano-
silica plate (Sigma-Aldrich), as described in Chapter 2. The band of [21α-2H1]-THA was excised 
from the plate, silica was crushed to powder and THA was extracted with EtOAc multiple times, 
(total volume 40 ml). The EtOAc fraction was filtered and dried using a high-vacuum pump 
overnight. The [21α-2H1]-THA was dissolved in 600 μl of CDCl3 and 
1H-NMR was measured.  
Strictosidine (39.3 mg) was incubated with 1 nM of SGD and 500 μM NADP+ with 50 units of T. 
brockii ADH and 1% v/v [2H6]-isopropanol in a total volume of 148 ml of 50 mM HEPES buffer 
(pH 7.5). HYS was added (final concentration 1.71 μM) and the reaction was incubated at 37 ˚C 
with shaking and monitored for completeness by LC-MS. After 6 h the reaction was complete 
and was stopped by addition of 150 ml of methanol. The reaction mixture was concentrated to 
dryness and then was resuspended in 50 ml H2O, basified with 2 ml triethylamine and extracted 
with 5 x 20 ml of ethyl acetate. [21α-2H1]-THA, [21α-2H1]-AJM and [21α-2H1]-19EA were isolated 
by preparative TLC and 1H-NMR spectra measured as described above. 1H-NMR spectra of 
deuterated compounds were compared with those of corresponding standards dissolved in the 
same solvent.
3.5.10 pH effect on product profile
Strictosidine was deglycosylated using purified SGD for 25 minutes at room temperature 
using assay conditions as described above. Strictosidine aglycon was then incubated at a final 
concentration of 300 μM at pH 5, 6, 7 and 8 in a buffer mix to avoid buffer ingredient effect on 
activity (50 mM Phosphate buffer, 50 mM citric acid, 50 mM HEPES, adjusted with NaOH or HCl). 
At time zero the enzyme, either THAS1 or HYS (1 μM final concentration), premixed with NADPH 
(500 μM) was added to the substrate solution. In parallel, a chemical reducing agent, NaBH4 
(3 mM final concentration), was added to deglycosylated strictosidine as a control reaction. All 
reactions were carried out in triplicate. An end-point sample (10 μl) was taken from each assay 
and prepared for UPLC-MS analysis by addition of 10 μl of 100% MeOH to stop the reaction, and 
then diluted 1 in 5 with H2O, and centrifuged for 10 minutes at 4000 rpm. UPLC-MS and data 
collection and quantification were performed as described above using the “separation method”.
3.5.11 CD spectra and analysis
Far ultraviolet (UV) CD spectra of the wild-type enzymes THAS1 and HYS, as well as the loop 
mutants of THAS1 and HYS were recorded on a Chirascan Plus spectropolarimeter (Applied 
Photophysics) at 20°C in 10 mM potassium phosphate buffer pH 7.0. Samples were analysed from 
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180 nm to 260 nm using a 0.5 nm step at a speed of 1 s per step. Four replicate measurements 
were performed on each sample and baseline correction was applied to all data. Spectra are 
presented as the CD absorption coefficient calculated on a mean residue ellipticity (MRE) basis.
Melting curves of HYS and the HYS loop2 swap mutant were also acquired by CD. The samples 
were subjected to temperature ramping at the rate of 1˚C min-1 from 20 ˚C to 90 ˚C. Data 
collection was done from 260 nm to 201 nm using a 1 nm step and 0.75 s time per point. Data 
were analysed using the Global 3 software. HYS melting point was measured as 61.0 ± 0.1 ˚C; 
enthalpy 351.5 ± 3.6 KJ/mol. HYS loop2 swap melting point was measured at 62.0 ± 0.1 ˚C; 
enthalpy 535.8 ± 4.5 KJ/mol.
3.5.12 Docking of cathenamine in THAS1 holo structure
Cathenamine was docked into the THAS1-NADP+ crystal structure using Autodock 4.2 (Morris, 
2009). The ligand (cathenamine) was prepared with 2 torsions at the C16, the rest of the molecule 
being rigid, and the receptor consisted of the desolvated high-resolution crystal structure. The 
search space was defined by a 40x40x40 Å box with a 0.375 Å grid spacing, centred between the 
nicotinamide ring and the side chain of Tyr56, and encompassed the entire active site cavity. 
Searches were performed using the Lamarckian Genetic Algorithm, consisting of 100 runs with 
a population size of 150 and 2,500,000 energy evaluations. A total of 27,000 generations were 
analysed and clustered with an RMS tolerance of 2 Å per cluster. Results were visualised using 
the Autodock 4.2 user interface. 
3.5.13 Testing of Zinc-apo THAS1 and HYS 
Zinc was removed from THAS and HYS by dialysis against EDTA for 24h at 4˚C following a published 
protocol (Hoagstrom et al., 1969). EDTA was removed by overnight dialysis at 4˚C using the same 
buffer without the addition of EDTA. THAS1 had heavy precipitate following the second dialysis 
and only the soluble fraction was used for subsequent assays. Protein aliquots were analysed by 
SDS-PAGE to verify that there was no degradation. The activity against deglycosylated strictosidine 
and the product profile was determined using the same conditions detailed in enzyme reaction 
testing. 
Zinc removal was verified by following the manufacturer’s instructions using the Zinc analysis 
kit (Sigma Aldrich). Boiling for 10 min was necessary to denature the proteins in order for the 
reagent to access the zinc.
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Discovery and characterisation of a Short-Chain Dehydrogenase/Reductase 
capable of reducing strictosidine aglycon
4.1 Introduction
4.1.1 Short-chain Dehydrogenase/Reductase family
The Short Chain Dehydrogenase/Reductase (SDR) family is a member of the Alcohol 
Dehydrogenase Superfamily, like the MDRs described in Chapters 2 and 3. These enzymes, as 
their name suggests, are usually shorter in length than the MDRs (Jörnvall et al., 1999) but, 
just like the MDRs, they have a Rossmann fold for NAD(P) binding. This enzyme family is of very 
old origin, and it is found throughout the kingdoms of life, even in viruses (Jörnvall et al., 1999, 
Kavanagh et al., 2008, Jörnvall et al., 2010), and are found in large numbers in plants (Moummou 
et al., 2012). In fact SDRs are thought to be the progenitors of the MDRs as they typically display 
earlier diversification than the MDRs (Strommer, 2011). The active site is characterised by a 
conserved catalytic tyrosine, which is usually accompanied by a lysine to give the conserved 
motif YxxxK (Jörnvall et al., 1995). The first characterised SDRs from plants were the tropinone 
reductases I and II from Datura stramonium (Portsteffen et al., 1992). 
4.1.2 SDRs in C. roseus 
The terpene moiety in the MIA pathway of C. roseus is cyclised and modified to yield secologanin, 
which is used to produce strictosidine. During the biosynthesis of secologanin, 10-oxogeranial 
undergoes a reductive cyclisation to yield nepetalactol and the enzyme responsible for the 
cyclisation is not a terpene synthase as would normally be expected, but instead is a member 
of the SDR family (Iridoid Synthase, ISY, Geu-Flores et al. (2012)). This enzyme is similar to the 
progesterone-5β-reductases which reduce the carbon-carbon double bond of progesterone 
(Gavidia et al., 2007)(fig. 79). C. roseus contains 5 ISY homologs, three of which have also been 
shown to reduce the ISY substrate, 10-oxogeranial (Munkert et al., 2015). It was demonstrated 
that many members of the progesterone-5β-reductase family have the ability to reduce and 
cyclise 10-oxogeranial even though the plants they are found in do not produce iridoids (Munkert 
et al., 2015). 
Figure 79: Reactions catalysed by Iridoid synthase and Progesterone-5β-reductase.
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The identification of one SDR that catalyses a critical step in MIA biosynthesis in C. roseus suggests 
there may be other SDRs participating in the pathway. Just as there are multiple MDRs in C. roseus 
which catalyse reactions in MIA biosynthesis (10HGO, HYSs, T3R) there may also be more than 
one SDR involved in this pathway. To investigate this hypothesis, gene candidates that were co-
regulated with known MIA biosynthetic genes were selected for screening in in vitro biochemical 
assays with various pathway intermediates as substrates. One candidate, Cro013448, was tested 
against 10-oxogeranial and was shown to have low activity against this substrate (the activity was 
not detectable by TLC whereas the activity of other candidates was detectable by TLC (Glenn, 
2013)). This SDR enzyme is not a member of the progesterone-5β-reductase family and was 
therefore intriguing. The low activity against this 10-oxogeranial terpene moiety indicated it is 
probably not its native substrate. This enzyme was tested against deglycosylated strictosidine, 
which is the central intermediate of the MIA pathway, and showed high activity, producing a 
molecule of unknown structure, which did not correspond to any MIA present in C. roseus leaf 
extracts. This chapter details the characterisation of this enzyme and its product and attempts 
to explain its role in the plant. 
4.2 Results
4.2.1 ADH10 cloning
As part of a screen to explore the activity of highly MeJa-upregulated reductases against the 
central MIA biosynthetic intermediate, strictosidine aglycon, the C. roseus transcriptome was 
searched for SDRs with high expression in MeJa-treated tissues. The gene coding for ADH10 was 
found to be relatively highly expressed in the C. roseus tissues analysed (fig. 80). It is located on 
a large whole genome contig (WGC), along with eight other SDRs or SDR fragments (Cr030915, 
Cr022958, Cr022957, Cr030568, Cr003140, Cr016747, Cr016749, Cr013447, and ADH10 
Cr013448). Interestingly there are multiple predicted cytochrome P450s from various families 
on this same contig (Cr028046, Cr023307, Cr013485, Cr003361, Cr016728, and Cr016743) as 
well as two 2-oxoglutarate and Fe(II)-dependent oxygenase superfamily proteins (Cr019418 and 
Cr027425), an alpha-beta hydrolase superfamily protein (Cr010307), and an SAM-dependent 
methyltransferase superfamily protein (Cr016723). 
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Figure 80: Expression profile of ADH10 (in red) and other ADH’s on the same whole genome contig 
(WGC 27). In blue is illustrated the expression profile of Cr003140, another highly expressed SDR 
found on the same contig.
ADH10 appears to be very highly expressed in MeJa-induced seedlings (>100 fpkm) and has a 
higher expression in roots and stem than it does in leaves or flowers. The SDR that is next to it on 
the genome has a very low expression in all tissues (maximum 9.7 fpkm in the stem).  All other 
SDRs on this contig have low expression except one, Cr003140, which has an expression profile 
considerably different to that of ADH10. 
The ADH10 gene cloned from cDNA differed from that predicted for transcript Cr013448. The 
predicted protein consisted of 312 amino acids whereas the ORF cloned from cDNA coded for 
299 amino acids. There were some discrepancies in the amino acid sequence of the predicted 
protein sequences (fig. 81). This resulted in an amino acid identity of only 80 %. It is not clear 
if these differences are due to problems with the assembly or because a different cultivar of C. 
roseus was used for cloning.
Figure 81: Alignment of predicted protein sequence of Cro013448 and the amino acid sequence 
of ADH10. Sequence 1: Cro013448; 2: ADH10.
4.2.2 Heterologous expression
ADH10 was expressed as a His6-tagged fusion protein in E. coli. Expression was tested for ADH10 
at various expression temperatures and also with various IPTG concentrations (fig. 82). After 
expression, the cells were lysed using the BugBuster kit and the soluble fraction was analysed by 
SDS-PAGE and visualised by staining with Coomasie Blue. The results indicate that expression of 
ADH10 is higher at 37 ˚C and very low at 10 ˚C. The concentration of IPTG used does not appear 
to have any significant effect.
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Figure 82: SDS-PAGE gel of expression trial of ADH10 with different temperatures and IPTG 
concentrations stained with Coomasie Blue. SoluBL21 E. coli cells harbouring ADH10 are induced 
with various concentrations of IPTG (0.1 to 1 mM) and allowed to express the protein at different 
temperatures (18: lanes 2-4, 10: lanes 5-7, and 37 ˚C: lanes 8-9). Lane one contains a protein 
molecular marker.
Large scale expression was done at 37 ˚C as that condition appeared to produce relatively high 
levels of protein. After purification by nickel column followed by gel filtration the protein was 
relatively pure (fig. 83). This was stored in Buffer D supplemented with the reducing agent TCEP 
and was used both for protein crystallisation and enzymatic assays. 
Figure 83: SDS-PAGE gel of ADH10 large-scale purification. Lane 1: Protein molecular marker; 
lanes 2-10: elution fractions after 2D purification by His-trap and gel-filtration of ADH10 
expressed in E. coli. 
4.2.3 pH assay with ADH10 
ADH10 reactions with strictosidine aglycon were carried out at different pH values to test the 
effect of the pH on the reaction. Strictosidine was deglycosylated in situ and then the cofactor, 
NADPH, and an aliquot of ADH10 was added to the reaction. A small panel of different buffers 
was used to test the activity of ADH10 by LC-MS. The reaction was sampled at 1 minute and 
10 minutes (table 12). The results of this assay suggest a larger quantity of product is formed 
when using citrate buffer at pH 6.0. All assays above pH 6.0 performed worse than all assays below 
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pH 6.0 in this endpoint assay, suggesting a lower pH is conductive for more product formation. 
As with the HYSs it is unclear if the increased product formation at low pH is due to the enzyme 
becoming more active or due to the increase in product equilibration into the isomer available 
for reduction by the enzyme, as described in Chapter 3. 
Table 12: ADH10 product formed in different pH buffers in endpoint assays. The highest 
performance was recorded in Citrate pH 6.0 buffer, highlighted in red. 
Peak response area
Buffer used 1 min 10 min
Phosphate pH 5.0 300048 546515
MES pH 5.5 213559 425088
Phosphate pH 6.0 251409 540379
Citrate pH 6.0 391654 651093
MES pH 6.5 178430 410661
Phosphate pH 7.0 111245 329108
Phosphate pH 8.0 52270 144047
HEPES pH 8.0 39150 131662
4.2.4 Kinetic studies of ADH10 with strictosidine aglycon
Spectrophotometric assays using a strictosidine concentration above 100 μM is not feasible 
as strictosidine aglycon is insoluble in water and forms precipitates which interfere with the 
absorbance reading. Therefore ADH10 could not be tested with starting concentrations of 
strictosidine above 100 μM. The initial velocity was highest at a substrate concentration of 100 
μM and decreased with the lower concentrations tested (fig. 84, A). As with many enzymes 
that use the reactive strictosidine aglycon as a substrate, large fluctuation and variability was 
observed during these assays and therefore no concrete conclusions were drawn from these 
experiments and results in triplicate are not reported. ADH10 (50 nM) was also tested at different 
pH values (6.0 to 7.5) with 100 μM of substrate (fig. 84, B). The results resembled those obtained 
when product formed was monitored by LC-MS (table 12) with the assay at pH 6.0 performing 
better than the reactions at higher pH.
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Figure 84: Activity assay of ADH10 with strictosidine aglycon. Consumption of NADPH was 
followed spectrophotometrically at 340 nm at four different concentrations of strictosidine. A: 
activity of ADH10 at different concentrations of substrate; B: activity of ADH10 at different pH 
with 100 μM substrate.
4.2.5 High resolution Mass-spectrometry and fragmentation
The LC-MS chromatogram of the enzymatic product did not correspond to authentic standards 
of any available MIAs. The purified reaction product was initially analysed by high-resolution MS 
to determine its exact mass and molecular formula (fig. 85). It was determined the product had 
a mass of 371.1967 m/z. This mass is very close (0.5 ppm error) to the calculated mass of 353 + 
H2O (371.1965 m/z). The fragmentation pattern of the 371 product indicated that it is an indole 
with the classic 144 fragment observed for other indole alkaloids (Sagi et al., 2015). The other 
abundant fragments are 353, and 342. The removal of hydroxyl group as water is responsible 
for the fragmentation into 353. The 342 fragment could potentially arise from the loss of a CH2O 
functional group.
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Figure 85: High-resolution MS-MS of the ADH10 product. The fragmentation of the product 
produces the fragments 353, 342, 324, and 144.
4.2.6 NMR characterisation of the ADH10 product
A large-scale reaction and NMR characterisation was necessary for determining the structure 
of the ADH10 product. Purification was carried out by TLC as opposed to preparative HPLC 
chromatography because the product was discovered to be unstable in the acidic chromatography 
conditions used in HPLC. The product mixture purified from the reaction presented multiple 
bands when analysed on TLC (fig. 86). The largest bands were initially tested using MS to 
determine which was the major product observed in the enzyme assays. It was found that the 
uppermost band (most hydrophobic) corresponded to the ADH10 product based on elution 
time and fragmentation pattern. Although there were some contaminants they were very low in 
concentration and therefore it was not necessary to further purify the product.
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Figure 86: Large-scale purification of ADH10 product. The EtOAc-soluble compounds were 
spotted on the left and the MeOH-soluble compounds were spotted on the right. An old sample 
of purified ADH10 product which had degraded was also ran for comparison. 
Figure 87: 1H-NMR of ADH10 product. Peaks determined to be due to contaminants are shaded 
teal. Numbering is done following strictosidine and vallesiachotamine numbering. 18-CH3 (at 
1.36 ppm) is not included in this figure. The ring D is indicated on the proposed chemical structure.
The ADH10 product was dissolved in CDCl3 and analysed exhaustively by different NMR methods 
including 1H-NMR (fig. 87), COSY, HMBC (fig. 92), H2BC, and ROESY (fig. 88). The combination of 
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these measurements allowed the assignment of the hydrogens to the corresponding carbons 
and also the assignment of the stereochemistry at all the carbons. Correlations between carbons 
and hydrogens are illustrated in figures 90 and 91. 
Figure 88: ROESY spectra of ADH10 product. The H-21 is picked out and the correlations with 18-
CH3 and the two H-5 are illustrated in dotted line. 
ROESY is able to detect correlations in space up to 5 Å of distance. Interestingly, the ROESY 
indicates that the conformation of the ADH10 product brings the H-21 into proximity with the 
C-5 hydrogens. Therefore the C-18-19-20-21 group must be positioned below the ring D of the 
molecule. This is reminiscent of the proposed orientation of the predominant conformation of 
deformyl-E-geissoschizine in which the two H-16 are in close spatial proximity to the Hβ-6 (Jokela 
et al., 1993) (fig. 89) and therefore there is precedence for such a correlation between distantly 
connected hydrogens. 
120
Figure 89: Deformyl-E-geissoschizine conformation. 6-C hydrogens are illustrated in blue and the 
16-C hydrogens are in red. The electron doublet of N-4 is also illustrated.
Figure 90: Correlations between carbons and hydrogens of the ADH10 product, as measured by 
NMR in CDCl3.
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Figure 91: HMBC correlations between carbons and hydrogens of the ADH10 product, as 
measured by NMR in CDCl3.
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Figure 92: HMBC of ADH10 product. Display is only of the aromatic region, including H-21. The 
satellite peaks of carbons are illustrated in grey for clarity. The carbons with correlations to the 
hydrogens are each coloured differently.
Correlations between the indole moiety and the remainder of the molecule were apparent 
through the C-2 and the C-7. By decreasing the contour level in the HMBC we observe a cross-
peak between H-21 and C-2 which is also correlated with the NH, thus confirming the two parts 
of the molecule are connected through the C-2 and C-7 (fig. 92).
Overall the correlations for this product suggest a structure that is similar to the natural MIA 
products vallesiachotamine and antirhine (fig. 93). Vallesiachotamine differs from the ADH10 
product at the C-21 and C-19 positions; C-21 of vallesiachotamine has an aldehyde and has a 
vinyl function at position C-19. Furthermore, vallesiachotamine is oxidised at the C-17-C-16 bond 
whereas the ADH10 product is reduced. Antirhine, although it is reduced, lacks the COOCH3 
function on C-16. The ADH10 product is  α-β unsaturated at position C-20-C-19 and has a hydroxyl on 
C-19. The ADH10 product was given the name 19,21-dihydro-17-dehydrovallesiachotamine, and 
the trivial name vitrosamine. Neither vallesiachotamine or antirhine are available commercially 
to compare spectra. As mentioned earlier the product does not seem to correspond to any 
product found in C. roseus leaf extracts, and has not been reported to have been isolated from 
any C. roseus tissue. The ADH10 product may be further derivatised by other enzymes, which is 
why it is not observable in C. roseus. 
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Figure 93: Vallesiachotamine
4.2.7 Results of deuterium labelling
Given the product structure it was apparent there were multiple bonds which could have been 
reduced by the action of ADH10. To pinpoint which bond was reduced, deuterium labelling was 
carried out using pro-S deuterium labelled NADPD. ADH10 is a member of the SDR family of ADHs; 
these typically transfer the pro-S hydride of the cofactor. The ADH10 product generated with this 
labelled cofactor was determined by LC-MS to have a mass of 372 (m/z) which corresponds 
to one hydrogen atom being replaced by a deuterium atom. This excludes the possibility that 
ADH10 could be performing a second reaction on the substrate by reducing an aldehyde moiety 
to produce a hydroxyl. The 1H-NMR analysis indicated that the H-17β (3.55) had disappeared 
and the J coupling constants of H-17α (10.9) shifted to 7.1 (fig. 94). COSY analysis of the product 
showed only a cross peak at 4.11 and the cross peak at 3.55 was missing. Taken together these 
data indicate that the cofactor hydride is added to the C-17 at the β position (above the ring D).
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Figure 94: NMR spectra of deuterated ADH10 product (top) compared to non-deuterated ADH10 
product (bottom). Signal from contaminants is coloured grey. 
4.2.8 Crystallisation
Crystallisation of the enzyme was attempted using commercially available screens and also 
with optimised solutions. ADH10 produced crystals overnight in certain conditions of the JCSG+ 
suite. These first hits were collected and analysed at the Diamond Light Source Synchrotron but 
unfortunately none diffracted to good resolution (below 2.5 Å). Therefore optimisation screens 
were setup with sitting drop in MRC 2-drop 96-well plates (fig. 95-97). Various conditions were 
tested and constituents of those conditions are detailed in table 13. It appears PEG is necessary 
for ADH10 crystallisation as well as a slightly acidic pH.
Table 13: Crystallisation hit conditions used in optimisation screens 
Condition Buffer pH Salt Precipitant
1 0.1 M MMT 4.0 - 25% PEG 1500
2 0.1 M MES 6.5 - 25% PEG 8000
3 0.1 M Bis-tris 5.5 0.1 M MgCl2 25% PEG 3350
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PEG % PEG 400 PEG 1500 PEG 3350 PEG 1500 PEG 3350 PEG 8000
30% a + a  +  H




0.1 M MMT buffer pH 4.0 0.1 M MES buffer pH 6.5
Figure 95: Optimisation screen using condition 1 and 2 from table 13. Columns containing drops 
with apo or NADP+ protein are indicated in gray. Columns containing drops with apo or NADPH 
protein are indicated in white. The PEG used in each column is indicated above the columns and 
the percentage of that PEG is indicated at the left of the figure. The buffer content is indicated 
below the column at the bottom of the figure. a : crystals in apo drops; + : crystals in NADP⁺-
containing drops; H : crystals in NADPH-containing drops.
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Figure 96: First crystallisation optimisation screen using condition 3 from table 13. Rows shaded 
in gray and pink contain 0.1 M and 0.2 M MgCl2 respectively. PEG 3350 is used throughout the 
screen. a : crystals in apo drops.
pH 5.5 8.5 PEG%
20
a 23.3
a  H a  H a  H a  H  H a 26.5
a a a a a a a a 30
Figure 97: Second crystallisation optimisation screen using condition 3 from table 13. A pH 
gradient was generated by mixing 1 M Bis-tris at pH 5.5 with 1 M Bis-tris propane at pH 8.5 in 
different amounts for a final concentration of 0.1 M buffer. Each well contained 0.2 M MgCl2 and 
PEG 3350 at different concentrations. a : crystals in apo drops; H : crystals in NADPH-containing 
drops. The wells shaded in gray contained showers of microcrystals. 
The highest resolution crystal was obtained from the MMT buffer optimised screen (table 13) 
in 0.1 M MMT with 24 % PEG 3350 (fig. 95). Unfortunately, the crystals that appeared in the 
NADPH-containing drops were very fragile and appeared to deflate when touched with a loop. 
The few crystals that were successfully mounted did not diffract to high resolution and were 
not analysed further. Interestingly, the apo crystals which diffracted were found to have a high 
occupancy of NADP⁺. This indicates that ADH10 is purified from E. coli already bound to NADP+ or 
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NADPH. For this reason, and because of the low resolution obtained with true apo crystals, the 
effort to produce better resolution apo crystals was abandoned. 
4.2.9 Crystal structure of ADH10
ADH10 is not a metalloenzyme and it was not soaked with heavy metals, therefore molecular 
replacement was used to phase the crystal structure. When submitted to Swiss Model (Arnold 
et al., 2006, Guex et al., 2009, Kiefer et al., 2009) the closest match is the opium poppy enzyme 
Salutaridine reductase (PsSalR, fig. 98, Higashi et al. (2011)). PsSalR has only 53.2 % identity with 
ADH10 and therefore it is not an ideal model for this enzyme. However, at the time of dataset 
collection all other characterised and crystallised proteins had lower similarity to ADH10.
Figure 98: PsSalR reduction reaction on salutaridine.
ADH10 crystallised as a globular dimer in the asymmetric unit. In solution ADH10 is present 
as a monomer (determined during gel filtration purification for crystallisation, results not 
shown). The structure is characterised by a core of seven parallel β-sheets framed on either 
side by α-helices. The active site cavities face each other and are framed by the flexible loop 
extending over the active site, here called “lid”. This lid extends from residue 100 to residue 128 
(100-VITDVEAVKKLNPAEDPADVDFSKIYKET-128) and is largely disordered in the crystal structure 
(fig. 99). The electron density in the lid area is too diffuse for accurate model building of the lid 
in this crystal structure. A lid reconstruction was attempted to coax more information from the 
data but extra density was not recovered after subsequent refinement using Refmac. Therefore, 
the lid section was truncated to the last residues which presented sufficient electron density 
(Val104 and Ala117). A version of the protein with the maximum amount of residues built into 
the density is used for illustration purposes here. The lid appears to wrap itself around the lid 
of the other monomer of ADH10 in the asymmetric unit in a head-to-head orientation (fig. 99). 
This brings the two active sites in proximity, across from each other (distance between the two 
NADP⁺ C4 is 17.2 Å).
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Figure 99: Overview of crystal structure of ADH10. Chain A is displayed in light blue and teal, 
chain B is displayed in gold and coral (body of the enzyme and lid, respectively). A and C: front 
view of the two chains in ribbon representation and space-filling respectively; B and D: top view 
of the two chains in ribbon representation and space-filling respectively. The NADP⁺ is visible as 
cylinders with green bonds in the ribbon representations.
An extensive network of amino acid side chains and backbone amides holds the cofactor in 
place in the enzyme active site (fig. 100). The residues Ile20, Val68, Asn94, and Ala254 interact 
either with the carbonyl oxygen and/or nitrogen on the protein backbone. There are also a large 
number of water molecules coordinated to the cofactor and to the residue network holding the 
cofactor in place (fig. 101). The predicted active site residues, Tyr223 and Lys227, coordinate the 
ribose hydroxyls of the cofactor through hydrogen bonding. These residues are predicted to be 
part of the classic SDR catalytic triad Ser-Tyr-Lys (Filling et al., 2002, Jörnvall et al., 1995).
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Figure 100: Electron density in the active site of ADH10. A: electron density around the cofactor, 
contoured at 0.55 Å of distance, the loop which lies over the cofactor is indicated; B: electron 
density around the water molecules within 2.5 Å of the cofactor, the water molecule coordinated 
to the active site tyrosine is indicated. 
129
Figure 101: Network of ADH10 residues holding the NADP(H) cofactor in place. The image 
is calculated using Poseview (Stierand and Rarey, 2010). The active site residues Tyr223 and 
Lys227 also interact with the cofactor ribose moiety (bottom left). Hydrophobic interactions are 
illustrated as green lines; hydrogen bonds are illustrated as dashed black lines. 
The active site appears to be easily accessible to the bulk solvent but appears to be largely 
hydrophobic as evidenced by the electrostatic potential map of the proteins' surface (fig. 102). 
This hydrophobic nature of the active site could be assisting the correct orientation of the 
substrate in preparation for catalysis. The aglycon substrate iminium would likely occupy the 
space occupied by the Tyr23-coordinated water molecule. 
130
Figure 102: Electrostatic potential map of the surface of ADH10. The NADP⁺ is illustrated as 
cylinders with green carbons and the Tyr223-coordinated water molecule is illustrated as a red 
sphere. The active site cavity is indicated by a red line.
4.2.10 Comparison to Salutaridine Reductase
One of the top hits when subjecting the ADH10 amino acid sequence to SwissModel (Kiefer et al., 
2009) is the BIA biosynthetic enzyme PsSalR (Higashi et al., 2011). The other two top hits are the 
recently published crystal structures of menthone neomenthol reductase and isopiperitenone 
reductase (MMR and IPR, described in Chapter 1) from Mentha piperita (Lygidakis et al., 
2016), but these enzymes act on a smaller, non-alkaloid,  substrate. Furthermore, MMR is not 
stereoselective for one product, which is different to both ADH10 and PsSalR which are both 
stereoselective, and IPR does not have a classic catalytic triad, it instead has a glutamate in place 
of the tyrosine. For these reasons the ADH10 crystal structure and active site are compared here 
to PsSalR. Pairwise sequence alignment of ADH10 and PsSalR protein sequences were done with 
ClustalW in Geneious v8 using a BLOSUM matrix. The two proteins share 53.2 % identity and the 
identity is spread out over the entire sequence (fig. 103). 
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Figure 103: Alignment of ADH10 and PsSalR with secondary structures annotated. Sequence 
numbering is based on ADH10. Identical sites are illustrated in red and similar sites in yellow. 
The secondary structure is shown as arrows for the β-sheets and as helices for the α-helices. 
A disulphide bond in PsSalR is shown by a green ‘1’. The lid sections do not share very many 
similarities (residue 100 to 128 in ADH10). 
An alignment of the ADH10 crystal structure and of PsSalR (PDB accession code: 3O26, Higashi 
et al. (2011)) from opium poppy (Papaver somniferum) was carried out in PyMol (v 1.1, DeLano 
Scientific LLC). The two structures are globally very similar with an overall RMSD of 0.618 Å (221 
residues aligned). The main differences were found in the lid sections of the two proteins (fig. 
104): in PsSalR the lid is mainly composed of α-helices and folds over the active site, whereas in 
ADH10 it appears disordered and interacts with the other monomer lid. PsSalR was crystallised 
as a monomer and therefore the lid is not interacting with another monomer. The lid of PsSalR 
has adopted a helical structure which folds over the active site (fig. 104, panel A). Given the high 
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structural similarity of ADH10 and PsSalR the lid of ADH10 could also adopt a helical conformation 
when in monomer form, similar to that seen in PsSalR. 
The catalytic triad (Ser-Tyr-Lys) is positioned in nearly identical orientation in PsSalR and in 
ADH10. Therefore the substrate specificity must arise from the substrate binding in the active 
site. Amino acids which are different in ADH10 compared to PsSalR are Asn98 (Ala102 in PsSalR), 
Met169 (PsSalR: Thr182), Phe253 (PsSalR: Leu266), and Leu258 (PsSalR: Met271) (fig. 104). The 
water molecule coordinated to the active site tyrosine is present in both structures at the same 
location. As in PsSalR ADH10 has a loop which lies over the cofactor in the active site (265-279 
in PsSalR, 252-266 in ADH10, fig. 104, panel A). This loop in fact carries both the Phe253 and the 
Leu258 of ADH10 which are Leu and Met in PsSalR. 
Interestingly, the cofactor is quite buried in both these proteins, as evidenced by the space-filling 
model (fig. 104, panels C and D). As suggested by Higashi et al. (2011), the mobility of the lid 
could be for easy loading and release of the cofactor during catalysis. Concerted conformational 
changes could be responsible for the binding and release of the cofactor and those would involve 
movement of the lid and also the loop section. 
Figure 104: Comparison of SalR and ADH10 superimposed crystal structures. ADH10 is illustrated 
in light gray and SalR is illustrated in gold in all panels. A: general overview of crystal structures, 
NADP⁺ is visible in the active site cleft; B: catalytic triad in the enzymes active sites illustrated 
as cylidners; C: ADH10 active site with catalytic triad (Ser167, Tyr223, and Lys227) and amino 
aicds which differ (Asn98, Met169, Phe253, and Leu258) illustrated as cylinders; D: PsSalR active 
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site with catalytic triad (Ser180, Tyr236, and Lys240) and different amino acids (Ala102, Thr182, 
Leu226, and Met271) illustrated as cylinders.
4.2.11 Mutations to ADH10 active site
Mutations to PsSalR Met271 and Asn272 had a detrimental effect to the activity of PsSalR. 
Mutations to Leu266 had an effect on the Km of the enzyme but not so much on the kcat, and 
mutations to Thr182 did not have a strong effect (Higashi et al., 2011). 
To explore the mechanism of action of ADH10, mutations were also made in this protein. The 
amino acids Lys227, Ser167, and Tyr223 are positioned in the active site near the nicotinamide 
ring of the cofactor (fig. 104, panel B). Each amino acid was mutated to an alanine to probe its 
role in the catalysis of reduction. Each mutant was expressed as a His6-tag fusion in E. coli and 
purified by Ni-NTA column. Expression was at similar levels for all mutants, and similar to the 
expression achieved when expressing the WT enzyme (fig. 105). 
Figure 105: SDS-PAGE analysis of ADH10 mutants expression. Lane 1: Molecular marker; 2: 
ADH10 K227A; 3: ADH10 S167A; 4: ADH10 Y223A.
Assays conducted with the mutant ADH10 indicate that Tyr223 is necessary for catalysis. When 
mutated to alanine the major product (371 and 353) is not produced but the minor product 
at m/z 353 is still produced (fig. 106). This is typical for SDR enzymes (Jörnvall et al., 1995). 
Mutation to the other active site amino acids Lys227 and Ser167 did not have a dramatic impact 
on the product profile, although they both qualitatively reduced the enzyme activity based on 
endpoint assays. Both mutants were functional and a product of mass 371 and also of 353 was 
detected at the expected retention time (fig. 106).
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Figure 106: LC-MS trace of ADH10 and its mutants. Y223A (orange), WT (red), S167A (blue), 
K227A (green).
Analysis of the enzyme assays using a longer LC-MS method was carried out to determine 
the nature of the reaction by-products. The chromatograms were compared to an enzymatic 
reaction performed with HYS in the same conditions. The by-product visible in some reaction 
traces (fig. 107) coelutes with THA. The very low amount of THA could be a result of background 
reduction of cathenamine in solution. However, it is not possible to exclude the possibility that 
ADH10 is capable of reducing the pro-THA iminium form of cathenamine. There is no evidence 
that ADH10 has the ability to produce AJM or 19EA. No other heteroyohimbines are visible in 
these enzymatic reactions. 
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Figure 107: LC-MS trace of enzyme assays with ADH10 and its mutants compared to a HYS 
reaction. Assays analysed by LC-MS using the “separation method” and monitored using an 
MRM developed for heteroyohimbines (353 m+/z). Black trace: HYS reaction, producing AJM, 
19EA, and THA; orange: ADH10 Y223A mutant; green: ADH10 K227A; blue: ADH10 S127A; red: 
ADH10 WT.
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4.2.12 Proposed mechanism for ADH10 product formation
While HYSs act on cathenamine or the iminium tautomer of cathenamine to form a 
heteroyohimbine (Chapters 2 and 3), ADH10 generates a completely different backbone. 
Therefore, ADH10 uses a different rearrangement product of strictosidine aglycon, one in which 
reaction of the aldehyde at C-17 (not C-21 as in cathenamine) cyclises to form the D ring. If 
ADH10 binds the enamine it could be actively catalysing the equilibration to the iminium through 
providing a water molecule in close proximity to the C-16 (as discussed for the HYSs mechanism 
in Chapter 3). It could also bind the correct isomer of the iminium if it is present in solution.
Reduction would occur in a concerted manner, with the NADPH C-4 hydride attacking the C-17 
from the top face of the substrate, thus forcing the electrons to move onto N-4 and then to 
abstract the proton from the Tyr223 hydroxyl (fig. 108). This is possible because of the basic 
side chain of Lys227 in very close proximity, which could lower the pKa of Tyr223 through the 
hydrogen bonding network with the cofactor ribose moiety. The Tyr223 abstracts a hydrogen 
from the ribose hydroxyl which in turn takes a hydrogen from Lys227. Lys227 can either take a 
proton from the solvent at this stage (there are many water molecules in the active site in close 
proximity) or could take one from the other hydroxyl of the cofactor ribose moiety to which it 
is also hydrogen bonded. The resulting product has the correct stereochemistry at C-17 and is 
released from the active site. The role of the active site serine, which is not essential according 
to mutagenesis studies, is not entirely clear. 
Figure 108: Mechanism proposal for reduction of strictosidine aglycon by ADH10. The cofactor 
and the hydrogens originating from it are illustrated in red; the active site residues and the 
hydrogens originating from them are illustrated in green; water molecule and the hydrogen 
originating from it are illustrated in blue. 
4.2.13 Abundance of the pro-vitrosamine substrate in solution
An attempt was carried out to measure the kinetic constants of ADH10 with spectrophotometric 
methods, but it was quickly realised that the pro-vitrosamine substrate is in such low concentration 
that it was not possible to carry out any meaningful kinetics. 
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Figure 109: Spectra of absorbance at 340nm of THAS1 and ADH10 reaction at pH 7 with 
strictosidine aglycon at 100 μM. Addition of the ADH10 was done after the THAS1 reaction had 
reached a plateau.
Figure 110: Equilibrium between the C-21 cyclised and C-17 cyclised aglycon is most likely not 
equal. The left part of the diagram represents the cyclisation between the N-4 and C-21 which 
is more abundant than the cyclisation between N-4 and C-17 on the right part of the diagram.
However, it was possible to calculate the relative abundance of the ADH10 substrate compared to 
the HYS substrates. The addition of THAS1 to a reaction mixture first allowed the determination 
of the abundance of cathenamine, the THAS1 substrate, in solution. THAS1 consumed the 
available cathenamine within 5 minutes. Addition of ADH10 after (or before) the THAS1 resulted 
in consumption of substrate as well, indicating that these two enzymes do not compete for 
the same substrate (fig. 109). The NADPH consumed in these experiments corresponded to the 
NADPH consumption when the enzymes acted in absence of the other. 
The difference in absorbance from the beginning to the plateau (ΔTHAS1) was calculated in 
triplicate and was determined to be 16.5 ± 2.5 % of the total strictosidine aglycon pool. The 
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same was done for ADH10 and it was determined that the pro-vitrosamine substrate of ADH10 
is present in 3.1 ± 0.7 % of the total strictosidine pool. That leaves approximately 80% of the 
substrate unavailable to either enzyme. This difference in equilibrium between the cathenamine 
and the vallesiachotamine forms is illustrated in fig. 110.
4.3 Discussion
4.3.1 Vallesiachotamine-type alkaloids
The alkaloid vallesiachotamine was first characterised by Djerassi et al. (1966)(fig. 111). This 
natural product has been shown to have some cytotoxic activity against human cancer cell lines 
with low-μM IC50 values (Feng et al., 2010). It was originally purified from bark of the South-
American plant Vallesia glabra (synonym V. dichotoma, Apocynaceae) and mass spectrometry 
and elemental analysis revealed it has the chemical structure C21H22N2O3 (Walser and Djerassi, 
1965). The authors noted that the compound is relatively unstable in presence of air or light, 
something which was also noted during this work with the product of ADH10. They propose 
that the precursor to vallesiachotamine is a corynantheine alkaloid, such as corynantheine. 
This precursor would undergo hydroxylation at the carbon adjacent to the N4 and could then 
equilibrate into an open form and ring closure could occur again after rotation of half the 
molecule around the C-15-C-14 bond (fig. 112). 
Figure 111: Vitrosamine compared to the MIA vallesiachotamine and antirhine. 
Isovallesiachotamine has the Z configuration at C-18,19 while vallesiachotamine has the E 
configuration. The ring numbering is indicated in the ADH10 product structure.
Djerassi et al. (1966) attempted to solve the structure of vallesiachotamine by reducing it 
with chemical reducing agents. They demonstrated that reduction of the enamine bond of 
vallesiachotamine with sodium borohydride in ethanolic solution is not possible, but is possible 
in a glacial acetic acid solution, which in theory lowers the pH to a value that allows equilibration 
to the iminium.
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Figure 112: Proposed generation of vallesiachotamine from geissoschizine. Redrawn from 
Djerassi et al. (1966).
Smith (1968) had observed that hydrolysis of strictosidine led to the formation of the two 
diastereomers of vallesiachotamine (at C-19). It is not clear why vallesiachotamine and not 
cathenamine would be formed under the conditions used, but perhaps cathenamine was 
produced but not stable enough to be characterised by Smith (1968). Kan-Fan and Husson (1979) 
also found that 4,21-dehydrogeissoschizine yielded a mixture of the vallesiachotamine isomers 
when incubated in a buffered solution at pH 4 for 24 h. However, how the authors were able to 
purify and use pure strictosidine aglycon isomers with such certainty is incomprehensible as we 
have observed a large mixture of interconverting isomers in solution with cathenamine being the 
most stable one (i.e. the most abundant) (Stavrinides et al., 2016). Shen et al. (1998) incubated 
purified strictosidine with a bacterial culture of Staphylococcus aureus at pH 7.2 and observed 
that after 24 h incubation a yellow precipitate had formed (bacteria possess non-specific 
glucosidases capable of deglycosylating strictosidine). Upon purification of this precipitate the 
workers discovered that it consisted of vallesiachotamine and isovallesiachotamine in a 2:1 ratio. 
Interestingly, the yield for this reaction was rather low (15 mg (5.25 moles) of yellow precipitate 
from 220 mg (116.6 moles) of initial strictosidine, or 4.5% molar yield).
4.3.2 Characterisation of ADH10
ADH10 is capable of reducing, in the presence of NADPH, strictosidine aglycon to yield a product 
of m/z 371 which is relatively unstable. A large-scale reaction and purification allowed a thorough 
characterisation of the product with NMR. 2D-NMR characterisation of the product allowed 
assignment of all carbons and hydrogens. The product, given the name vitrosamine, appears to 
have the same stereochemistry at C-3 as strictosidine but ring D has been cyclised in a manner 
similar to vallesiachotamine, rather than cathenamine (fig. 113 below). All previously reported 
alcohol dehydrogenases found in the MIA pathway proceed via the intermediate cathenamine. 
However, the structure of the vitrosamine clearly shows that an alternative isomer of strictosidine 
aglycon is reduced (fig. 113). The iminium is formed by equilibration of the precursor by proton 
addition at C-16 to yield a carbon with (S) stereochemistry. Reduction by ADH10 with the help of 
the cofactor NADPH at C-17 produces the final product with a m/z of 371. 
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Mutations to the active site showed that Tyr223 is necessary for generation of the main WT 
product (371 and 353). Mutations to Lys227 did not have such a detrimental effect on the activity 
of ADH10 compared to the Tyr223 mutation, and mutation to Ser127 did not have much effect 
on the final product amount of the reaction. This is in line with previous reports of the active site 
tyrosine being critical for catalysis (Chen et al., 1993, Filling et al., 2002). Therefore this enzyme 
consists of a classic Ser-Tyr-Lys triad, with the tyrosine being responsible for the catalysis. This 
is also evident in the crystal structure of ADH10 where we observe Tyr223 and Lys227 in direct 
contact with the cofactor ribose hydroxyl groups. Furthermore, Tyr223 is coordinating a water 
molecule in the active site in close proximity to the nicotinamide C-4, which provides the hydride 
during reduction of the substrate. The substrate appears to undergo hydroxylation at the C-19 
position to yield the second hydroxyl group (fig. 114 in section 4.3.4, in lilac). It is not clear if this 
hydration is enzymatically catalysed or spontaneous.
4.3.3 Comparison to heteroyohimbine biosynthesis
After deglycosylation, strictosidine aglycon can rearrange to produce different backbones. 
Dialdehyde formation is followed by dehydration and ring closure. While most alkaloids form from 
cathenamine or dehydrogeissoschizine, the work presented here demonstrates that alkaloids can 
also form from an alternative ring closure event (fig. 113). In the case of cathenamine the ring 
closure happens from the aldehyde adjacent to C-21. In the case of vallesiachotamine, antirhine, 
and vitrosamine the ring D closure happens from the aldehyde adjacent to C-17. This alternative 
cyclisation gives rise to more chemical diversity and results in a backbone with different features 
to those found on the yohimbine and heteroyohimbine molecules. 
141
Figure 113: Backbone rearrangement of strictosidine aglycon. Strictosidine aglycon can rearrange 
to give rise to different backbones. Rotation around the C-15-C-20 bond (pink arrow) and 
subsequent cyclisation of ring D can give rise to the cathenamine and geissoschizine backbones. 
On the other hand rotation around the C-14-C-15 bond (blue arrow) and subsequent cyclisation 
of ring D can give rise to the substrate of ADH10, leading to vallesiachotamine and antirhine.
Interestingly, the major product of ADH10 is the stereoisomer with (S) stereochemistry at C-16. 
The enzyme might be selective for that stereoisomer that spontaneously forms in solution, or 
as with the HYS enzymes, ADH10 could directly generate this stereocentre by controlling the 
enamine/iminium tautomerisation.
4.3.4 Mechanism of ADH10 product formation
Equilibration of strictosidine aglycon into the ADH10 pro-vitrosamine substrate can occur 
in solution. First, the dialdehyde intermediate rotates around the C-14-C-15 bond (fig. 114). 
Cyclisation by condensation of the amine and C-17 aldehyde occurs and the stereocentre at C-16 
can be set at any point thereafter by equilibration between the imine and enamine form of the 
molecule, just as with cathenamine. Based on the configuration of C-16 of the ADH10 product it 
appears that either the enzyme or the pro-vitrosamine substrate favours one steric configuration 
over another, as is observed with the preference of HYS for cathenamine over epi-cathenamine. 
The ADH10 appears to selectively accept the C-17-N-4 cyclised iminium intermediate from 
solution rather than cathenamine or 19-epicathenamine. Despite the structural information 
available for ADH10, it is still unclear what molecular features of the active site are responsible 
for this substrate selectivity.
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Figure 114: Hypothetical mechanism for generation of the ADH10 product from strictosidine. 
Strictosidine aglycon is illustrated equilibrating to the dialdehyde form and then rotation of the 
C-14 and C-15 bond occurs, bringing the aldehyde into proximity of the nitrogen. Cyclisation
occurs and loss of water follows which gives rise to the iminium. Hydration of the alkene at C-19
generates the hydroxyl group. The timing of the reaction illustrated in lilac is not known. ADH10
finally catalyses the reduction of the iminium and gives rise to the final product, vitrosamine.
Figure 115: Vallesiachotamine
Here I propose that vallesiachotamine (fig. 115) is naturally occurring in plants which produce 
deglycosylated strictosidine, and can be produced from strictosidine aglycon without any need 
for enzyme activity. The product of ADH10 is a direct reduction product of the deglycosylated 
strictosidine intermediate which is also the precursor to vallesiachotamine. It is not clear if ADH10 
can also reduce vallesiachotamine; to determine that an assay with purified vallesiachotamine 
would be necessary and unfortunately this compound is not available.
It is not clear if the role of ADH10 in planta is to produce the product that is observed in vitro. 
Colleagues attempted to silence ADH10 by Virus Induced Gene Silencing, but no clear metabolic 
changes were observed. Given the high levels of ADH10 expression and the lack of observable 
vitrosamine it is reasonable to suggest that reduction of strictosidine aglycon is not the primary 
role of ADH10 and the activity observed is a spurious discovery. Nevertheless, the discovery of 
this enzyme enriches our understanding of the complexity of biosynthetic pathways in plants 
and adds a new enzyme to our biosynthetic toolkit. 
143
4.3.5 Comparison to HYSs of C. roseus 
ADH10 provides a parallel to the heteroyohimbine synthases discovered and described in the 
previous chapters. Although it is a member of the SDR family while the HYSs are members of the 
MDR family, ADH10 also reduces an iminium of deglycosylated strictosidine, as do the HYSs. The 
lack of formation of any significant amount of heteroyohimbine in the ADH10 reaction indicates 
it is selective for the alternatively cyclised strictosidine aglycon substrate in its active site. Efforts 
to dock the supposed substrate into the active site of the ADH10 crystal structure did not result 
in an unambiguous docked substrate orientation (results not shown). The residues framing the 
active site, either on the loop or the flap could be interacting with the substrate in a way that 
is not easy to foresee. Therefore it is difficult to understand how the active site of ADH10 is 
stereoselective for the alternatively cyclised substrate.
Figure 116: Reduction parallels between ADH10 reaction (1), the proposed (enzyme not yet 
discovered) 4,21-dehydrogeissoschizine reduction (2), and the HYS reaction (3). The double 
bond (probably) reduced is indicated in red and the proton originating from NADPH is indicated 
in green. 
ADH10 reduces pro-vitrosamine iminium from the opposite face than the HYSs using the pro-S 
hydride of the NADPH cofactor rather than the pro-R. This is a result of the orientation in which 
the substrate docks in the active site. This could be a guide to determining which type of enzyme 
could do similar reduction reactions in C. roseus and related plants. As the substrate is so similar 
in all these three cases (fig. 116) it is reasonable to suggest a similar enzyme could be reducing 
4,21-dehydrogeissoschizine into geissoschizine (the proposed precursor to many downstream 
MIA) as well. To find that enzyme a future researcher could start by incubating a crude C. roseus 
protein mixture with pro-R or pro-S labelled NADPD to determine which type of enzyme carries 
out the reduction. SDRs typically dock the cofactor in a way that the pro-S hydrogen is involved 
in reduction, and MDRs typically dock the cofactor in the opposite orientation. As demonstrated 
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here the substrates of these two enzymes also dock in opposite orientations in ADH10 and in 
HYSs, displaying the opposite face of the molecule to the cofactor. If 4,21-dehydrogeissoschizine 
(the substrate in reaction 2) binds to the active site in the same manner then the labelling pattern 
would be indicative of the family of enzyme responsible for the reaction.
4.3.6 Similarities of ADH10 and Salutaridine Reductase
Although the enzymes structures are very similar, ADH10 and PsSalR catalyse different reactions. 
The high overlap in the active site cavities raises questions about the specificity of the enzymes 
and whether it is possible that ADH10 could also reduce salutaridine, or if PsSalR could also 
reduce strictosidine aglycon. Assays on substrate specificity of PsSalR done by Geissler et al. 
(2007) showed that the enzyme was specific for salutaridine, and stereospecifically produced 
7-(S)-salutaridinol (fig. 117). Other substrates (intermediates from the morphine biosynthesis 
pathway) were not reduced by PsSalR, and neither were other plant SDR substrates such as 
tropinone and menthone. Strictosidine aglycon was not tested as substrate, but given the enzymes 
preference for salutaridine and disfavour of other morphine biosynthesis intermediates it would 
be very surprising if it accepted the substrate and catalysed the imine reduction. Salutaridine (or 
any other morphine biosynthesis intermediate) was not tested as substrate for ADH10; therefore 
it is not possible to draw any conclusions on its substrate specificity. 
Figure 117: Proposed mechanism of salutaridine reduction by PsSalR. Figure redrawn from 
Geissler et al. (2007). The NADPH cofactor is drawn in red; the active site triad residues in green; 
substrate and product in black. The colour of the hydrogens of the product reflect where they 
originate from. 
4.3.7 Precedence for SDR imine reductases
Reductases have great importance in the chemical synthesis industry, especially for generation 
of chiral products. There is interest in development of stereoselective imine reductases as 
biocatalysts (Scheller et al., 2014). Extensive studies have been conducted on imine reductases 
(IREDs) of Streptomyces sp. which are also members of the SDR enzyme family. Two IREDs with 
opposite stereoselectivity were discovered in two different Streptomyces strains, an (S)-IRED 
(Mitsukura et al., 2013), and an (R)-IRED (Mitsukura et al., 2011). Screening of the two enzymes 
against a panel of imine molecules revealed that they are promiscuous, and both have varying 
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amounts of preference for the different substrates and also different degrees of stereospecificity 
for the final products (Leipold et al., 2013, Hussain et al., 2015). Interestingly, for substrates 
tested for both IRED enzymes, the resulting products were usually of opposite configuration, 
suggesting that the enzymes were binding the substrates consistently in opposite orientations. 
Figure 118: Comparison of orientation and position of hydride in ADH10 and (R)-IRED products. 
The hydride originating from NADPH is indicated in green in each case. The ADH10 catalyses the 
reduction to yield a pro-R hydride, as does (R)-IRED. 
Hussain et al. (2015) were able to demonstrate that (R)-IRED is able to reduce an imine of a 
molecule similar to the MIA (fig. 118, right). This enzyme was capable of producing the (R) isomer 
with 74 % enantiomeric excess. However, during analysis of the ADH10 reaction products by LC-
MS and NMR only the pro-R isomer has been detected. This suggests the binding constraints on 
the ADH10 substrate are larger than the constraints posed on (R)-IRED and the tested substrate. 
Binding of the ADH10 substrate in an opposite orientation would be non-conductive to successful 
reduction. 
The Imine Reductase database (www.ired.biocatnet.de (Scheller et al., 2014, Fademrecht et al., 
2016)) lists 12 sequences of IREDs originating from Eukaryotes. All the 12 sequences are from 
Eurotiomycetidae, more specifically from the families Aspergillaceae and Ajellomycetaceae. 
A BLAST search using ADH10 with a generous cutoff value of e-10 did not result in any hits. 
C. roseus ADH10 shares very low amino acid identity with these eukaryotic IREDs (maximum
of 15.6 % with Aspergillus oryzae IRED). This could indicate that ADH10 has evolved its imine
reducing capability independently of these fungal IREDs. As only a handful of eukaryotic IREDs
(other than the HYSs and the ADH10 described here) have been described so far it is not possible
to draw any concrete conclusions on this subject yet.
Some IREDs have been crystallised (for example PDB: 4OQY (Huber et al., 2014), and PDB: 3ZHB 
(Rodríguez-Mata et al., 2013)) and although they share some similarities with SDRs they have 
diverged from the SDRs quite considerably. Apart from the NADPH-binding domain, which 
contains the Rossmann fold, the IREDs possess a distinct dimerization domain at the C-terminal 
end composed mainly of α-helices. This is not found in the C. roseus ADH10 structure, although 
the “flap” appears to be promoting an enzyme dimerization in the crystal structure. 
Interestingly, there is an SDR enzyme in the BIA biosynthetic pathway which appears to reduce an 
iminium moiety. Sanguinarine Reductase (SanR) from California poppy (Eschscholzia californica) 
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reduces sanguinarine to produce dihydrosanguinarine (Weiss et al., 2006) (fig. 119). This enzyme 
was not crystalized but instead a homology model was built based on the closest homolog (PDB 
accession code: 1XQ6, an enzyme from Arabidopsis thaliana of unknown function)(Vogel et al., 
2010). The alkanolamine form of the substrate (fig. 120) was docked into the structure, but it is 
not clear if docking of sanguinarine was also attempted but unsuccessful. The authors therefore 
propose an unusual mechanism of reduction that involves the alkanolamide form of the substrate 
and the serine of the catalytic triad (fig. 120).
Figure 119: Reduction catalysed by SanR. 
Figure 120: Proposed mechanism of SanR. Redrawn from Vogel et al. (2010). The active site 
residues are illustrated in green, the NADPH and the hydrogen originating from it are in red, and 
the substrate and product in black.
It is not reported if the workers used labelling to determine which cofactor hydride was transferred 
to the product (the pro-S or the pro-R), but given their molecular model it is more likely that the 
pro-S hydride is transferred, and therefore their mechanism proposal was probably mistaken. 
Likewise, it is not reported if labelling of the product was attempted. Consequently, it is not 
possible to say with any certainty without any labelling studies which face of the molecule the 
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hydride is oriented towards. If labelling had been carried out it would provide more evidence for 
the accurateness of the docking. 
A mutagenesis was carried out on EcSanR to determine which residues are necessary for catalysis 
and substrate binding (Vogel et al., 2010). Of the catalytic triad only the serine was mutated (to 
alanine) but it is not clear why the workers did not mutate the other residues of the catalytic 
triad. Mutation to the serine (Ser153Ala) resulted in a reduction of catalytic efficiency (4 % 
Vmax/Km compared to 100 % of WT). Without studying the effect of mutations on the other two 
residues of the catalytic triad it is not possible to say with certainty that Ser153 is the residue 
responsible for catalysis. Such a mutation could have an effect on the active site dynamics, such 
as charge and substrate docking, and therefore the reduction in catalytic efficiency could be due 
to different factors. It is possible that EcSanR is in fact an imine reductase, and that it uses either 
the active site serine or tyrosine to catalyse the reaction in the same manner that ADH10 does. 
A protozoan SDR enzyme, Pteridine Reductase (PTR1) from the parasites Leishmania and 
Trypanosoma (PTR1, (Gourley et al., 2001)), is an interesting detoxification enzyme which 
reduces an imine. This enzyme is involved in the resistance to dihydrofolates which are used as 
inhibitors for the essential metabolism of folates in these parasites. PTR1 is capable of reducing 
its substrate in two distinct ways (fig. 121). The first reaction is a reduction of an imine involving 
the classic SDR tyrosine-based catalysis. The second reduction, also of an imine, involves a 
coordinated water molecule and an arginine present on the opposite side of the active site to the 
tyrosine. In the first reduction the proton originates from tyrosine, but in the second reduction 
the two protons originate from the coordinated water molecule and the coordinated cofactor 
phosphate group.
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Figure 121: Double reduction of dihydrofolate by PTR1. Redrawn from Gourley et al. (2001). The 
hydride originating from the NADPH cofactor is indicated in red; the water molecule implicated 
in the 2nd reduction is illustrated in blue; the active site residues implicated in the catalysis are 
illustrated in green; A represents the cofactor phosphate that interacts with the substrate. 
PTR1 was crystallised as a complex with the cofactor and substrate and it appears to dock in a 
parallel orientation to the cofactor nicotinamide ring (Gourley et al., 2001). This enzyme does 
not have a “flap” like ADH10 or PsSalR and therefore direct parallels cannot be drawn between 
these. However, the mechanism proposed for the first reduction is similar to the proposed 
mechanism for reduction of pro-vitrosamine by ADH10. 
4.4 Conclusions
The discovery of ADH10 from C. roseus indicates that an SDR can reduce strictosidine aglycon, 
and therefore should also be included in screening efforts for discovery of biosynthetic enzymes 
implicated in MIA pathways both in C. roseus and also in other MIA-producing plants. The 
product of ADH10, vitrosamine, is not detected in tissues of C. roseus, and has in fact never been 
described in the literature. There could be different factors for this, but an obvious explanation 
is that it is an “unnatural natural product” in that the product is not formed normally in vivo but 
can be produced in vitro. 
ADH10 could be responsible for the reduction of another substrate in vivo, but Virus Induced 
Gene Silencing of ADH10 done by collaborators in the past did not show any significant decrease 
in any of the major MIA of C. roseus. ADH10 could be acting upon a much less abundant substrate, 
or its product could be transient and degraded or metabolised very fast in vivo. What’s more, this 
in vitro product could be the result of a non-specific reaction and ADH10’s true substrate could 
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be a similar but unstable product of another enzyme (such as a P450, or another reductase) 
acting on strictosidine aglycon. This phenomenon has been observed previously with secondary 
metabolism steps in MIA biosynthesis (Krithika et al., 2015, Qu et al., 2015). On the other hand, 
ADH10 could be part of a strictosidine aglycon detoxification suite of enzymes, as discussed 
for the HYSs in Chapter 3. Enzyme redundancy (as seen with the 5 HYSs) could mask any effect 
the Virus Induced Gene Silencing might have produced. There are no highly similar enzymes 
to ADH10 in the C. roseus genome, but even a low identity of ~53 % could not exclude the 
possibility that another enzyme could act as a candidate for the same reaction. This is what is 
seen with the HYSs, which do display a relatively low percentage of protein identity. 
The similarity between ADH10 and the benzylisoquinoline biosynthetic enzyme PsSalR from the 
distantly related opium poppy is intriguing. This hints that perhaps this enzyme, or something 
similar, could be found in other organisms throughout the plant kingdom. A further investigation 
into other plants could reveal the extent to which enzymes with the lid and loop features are 
ubiquitous or not. 
Why this branch of strictosidine-derived MIA is not as well developed as that of the corynantheine, 
iboga, and aspidosperma branches could stem from the fact that the substrate is not present in 
high enough amounts. As the experiments described in this chapter show, cathenamine forms 
approximately 14-20 % of the strictosidine aglycon pool whereas the ADH10 substrate forms 
just 2.4-4 % of the pool. The inherent reactivity and equilibration speed of the different forms 
of strictosidine aglycon governs the more abundant species and backbones which the plant can 
then utilise and build upon.
The discovery of this enzyme capable of reducing a different form of strictosidine aglycon opens 
the door to molecular engineering. This enzyme adds to the biosynthetic toolkit available for 
heterologous expression and production of “unnatural natural products”. It also expands the 
already large chemical diversity possible from the central MIA precursor, strictosidine. 
4.5 Materials and Methods
4.5.1 General molecular biology techniques used
Polymerase chain reaction, description of vectors used, RNA extraction and cDNA production, 
and details of the E. coli culture media used are detailed in Chapter 2.
4.5.2 Cloning of ADH10
Primers for amplification of the gene identified by Glenn (2013) from C. roseus cDNA 
were designed based on the ORF of transcript Cro013448 (ADH10) with pOPINF (Berrow 
et al., 2007) overhangs 5’ AAGTTCTGTTTCAGGGCCCGGCCGCCATGGGTACC  and 3’ 
ATGGTCTAGAAAGCTTTATTCAAACGATGACTCCTCGC for directional cloning of ADH10 into the 
pOPINF vector. PCR was performed as detailed in Chapter 2 and the amplified gene fragment 
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was gel-purified from 1% agarose gel (Promega, UK) and cloned into the E. coli expression 
vector pOPINF following the manufacturer’s instructions for ligation. Vectors were transformed 
into chemically competent E. coli Top10 cells by heat shock at 42˚C for 30 seconds and then 
spread-plated onto LB+agar plates supplemented with carbenicillin (100 μg/mL). After a night 
of growth at 37 ˚C positive clones were identified by PCR using the gene-specific primers above 
and the HotStart Taq polymerase (Qiagen, UK). Positive colonies were grown overnight in 4 mL 
of LB media supplemented with the appropriate antibiotics at 37 ˚C. The following day plasmids 
were isolated from the cultures using the miniprep kit (Qiagen) according to manufacturer’s 
instructions. Vectors were verified visually by running on a 1% agarose gel at 100 V and the 
identity of the inserted sequence was confirmed by Sanger sequencing.
4.5.3 ADH10 expression assay
Chemically competent SoluBL21 E. coli cells (Novagen®, Merck Millipore, Massachusetts, USA) 
were transformed by heat shock at 42 ˚C with pOPINF plasmid containing the ADH10 coding 
sequence in frame with the N-terminal His6-tag. Expression of His6-tagged ADH10 protein in E. 
coli was tested in small scale at various temperatures and with different IPTG concentrations. 
Transformed cells were added to 50 mL starter culture of liquid LB media supplemented with 
carbenicillin (100 μg/mL) and incubated at 37 ˚C overnight with 200 rpm shaking. The cells were 
diluted 1:100 in 100 mL of 2 x YT media supplemented with carbenicillin (100 μg/mL) and allowed 
to grow at 37 ˚C with 200 rpm shaking. Two cultures were grown at 37 ˚C until an OD600 of 1.2 
and were induced by 1 and 0.1 mM IPTG respectively and allowed to express protein at 37 ˚C 
for 3.5 h. Cultures for expression at 18 or 10 ˚C were allowed to reach an OD600 of approximately 
0.6 and then chilled on ice before addition of 1, 0.5, or 0.1 mM IPTG. The cultures at lower 
temperature were incubated overnight at the respective temperatures for protein expression. 
The cultures at 37 ˚C were removed after 3.5 h and cells were pelleted by centrifugation at 
4000 rpm and the supernatant removed. Cell pellets were stored at -80 ˚C until testing the next 
day. Cells were analysed for protein expression using the BugBuster® kit (Merck Millipore, UK) 
following manufacturer’s instructions. An aliquot of each soluble fraction was analysed by SDS-
PAGE. 
4.5.4 ADH10 large-scale expression and purification
Cultures of SoluBL21 E. coli harbouring the pOPINF vector with ADH10 (2 L of 2 x YT) were 
prepared as described above. These were allowed to grow to an OD600 of 1.2 at 37 ˚C before 
inducing with 0.1 mM IPTG. Expression was done at 37 ˚C with 200 rpm shaking for 3.5 h, after 
which time the cultures were chilled on ice and then spun down at 4000 rpm for 10 min to 
pellet the cells. The pellet was resuspended in 200 mL of Phosphate Buffered Saline solution and 
pelleted again by centrifugation at 4000 rpm for 10 min. The supernatant was removed and the 
cell pellet was stored at -80 ˚C overnight and the next day they were thawed and resuspended 
in 100 mL Buffer A (50 mM Tris-HCl pH 8, 50 mM glycine, 500 mM NaCl, 5% glycerol, 20 mM 
imidazole) supplemented with 2 mM of 2-β-mercaptoethanol (Sigma) along with EDTA-free 
protease inhibitor (Roche Diagnostics Ltd.). Cells were lysed using sonication for 4 minutes on ice 
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using 2 second pulses with a 5 minute pause after 2 minutes on ice. Cell debris was pelleted by 
centrifugation at 17 x 1000 g for 20 min and all large-scale purification steps were done at 4 ˚C. 
His6-tagged ADH10 was purified on an ÄKTAxpress purifier (GE Healthcare) using a HisTrap FF 
5 mL column (GE Healthcare) equilibrated with Buffer A. The sample was loaded at a flow rate of 
4 mL/min and step-eluted using Buffer B (50 mM Tris-HCl pH 8, 50 mM glycine, 500 mM NaCl, 5% 
glycerol, 500 mM imidazole) supplemented with 2 mM of 2-β-mercaptoethanol (Sigma). Eluted 
protein was subjected to further purification on a Superdex Hiload 26/60 S75 gel filtration column 
(GE Healthcare) at a flow rate of 3.2 mL/min using Buffer D (20mM Hepes, pH 7.5 150mM NaCl) 
also supplemented with 2 mM of 2-β-mercaptoethanol (Sigma) and collected by a fractionator 
into 8 mL fractions. The fractions were analysed by SDS-PAGE and those containing no traces 
of other contaminating proteins were pooled. The protein was concentrated in a 10 KDa cutoff 
Millipore filter (Merck Millipore) and buffer exchanged into Buffer D supplemented with 0.5 mM 
TCEP. The concentration was measured spectroscopically using the calculated MW and extinction 
coefficient (21680 L mol-1cm-1).
4.5.5 Crystallisation and data collection
Purified protein at a concentration of 10.76 mg/mL was used for crystallisation assays in the 
commercial suites PEG (Qiagen), PACT (Qiagen), and JCSG+ (Molecular Dimensions). Crystallisation 
screens were conducted by sitting-drop vapour diffusion in MRC2 96-well crystallization plates 
(Swissci) with a mixture of 0.3 µL well solution from the suites and 0.3 µL protein solution. One 
drop was setup without cofactor (apo) and one drop was setup to contain NADP⁺ (Sigma Aldrich) 
at a final concentration of 1 mM for co-crystallization studies. Solutions were dispensed by 
an OryxNano robot (Douglas Instruments). Prepared screens were placed at 19 ˚C for crystal 
formation. Optimisation screens were setup using the plate dispensing function of the Oryx8 
robot (Douglas Instruments). Crystals were cryo-protected with well solution containing 25% 
ethylene glycol for 1 minute and frozen in liquid nitrogen. 
Data collection was carried out essentially as described in Chapter 3 with some modifications. 
The structure was solved by molecular replacement with the crystal structure of PsSalR (3O26, 
Higashi et al. (2011)) using PHASER (McCoy et al., 2007). The asymmetric unit corresponded 
to two monomers in a back-to back orientation, but after consideration one of the chains was 
placed in the symmetry position to produce the head-to-head orientation described here which 
had a larger contact area. The structure was refined in REFMAC5 with TLS refinement (Winn et 
al., 2003).
4.5.6 Accurate mass and fragment determination
A sample of purified ADH10 product was direct-injected on the Synapt G2 HDMS mass 
spectrometer (Waters). The sample was infused at 5-10 μL min-1 using a Harvard Apparatus 
syringe pump. The instrument was calibrated using a sodium formate solution. The sample was 
analysed for 2 min with a scan time 1 sec in the mass range of 50-600 m/z. Capilary voltage was 
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3.5 V, cone voltage 40 V, source temperature 120 ̊ C, desolvation temperature 350 ̊ C desolvation 
gas flow 800 L/h. Leu-enkephaline peptide (1 ng/μL) was used to generate a dual lock-mass 
calibration with [M + H]= 556.2766 and m/z=278.1135 measured every 10 sec. For MS2, the 
precursor ion of m/z 371 was selected and fragmented with collision energy of 20. Spectra 
were generated in Masslynx 4.1 by combining a number of scans, and peaks were centred using 
automatic peak detection with lock mass correction. Accurate mass of product was found to be 
353.1862 m/z and 371.1967 m/z for the two major species present in solution. 
4.5.7 Large scale reaction with deglycosylated strictosidine and product purification
Strictosidine (30 mg) was incubated in 100 mL (final concentration 566 μM) with 50 mM citrate 
buffer pH 6, and 40 μL of SGD (10 nM). NADPH and ADH10 were added (final concentration 
700 μM and 3 μM respectively) and the reaction incubated at 37˚ C with gentle shaking. 
Reaction completion was followed by mass-spectrometry, and at 2 h extra ADH10 was added 
(concentration brought to 6 μM). 
The reaction was basified to stop the reaction at 4 h by addition of NaOH to pH of approximately 
9.5 and the product was extracted multiple times with a total of 100 mL of ethyl acetate (EtOAc). 
The EtOAc fraction was dried under vacuum and resuspended in 100 μL of EtOAc. A nano-silica 
TLC was basified with tri-ethylamine (TEA) and the EtOAc product was loaded onto the plate. 
Some residue was still visible in the product vial and therefore it was resuspended in 100 μL of 
methanol and loaded onto the TLC as well. The TLC was ran in 50:50:1 EtOAc:Hexanes:TEA. 
The product band was excised from the silica with a scalpel and the silica was crushed in the 
presence of 50 mL EtOAc and the solution was filtered and dried under vacuum overnight. The 
precipitate was resuspended in 300 μL of CDCl3 and a 
1H-NMR was recorded. For unambiguous 
assignment of the structure 1H-H correlated spectroscopy (COSY), heteronuclear multiple 
quantum coherence experiment via direct coupling (HMQC), and heteronuclear multiple bond 
correlation spectrum (HMBC) were recorded by collaborators on a Bruker Avance III HD 700 NMR 
Spectrometer (16.4 T , 1H operating frequency 700 MHz) equipped with TCI  H-C/N-D 1.7 mm 
microcryoprobe.
4.5.8 Deuterium labelling of ADH10 product
Deuterated ADH10 product was produced by using deuterated cofactor (NADPD). Strictosidine 
(15 mg) was incubated in HEPES buffer (50 mM, pH 7.0) with 200 μM NADP⁺ in a total volume 
of 141 mL. NADPD was generated in situ by using 1-D deuterated D-glucose (250 μM Cambridge 
Isotope Laboratories Inc., USA) and Glucose dehydrogenase (800 U, from Pseudomonas sp., 
Sigma) as an NADPH regeneration system. Purified SGD and ADH10 (1 μM final concentration) 
were added and the reaction was incubated at 31 ˚C for 16 hours with 70 rpm shaking. 
The reaction was basified to approximately pH 9 by addition of saturated NaOH and alkaloids 
were extracted multiple times in a total volume of 120 mL of EtOAc. The extract was dried using 
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a rotary evaporator.  A high-resolution silica TLC plate (nano-silica plate, Sigma-Aldrich) was pre-
soaked with TEA and the sample was loaded and ran using 50:50:1 EtOAc:Hex:TEA. The highest 
band was excised with a scalpel and crushed multiple times in a total volume of 50 mL MeOH 
and filtered into a clean flask. The extract was dried using a rotary evaporator and then placed 
on a high vacuum pump overnight as it was noted that the extracted compound is hygroscopic. 
The sample was resuspended in 500 μL of CDCl3 and the 
1H and COSY were measured on a Bruker 
Advance NMR instrument operating at 400 MHz for 1H equipped with a BBFO plus 5 mm probe.
4.5.9 pH assays of ADH10 with strictosidine aglycon
To determine the best pH/buffer combination for use during ADH10 reactions, a small panel 
of buffers was assayed. Strictosidine (300 μM) was incubated with purified SGD in deionised 
water for 15 min at room temperature. Then the reaction was split into eight tubes containing 
different buffers. The buffers used are (in order of increasing pH): Phosphate pH 5.0, MES pH 5.5, 
Phosphate pH 6.0, Citrate pH 6.0, MES pH 6.5, Phosphate pH 7.0, HEPES pH 8.0, and Phosphate 
pH 8.0. All buffers were used at a concentration of 50 mM. NADPH (500 μM) was added, followed 
by 1 μM of purified ADH10. The reactions were mixed and an aliquot was taken at 1 min and at 
10 min and prepared as usual for analysis by LC-MS. 
The analysis was carried out on a UPLC (Waters) equipped with an Aquity BEH C18 1.7 μm 
2.1 x 50 mm column connected to Xevo TQS (Waters). The capillary cone volatage, the source 
temperature, cone and desolvation gas flows were all the same as described in Chapter 2. The LC-
MS analysis was done as described in Chapter 2 using both the “fast method” and the “separation 
method”. A calibration curve specific for the ADH10 product was not made as the product is 
not available commercially. Therefore absolute quantification of the product in each sample is 
not possible. However, as the product has a signal at 353 m/z and it fragments into the same 
fragment as THA and AJM it is detected by the same MRM used to detect the heteroyohimbines. 
A manual integration of the peaks was done using the MassLynx software (Waters) using 200 
peak to peak amplitude for noise reduction.
4.5.10 Spectroscopic assays
Strictosidine (100, 75, 50 or 25 μM) was deglycosylated by purified SGD (10 nM) for 30 minutes 
at 30 ˚C in a spectrophotometer cuvette in a total volume of 800 μL of citrate buffer pH 6.0 
(50 mM). The completion of the reaction was verified by mass-spectrometry. NADPH (100 μM) 
was added to the reaction and mixed by pipetting. The reaction was monitored at 340 nm on 
a spectrophotometer (Cary 50 Bio, Varian) at room temperature. After verifying the NADPH 
absorbance was stable (approximately 3-5 minutes) ADH10 (100 nM) was added and mixed by 
pipetting. The initial velocity was recorded using the least squares regression of the Cary WinUV 
Kinetics Application v. 3.00(182) (Varian).
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4.5.11 Combination of ADH10 and THAS1 
A spectrophotometric assay was done in similar conditions to those described above. Strictosidine 
(100 μM) was deglycosylated by SGD at 30 ˚C in a spectrophotometer cuvette for 30 minutes 
in citrate buffer (50mM, pH 6.0). NADPH (100 μM) was added to the reaction and mixed by 
pipetting. After verifying that NADPH absorbance was stable, purified THAS1 (1 μM) was added 
and mixed. The reaction was allowed to progress until the plateau was reached (approx. 7 
minutes), and then ADH10 (1 μM) was added to the reaction and mixed and the reaction was 
allowed to reach the steady-state. The difference in NADPH (ΔABS340) was recorded before 
addition of each enzyme, and at the point the reaction reached the plateau. The assay was done 
in triplicate. The inverse reaction (ADH10 added first, then THAS1) was done once to verify the 
reverse is also true.
4.5.12 Active site mutations
The crystal structure revealed several amino acids in the active site cavity that could potentially 
be part of the catalytic triad. To verify their role in catalysis these three residues were each 
mutated to alanine by mutating the codon (Ser167->Ala167: TCC->GCC; Tyr223->Ala223: TAT-
>GCT; Lys227->Ala 227: AAA->GCA). The mutant ADH10 gene fragments were obtained from 
IDT with the pOPINF overhangs included. Ligation into pOPINF and clone selection was done as 
described above. Small-scale expression of mutants was done at 37 ˚C as described above as 
well, but purified on small-scale as described for the candidate enzymes in Chapter 2. 
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Gene duplication in C. roseus has allowed the development of MIA 
chemical diversity through neofunctionalisation
5.1 Introduction
C. roseus belongs to the Apocynaceae family, which is one of the largest angiosperm families 
with approximately 5000 species (Straub et al., 2014).  It is an economically important family 
comprising many species with secondary metabolites used as drugs (Aslam et al., 2010, Singh, 
2008). Many members of the Apocynaceae family produce MIA, the chemical diversity of which 
relies on the elaborate enzymatic modification of the branch-point biosynthetic intermediate 
strictosidine (Rueffer et al., 1978). Deglycosylation of strictosidine by the action of SGD generates 
a reactive intermediate which can rearrange to generate a plethora of different carbon skeletons.
However, the evolution of SGD poses a trade-off for the strictosidine-producing plant. 
Strictosidine aglycon can be beneficial for the plant because it can provide some defence against 
herbivory (Guirimand et al., 2010, Sudžuković et al., 2016, Luijendijk et al., 1996). The reactivity 
of this compound means that it can cross link amines and nucleotides, making this a highly toxic 
compound. At the same time however, this compound can potentially endanger the host cell 
itself. 
Figure 122: Strictosidine and SGD have a different subcellular localisation. STR (represented by a 
green circle) is located in the vacuole (orange section of the cell). It produces strictosidine inside 
the vacuole, represented by blue stars. Strictosidine can be transported out of the vacuole via 
a vacuolar tranporter (indicated as a white circle). It can diffuse into the nucleus, represented 
by a blue circle, where it can be deglycosylated by SGD (represented by a yellow circle). The 
reactive strictosidine aglycon, represented by a red star, can attack the cell constituents and 
cause damage if not neutralised.
The tight regulation of compartmentation of the strictosidine pool (in the vacuole) and SGD (in 
the nucleus, fig. 122) circumvents this problem until wounding by herbivore causes the cell to 
rupture and the two to mix (Guirimand et al., 2010). The strictosidine, which is exported from 
the vacuole, can find its way to the nucleus and be deglycosylated by SGD. Enzymes that can 
neutralise this reactive intermediate fast and efficiently could allow the plant to bypass the toxic 
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effect of background strictosidine aglycon production. It is not unreasonable to suggest that when 
strictosidine and strictosidine glucosidase had first evolved and started producing strictosidine 
aglycon, a positive selection pressure started acting on those plants to favour enzymes capable 
of neutralising the reactive intermediate. After the evolution of the first enzymes able to modify 
or reduce the reactive intermediate a host of other pathways could evolve which could take 
the new compounds and build on them, thus expanding the chemodiversity currently found in 
today’s MIA-producing plants. 
The previous three chapters of this thesis have detailed the discovery and characterisation of 
enzymes that can act upon this reactive intermediate. For example, the different heteroyohimbine 
synthases (HYSs) detailed in Chapters 2 and 3 can take strictosidine aglycon and reduce it to 
a mixture of heteroyohimbines. The discovery of the related HYSs, and the recent discovery 
of related MDRs that take part in other parts of the pathway (10HGO (Miettinen et al., 2014), 
T3R (Qu et al., 2015)), gives us an unprecedented opportunity to study the evolution at this 
branchpoint (fig. 123). 
Figure 123: Abundance of reductases in the MIA biosynthetic pathways of C. roseus. The 
reductases implicated in the various reactions and their predicted copy number are indicated 
in blue.
5.1.1 The birth of new enzymes through gene duplication
Gene families arise as a result of gene duplications, followed by divergence and differentiation of 
these gene copies (fig. 124).  Through mutation, a few of these duplicated genes can eventually 
give rise to new functions. If the new function imparts a selective advantage, the mutated gene 
is retained by the organism.
It is interesting to look at lineage-specific duplication events because they could be the 
manifestation of different evolutionary forces (such as abiotic or biotic stress) and the 
adaptations to those stresses that the lineage has achieved. A duplicated protein can be retained 
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in an organism if the duplication somehow allows adaptation. This adaptation may come in the 
form of recruitment of the newly duplicated protein into a new pathway, to perform a new 
function, or even to be expressed in a different manner to the original protein. The recurrence 
of duplications in a specific gene family in a short time could indicate an increased selection 
pressure acting on, for example, a specific branch of a given metabolic pathway. 
Figure 124: Two proteins are said to be paralogous if they are derived from a duplication event 
and orthologous if they are derived from a speciation event. Species 1 has two homologous 
genes, A and B, which are descendent from a duplication event. Species 2 has a gene which is an 
ortholog to both gene A and B from species 1 because they diverged during a speciation event. 
Gene C is only considered an ortholog to gene B because gene A has diverged in function since 
duplication whereas gene B has retained the ancestral function. 
It is generally accepted that a gene can undergo mutational drift which can lead to the acquisition 
of a novel function. However, most theories based on this assumption posit that an enzyme 
would first evolve to be promiscuous through an expanded substrate recognition and later, if 
selection pressure is present, would tend towards increased substrate specificity (Weng et al., 
2012). However, it is not known if this is always the case.
Different models of neofunctionalisation have been proposed over the years. The “innovation, 
amplification and divergence” (IAD) model of neofuntionalisation posits that constant selection 
can act on genes and still lead to the evolution of two separate activities from the same ancestor. 
An enzyme with a necessary primary function could have a secondary function which is beneficial 
to the organism. Mutants which have increased activity for the secondary function but retain the 
necessary levels of activity for the primary function may be difficult to achieve. Therefore, the 
adaptive function is achieved faster by duplication of the gene. By amplifying the gene dosage, 
the organism can increase the secondary function dose without hampering the primary function. 
The new copy is now free from selection for the original function and can undergo mutagenesis 
which can lead to increased efficiency in the secondary function (Bergthorsson et al., 2007).
A similar, but subtly different, method for neofunctionalisation, known as “escape from adaptive 
conflict” (EAC) posits that a gene coding for an enzyme with two contradicting functions (which 
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are mutually exclusive) cannot specialise for either without losing the activity for one of the 
functions. To circumvent this conflict the gene is duplicated, which allows each copy to undergo 
selection for one of the functions. However, to identify genes duplicated for EAC is difficult and 
involves identification of the ancestral state of the genes through phylogenetic reconstruction 
and extensive knowledge of the function of the orthologs in related organisms (Des Marais and 
Rausher, 2008). 
The literature is replete with examples of duplicated and neofunctionalised genes in plants. 
Weng et al. (2012) offer a good overview of such cases in many different plants. Such examples 
include diverse enzyme families and functions such as: the Lysine/Ornithine Decarboxylases (L/
OCDs) in quinolizidine alkaloid producing plants could have been derived from common plant 
OCDs (Bunsupa et al., 2012); terpene synthases in rice implicated in plant herbivore defence and 
have been subjected to positive Darwinian selection (Chen et al., 2014); the betalain biosynthetic 
enzymes of the Caryophylales which recently underwent neofunctionalisation after duplication 
(Brockington et al., 2015); and the latex-producing enzymes in the rubber tree Hevea brasiliensis 
which were found to be in tandem-duplication clusters (Lau et al., 2016).
5.1.2 Gene duplication and heteroyohimbine biosynthesis
The HYSs are most similar to the Cinnamyl Alchohol Dehydrogenases and the closely related 
Sinapyl Alcohol Dehydrogenases (CAD and SAD, respectively). These MDR enzymes evolved in 
plants (Riveros-Rosas et al., 2003) and are implicated in lignin biosynthesis. Studies of these 
enzymes in other plant species have revealed they are often duplicated. There are 8 CAD-like 
paralogs in Arabidopsis thaliana, some of which are present in duplicated blocks (Kim et al., 
2004). The genes identified had varying amounts of identity to each other (from 45.9 to 98.4%) 
which indicates some copies are more ancient than others and have diverged considerably. An 
array of three tandem duplicated AtCAD genes was discovered on the A. thaliana chromosome 
4 and a phylogenetic tree indicates that these 3 paralogs are the most closely related, indicating 
that they are the product of a recent local duplication event. In Populus trichocarpa 15 CAD 
paralogs were identified and their chromosomal location was identified (Barakat et al., 2009). 
Generally, it was found that many of the CAD duplications had occurred locally but whole 
clusters of duplicated CAD genes are found duplicated in other parts of the plants’ genome and 
these in theory have arisen from whole genome duplications and rearrangements (Barakat et al., 
2009). These CAD duplicates have been investigated in detail in A. thaliana and although they all 
displayed CAD-activity, the Km, kcat, and their relative expression in the tested tissues all varied 
considerably (Kim et al., 2004). It is not known if these duplicates have activity against other, 
non-lignin-related substrates in planta.
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5.1.3 Overview of this chapter
The C. roseus transcriptome contains multiple MDR reductases expressed in different tissues 
and at different levels. In this chapter a study of the evolution of these reductases, and more 
specifically of the HYSs, reveals the interesting dynamics present at these loci. The duplication 
and divergence of these enzymes has profound implications for the chemical diversity found in 
the MIA and other secondary metabolic pathways. Heteroyohimbine synthesis appears to be 
possible with different MDR active sites, as evidenced by the discovery of multiple HYSs in C. 
roseus which do not have identical active sites, and in fact are quite variable (detailed in Chapter 
2 and 3). This information indicates that although the HYS enzymes have probably originated 
from a common ancestor, there has not been any selection pressure to maintain specific amino 
acids in the active site or the active site loops. However, for reasons that are not well understood, 
there appears to be a positive selection pressure to maintain multiple copies, as evidenced by 
the multiple MDRs which display HYS activity. This flexibility in active site architecture allows the 
genes to drift over time which consequently has facilitated the appearance of genes that further 
elaborate on the MIA scaffold. For example, it is possible that the extensive gene duplication of 
the HYS has led to the emergence of T3R, a late stage MIA biosynthetic enzyme, which has lost 
the ability to catalyse the production of heteroyohimbines but has gained the ability to catalyse 
the reduction of a downstream MIA.
5.2 Results
5.2.1 Genomic organisation of the C. roseus ADHs 
The recent sequencing of the C. roseus genome (Kellner et al., 2015) has allowed an investigation 
into the duplication of the ADHs to be carried out in this plant. Firstly, the genomic context of 
the C. roseus ADHs was investigated. Each gene annotated as an ADH was submitted to BLAST 
against the C. roseus WG assembly contigs (WGC, version 2.A, Buell and Kim, in preparation). A 
close inspection of the results reveals that there are 68 contigs containing ADHs (table 14). Of 
these, 28 have more than one ADH. The WGC numbers 12, 24, 27, 106, 126, 286, 371, and 420 
each contain an ADH which has been shown experimentally to catalyse a reduction or oxidation 
in the MIA pathway of C. roseus. Interestingly, on the WGC which contain ADHs of different 
families these ADHs are usually separated by many other genes and are never in direct proximity. 
However, it is common in the WGC containing multiples of a single ADH family, such as the 
MDR family, that these genes are in tandem with each other, suggesting tandem duplication was 
responsible for the origin of the arrangement.
Table 14: Catharanthus roseus Whole Genome contigs containing an ADH gene. 









3 2453204 4 4/4 a
6 2384693 3 1/3 1/3 1/3
7 2383327 3 3/3 a
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8 2247593 2 2/2
11 2076047 4 3/4 a 1/4
12 2081351 1 1/1
13 2021668 2 2/2
24 1697648 4 4/4 a
27 1651656 6 6/6 a
34 1538188 1 1/1
39 1408578 2 2/2 a
44 1360256 1 1/1
45 1340673 1 1/1
50 1276821 2 2/2 a
51 1259040 4 4/4 a
54 1274735 1 1/1
56 1206958 3 1/3 2/3 a
62 1164002 3 3/3 a
65 1177834 1 1/1
67 1180532 1 1/1
78 1117415 4 1/4 1/4 2/4 a
82 1104218 3 2/3 1/3
87 1031804 6 6/6 a
94 1028141 1 1/1
101 967572 1 1/1
106 953033 5* 4*/5* a 1/5*
107 954116 1 1/1
126 910264 10 10/10 a
127 899872 5 5/5 a
136 855973 2 2/2
148 823799 1 1/1
155 826119 1 1/1
171 794550 1 1/1
172 799169 1 1/1
189 753374 1 1/1
191 750583 1 1/1
210 721081 1 1/1
213 712053 2 1/2 1/2
243 649553 1 1/1
267 557226 2 2/2
280 591668 1 1/1
286 560763 4 1/4 3/4 a
298 547598 1 1/1
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371 455742 2 2/2
387 458743 2 1/2 1/2
406 430839 1 1/1
420 420531 1 1/1
432 406618 1 1/1
504 321640 1 1/1
534 322847 2 2/2 a
569 289805 5 3/5 a 2/5 a
584 291195 1 1/1
602 276623 1 1/1
603 258472 1 1/1
617 272626 1 1/1
647 175517 1 1/1
651 257338 2 2/2 a
666 239967 1 1/1
755 192998 1 1/1
849 144742 1 1/1
935 100892 1 1/1
976 106701 1 1/1
1094 77432 1 1/1
1157 57567 1 1/1
1309 9014 1 1/1
1312 39141 1 1/1
3258 2785 1 1/1
4337 2026 1 1/1
The table is based on the WG assembly number 2 version A. The number of ADHs present is indicated 
as well as the number of MDRs or SDRs. The contigs containing an ADH proven to be participating in 
the whole MIA pathway are in bold and italic font. The group ‘other ADH’ comprises examples from the 
Aldo-keto reductases (AKR), and the Aldehyde dehydrogenases (ALDH). Contigs in red span the entire 
length of the ADH gene on them, therefore it is not possible, with the current alignment, to know if 
there are other genes next to that ADH.
¥ the size is based on the location of the last gene aligned onto that contig
*This contig contains the HYS duplication and is not of good enough quality to determine if there are 4 
or more copies of HYS. 
a Denotes that two or more of the ADHs are in tandem with at most one other gene between them
ADH10, the SDR described in Chapter 4, is present on the WGC number 27 along with 5 other 
SDRs. The HYSs, described in Chapters 2 and 3, are distributed on different contigs; THAS1 and 
THAS3 are on WGC 371; THAS2 is on WGC 126, which contains 9 other MDRs, one of which 
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(Cr023176) has been shown to be a 10HGO (Krithika et al., 2015); HYS and THAS4 appear 
to be localised in a tandem duplication together with 3 other similar MDRs not found in the 
transcriptome (Góngora-Castillo et al., 2012) on the WGC 106.
5.2.2 Analysis of the ortholog groups present in the MDRs and SDRs of C. roseus
The MDRs and SDRs present in C. roseus could be descended from different families of MDR 
and SDR respectively. To determine what the distribution of these genes is in C. roseus, all the 
MDR and SDR sequences were submitted to BLAST against the Clusters of Orthologous Groups 
(COG, (Tatusov et al., 1997) database using the NCBI batch BLAST server (www.ncbi.nlm.nih.gov/
Structure/bwrpsb/, table 15). 
All C. roseus transcripts annotated as MDRs were identified as belonging to the Zinc-dependent 
ADHs. Twenty-nine of the MDRs were identified as being part of the COG1064 group which 
is classified based on D-arabinose 1-dehydrogenase. COG1064 also contains the CAD/SAD 
enzymes. Eight MDRs were best identified as belonging to the COG1062 (formaldehyde 
dehydrogenase and related Zn-dependent dehydrogenase) group, and one to the COG1063 
(threonine dehydrogenase and related Zn-dependent dehydrogenases) group. Many of the 
remainders are part of the COG0604 groups which contain the quinone reductases (QOR), and 
two homologs are part of the COG2130 group which is represented by a curcumin reductase 
(CurA). One member is COG0647, which constitutes the ribonucleotide monophosphatase NagD 
and the haloacid dehydrogenase (HAD) superfamily. 
Table 15: COG of MDRs from C. roseus.
Gene locus COG e-value Gene locus COG e-value
THAS3 1064 7.74 e-88 Cro022431 1064 1.18e-92
THAS2 1064 7.63 e-95 Cro008301 1064 6.30e-98
THAS4 1064 1.76 e-92 Cro001761 1064 1.79e-112
HYS 1064 1.07 e-89 Cro024150 0647 1.30e-27
Cro017994 1064 5.17 e-97 Cr2141 1064 3.80e-132
Cro011702 1064 2.18 e-102 Cro023176 1064 2.59e-117
Cro030442 1064 1.26 e-119 Cro024340 0604 6.30e-66
Cro006840 1064 1.57 e-118 Cro016395 1062 2.09e-144
Cro022770 1064 3.86 e-96 Cro029195 2130 2.43e-122
Cro033537 1064 2.57 e-93 Cro013040 2130 7.05e-122
Cro033062 1064 5.89 e-80 Cro017213 1064 8.86e-92
Cro011226 1064 1.09e-114 Cro019170 1062 2.36e-149
Cro033830 1062 2.48e-126 Cro020524 0604 1.06e-73
Cro027234 1064 3.99e-102 Cro020525 0604 3.14e-73
Cro005375 1062 1.34e-116 Cro015403 1062 1.42e-156
Cro027079 1064 1.02e-98 Cro017625 1063 6.33e-96
Cro025489 1064 7.83e-104 Cro018598 0604 2.79e-64
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Gene locus COG e-value Gene locus COG e-value
Cro019494 1064 4.93e-116 Cro019716 1062 8.88e-158
T3R 1064 1.10e-106 Cro015629 1062 8.50e-152
Cro026235 1064 3.42e-102 Cro018442 0604 3.34e-100
Cro027235 1064 1.19e-109 THAS1 1064 5.23e-98
Cro016729 1064 4.13e-74
The SDRs generally had a lower e-value to the COG domains in the NCBI database (table 
16). This is probably reflective of their high sequence divergence (typically between 15-30 % 
pairwise identity (Jörnvall et al., 1999)). Most of the SDRs (31 out of 54) corresponded best to 
the COG1028 which corresponds to the group “Dehydrogenases with different specificities” of 
the SDRs. ADH10 (Cr013448) is a member of this group. Another highly represented group (16 
homologs) is the COG0451, which is classified as “Nucleoside-diphosphate-sugar epimerases”, 
and which contains the progesterone-5β-reductases. The early MIA biosynthetic enzyme ISY and 
its homologs belong to this COG. The COG0300, corresponding to a general SDR prediction of 
unknown function, has 3 homologs in the C. roseus genome.
Table 16: COG of SDRs from C. roseus. 
Gene locus COG e-value Gene locus COG e-value
Cr013448 1028 1.64E-40 Cr028099 1028 1.75E-62
Cr033739 1028 1.43E-30 Cr027571 0300 5.06E-55
Cr022864 1028 1.04E-33 Cr027322 1087 1.37E-156
Cr013184 1028 7.86E-63 Cr001335 0300 7.11E-52
Cr013447 1028 1.60E-32 Cr016749 1091 9.21E-48
Cr027095 0451 3.93E-40 Cr016747 1028 1.19E-33
Cr003140 1028 9.85E-39 Cr022212 1028 1.50E-52
Cr028100 1028 2.13E-62 Cr010887 1028 4.71E-61
Cr017503 0451 8.89E-09 Cr001750 1028 1.75E-57
Cr017502 0451 8.13E-11 Cr017031 1028 2.44E-26
Cr030915 0451 1.15E-33 Cr018552 1028 6.19E-60
Cr023278 1028 1.66E-35 Cr022484 0451 2.83E-39
Cr023367 1028 9.77E-49 Cr002309 1028 3.51E-27
Cr010996 1028 1.14E-75 Cr018601 0451 6.67E-35
Cr014890 1028 1.37E-68 Cr008727 0451 5.31E-36
Cr023217 1028 1.63E-47 Cr001235 1028 1.35E-63
Cr006167 0451 1.72E-38 Cr019769 0451 8.34E-45
Cr022002 1028 4.89E-33 AIW09146.1 0451 1.24E-08
Cr001031 0451 1.55E-13 Cr025915 1028 5.97E-33
CrISY 0451 1.82E-06 Cr003619 0451 3.39E-43
Cr033366 1028 7.00E-34 AIW09148.1 0451 1.25E-07
Cr033093 1028 1.94E-55 Cr011094 0300 1.43E-51
Cr000253 1087 1.02E-144 Cr023179 1090 2.25E-107
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Gene locus COG e-value Gene locus COG e-value
Cr019499 1028 4.48E-30 Cr008631 1028 1.82E-28
Cr028501 1028 1.33E-78 Cr004988 1028 8.54E-58
Cr028094 1028 5.63E-60 Cr002470 0451 1.61E-74
Cr028096 1028 3.84E-66 Cr011896 0451 4.60E-39
These results suggest that in both enzyme families there is high divergence which is consistent 
with findings from other published surveys of these families in genomes (Jörnvall et al., 1999, 
Moummou et al., 2012). 
5.2.3 Phylogeny of the C. roseus MDRs
Studies of large gene families, such as that of the MDRs, are facilitated by phylogenetic analysis. 
This method of analysis can identify distantly related paralogs and can illustrate the evolutionary 
relationship between two enzymes which might perform different functions or exhibit a similar 
function but with a different spatio-temporal distribution. A phylogenetic analysis of the MDRs 
contained in the C. roseus transcriptome and genome was undertaken in order to better 
understand the dynamics of the duplications and neofunctionalisation. Alignment using fsa 
resulted in 99.5 % of sites with gaps, compared to mafft which produced 75.6 % and muscle 
which produced 78.4 %. PRANK, although it went through multiple iterations comparing the 
alignments to a parsimony tree it had generated, had only managed 84.2 % sites with gaps. 
ClustalOmega aligned the sequences with 77.4 % gaps (fig. 125, and appendix 5) and was overall 
similar to the muscle alignment, but tended to avoid opening gaps to account for proteins with 
very divergent sequences. 
Figure 125: Example section of MDR ClustalOmega alignment. For full alignment please look 
at Appendix 5. The identical sites are shaded red and the similar sites are shaded orange. The 
shading threshold used is 50 %. Gaps in alignment are illustrated by a ‘-‘.
The MDR protein sequences, aligned with ClustalOmega (Sievers et al., 2011), were analysed by 
Bayesian inference using the program MrBayes (Ronquist et al., 2012). Two independent runs of 
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Multiple-chain Markov chain Monte Carlo (MC3) were executed to test all amino acid models. 
The first run converged to model 5 (WAG) quite fast, which is similar to the result of Maximum 
Likelihood analyses. The exchanges between chains were low and therefore chains were heated 
by 0.125 (default is 0.10). The result was a better sampling across the model space; the average 
effective sample size was above 2000 for the heated runs compared to just above 900 for the 
default runs (see appendix 1 fig. 2 for convergence graphs). The gamma shape parameter, which 
allows the alignment sites to evolve at different rates for each other, was tested as a fixed state 
across all sites (mixed model), or allowed to vary across the alignment (mixed model + gamma). 
Stepping-stone simulation with 1 000 000 iterations was also carried out in MrBayes to verify the 
likelihood of the tree produced by Bayesian inference. 
A phylogenetic tree was produced from the alignment generated above using a Maximum 
Likelihood approach as well. This was done primarily to verify the reproducibility of the topology 
and to gauge the branch support through a different method. The PhyML online server (http://
www.atgc-montpellier.fr/phyml/)(Guindon et al., 2010) was used for this analysis, with the 
automatic model selection enabled, and the gamma shape parameter was also allowed to vary, 
as in the Bayesian inference described above. The resulting tree length was estimated to be 
26.5371 which is almost identical to the tree size estimated with Bayesian inference (26.2916). 
The likelihood for the produced tree was similar to the estimation with Bayesian inference and 
the stepping stone sampling (-23866.80, -23967.83, and -26194.55 respectively). The estimation 
of the gamma shape parameter (2.280) was very similar to that estimated with Bayesian inference 
as well (2.211).
The resulting phylogenetic trees were in general all very similar (fig. 126, 127). The most striking 
feature of the trees is that two groups of MDRs appear to be evolving at different rates. The 
first group, characterised by long branches and few duplications, contains 17 MDRs. The length 
of the branches reflects the divergence these enzymes have undergone since the last common 
ancestor. Conversely, the other group, comprising 27 MDRs (including the HYSs), is characterised 
by short branches and repeated branching. This is reflective of numerous recent duplications. 
The main differences between the phylogenetic tree constructed with Bayesian inference 
or Maximum Likelihood (PhyML) were in the relationship between the two 10HGO enzymes 
(Cr033830 and Cr005375, orange clade in fig. 126-128). Both of these relationships are well 
supported by relatively high posterior probabilities. The section of the trees encompassing the 
HYSs (fig. 126-128) is well supported, but differs slightly in the origin of Cr027234 and Cr027079 
(green clade fig. 126-128). In the tree produced with PhyML, these enzymes appear to have 
evolved after the separation of THAS2 and THAS3 (fig. 126, blue and green clades), but this node 
is not supported by high Bootstrap support (40). However, in the Bayesian inference analysis the 
three branches are present as a trifurcation. The posterior probability is still low (53), but higher 
than the node Bootstrap support in the PhyML tree, and therefore the scenario presented in the 
MrBayes tree (fig. 126) is more conservative. This indicates there is not enough information in the 
data to resolve the relationships at this node. As Cr027234 has been shown by collaborators to 
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also act on strictosidine aglycon, but to yield a different product (unpublished), there is interest 
in resolving these relationships. However, given that half of the enzymes in that clade (fig. 126, 
blue clade) have been shown to be HYSs, it is reasonable to suggest that the progenitor enzyme 
was a HYS, and that the function of Cr027234 is novel and specific to that branch. Similarly, T3R 
(fig. 126 purple clade), the MDR shown to catalyse the reduction of a downstream MIA in C. 
roseus (Qu et al., 2015), is also included in the HYS clade (fig. 126, green clade). This strongly 
suggests that T3R has evolved from a duplication of an ancestral HYS copy which also gave rise 
to the THAS1-THAS4-HYS clade. 
The C. roseus MDRs which show homology to the Rauvolfia serpentina Vomilenine Reductase 2 
(RsVR2, Geissler et al. (2015)) all cluster together inside a sister clade to the HYS clade (fig. 126 
and 127 in red). RsVR2 catalyses the reduction of vomilenine, a downstream MIA also produced 
from strictosidine in R. serpentina (fig. 14, Chapter 1). It is not known if any of these homologs 
(Cr022770, Cr008301, Cr017213, and Cr006068) are able to catalyse the same reduction as RsVR2 
but that clade could represent another group of MDRs capable of reducing MIA substrates.
Since all the HYSs discovered in C. roseus are grouped together, it can be concluded that these 
genes likely arose as a duplication of an ancestral gene which was probably a HYS. Cr023176, a 
member of a sister clade (Cr019494, Cr016729, and Cr023176) to the HYS clade has been shown 
to be a 10HGO (Krithika et al., 2015). This suggests the ancestor to this and the HYS clade could 
have been either a HYS or a 10HGO. However, it is not possible to determine what activity the 
ancestral enzyme possessed without ancestral reconstruction or extensive sampling of enzyme 
activity of that clade in both C. roseus and related species. The ancestral enzyme could also have 
displayed a CAD/SAD activity; Cr2141, present on another sister clade to the HYS clade, has 
previously been shown in our group to be an SAD enzyme (Yerkes, 2010). Although many of the 
MDRs included in this phylogenetic tree have not been experimentally assayed, the sampling of 
candidates described in Chapter 2 suggests HYS activity is found primarily in this clade (fig. 126, 
blue clade). 
171
Figure 126: Bayesian phylogenetic tree of MDRs. This tree is based on a mixed amino acid model 
+ gamma. The posterior probability of each node is indicated next to each node. The HYS clade 
is coloured in blue; T3R is purple; the Cr027234 clade in green; the VR2-homologous clade is 
illustrated in red; and the 10HGO clade is in orange; the bar indicates the changes per site.
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Figure 127: Maximum Likelihood phylogenetic tree of MDRs. Tree produced through online server 
of PhyML. Bootstrap support values are printed next to each node. The HYS clade is coloured in 
blue; T3R is purple; the Cr027234 clade in green; the RsVR2-homologous clade is illustrated in 
red; and the 10HGO clade is in orange; the bar indicates the changes per site.
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Figure 128: Phylogenetic tree of MDRs in C. roseus in radiating representation. The MDR clades 
are coloured as in fig. 126 and 127: HYS clade: blue; T3R: purple; Cr027234 clade: green; RsVR2-
homologous clade: red; and 10HGO clade: orange; the bar indicates 0.5 changes per site. This is 
the same tree as the one displayed in fig. 126.
The radiating representation puts into perspective how recently some of these MDR duplications 
occurred, particularly for the genes in the bottom part of the tree. It is apparent from this tree 
that a group of MDRs has been duplicated throughout the evolutionary history of C. roseus and 
gave rise to the enzymes (HYSs, T3R) capable of catalysing a reduction of a MIA. Two of the 
10HGO (Cr033830 and Cr005375, orange clade in fig. 126-128) on the other hand have not arisen 
from recent radial expansion but rather appear to be offshoots of a smaller clade of MDRs. It is 
unknown if the C. roseus RsVR2-homologous enzymes (red clade in fig. 126-128) are capable of 
catalysing the same reduction as RsVR2, but the substrate (vomilenine) is not found in C. roseus.
5.2.4 Phylogenetic analysis of the C. roseus SDRs
A phylogenetic analysis of the SDR homologs in C. roseus was undertaken to better understand the 
evolution of this family in this plant. This family includes the critical enzyme of iridoid biosynthesis, 
ISY (Geu-Flores et al., 2012), and also ADH10, which, as described in Chapter 4, can reduce 
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strictosidine aglycone to produce a newly discovered molecule similar to vallesiachotamine. 
Interestingly, ADH10 is present in a large WGC, number 27 (table 14), which contains at least 6 
SDRs. An investigation into the phylogeny of this group and into the duplication abundance was 
undertaken to compare to the duplication history of the MDRs, and more specifically the HYSs, 
with the SDRs.
Alignment of the protein sequences was done using ClustalOmega. The high sequence divergence 
between the proteins was evident in the alignment as many sections (particularly the C-terminal 
region) were highly different and alignment in those sections presented mostly indels. This is to 
be expected because, as discussed in Chapter 4, SDRs can vary considerably in the length and 
sequence of the C-terminal domain. Indeed, the minimum sequence identity at sites without an 
indel was just 5.81 % and the largest gap had a length of 130 amino acids (full alignment can be 
found in Appendix 6). Maximum likelihood was used to infer phylogenetic trees through PhyML. 
Bayesian inference was not attempted due to computational limitation.
PhyML using the WAG model for amino acid substitution with the site rate allowed to vary 
(4 gamma states) resulted in a tree of larger length than that of the MDRs (50.67 and 26.53 
respectively). The gamma shape parameter was found to have a value of 2.672, which is similar 
to that found for MDRs. The analysis using the PhyML online server gave very similar results; 
tree length was 50.70 and the gamma shape parameter was determined to be 2.627. The 
preferred model in this case was the WAG + gamma + F (empirical equilibrium frequency). The 
log-likelihood of this tree was found to be - 39976.83 which is very similar to the log-likelihood of 
the tree determined using the command-line PhyML (-39977.67). The tree built using the online 
PhyML server is shown below (fig. 129) but is in general very similar to that obtained through the 
command line PhyML (Appendix fig. 3).
175
Figure 129: Phylogenetic tree of the SDR superfamily in C. roseus. Tree was constructed using 
PhyML; Bootstrap support (number of times the node was returned out of 300 iterations) is 
printed next to the nodes; ADH10-like clade is illustrated in red; ISY-like clade is in blue. ADH10: 
Cr013448. The bar at the bottom represents the distance to 0.6 changes per site.
ADH10 is part of a small clade (fig. 129, red) which is separated from the ISY clade (fig. 129, 
blue). This supports the COG analysis that determined that these two enzymes were members 
of different SDR groups. The tree suggests that ADH10 is part of a block of relatively recently 
duplicated SDRs. It is not known what function the other SDRs in the ADH10 clade carry out. 
ISY is also part of a recent duplication and the other members of that clade (fig. 129, blue) have 
been shown to also display ISY activity (Munkert et al., 2015). A better sampling of the SDRs in 
C. roseus would allow a more detailed understanding of the SDR phylogenetics, and how this 
relates to secondary metabolism.
An in-depth characterisation of the SDRs of plants found that some subfamilies of the SDRs had 
evolved after the split of vascular plants from Bryophytes (Moummou et al., 2012). Interestingly, 
PsSalR, the enzyme used for molecular replacement when solving the crystal structure of 
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ADH10 (Chapter 4), is a member of one of these groups, and therefore ADH10 is as well. These 
subfamilies had expanded through duplications in the vascular plant genomes and have given 
rise to many enzymes involved in secondary metabolism (Moummou et al., 2012). These data 
allowed the authors to suggest that the SDRs in plants were used as an adaptative character 
during land colonisation and development of the vascular apparatus. 
5.2.5 Comparison of C. roseus duplication blocks to other plant genomes
The discovery that CAD and SAD enzymes are found in duplicated blocks in Populus (Barakat et 
al., 2009), rice (Tobias and Chow, 2005), and Arabidopsis (Kim et al., 2004) suggests that these 
enzymes are often duplicated and the copies are retained in the genome. The largest cluster of 
duplicated MDRs in C. roseus (WGC number 126) contains 10 MDRs (fig. 130). To test whether 
this block is similar to the CAD/SAD duplication blocks observed in other species, a phylogenetic 
alignment between the gene copies found in the WGC126 cluster and MDR copies in other plant 
genome clusters was attempted.
The ensembl Plant Genome Database was used for this analysis as it hosts many of the assembled 
plant genomes available. This database also has the advantage that it has pre-aligned syntenic 
blocks of genomes. Unfortunately, it is not currently possible on this database to conduct syntenic 
alignments of a query sequence.
Figure 130: MDR cluster arrangement on WGC 126. The arrows point in the direction of the gene 
ORF; the cluster is not drawn to scale.
The WGC 126 cluster member MDR Cr2141 was chosen as bait for this phylogenetic analysis 
because this gene robustly and repeatedly aligned onto all of the plant genomes queried. Cr2141 
was submitted to BLAST against the A. thaliana genome assembly on the ensembl Plant Genomes 
Database using the TBLASTN tool. A. thaliana is the only plant genome in this database onto 
which all others have been syntenically aligned. A close inspection of A. thaliana chromosome 4 
(region 17840497-17867094) revealed that there are 3 highly similar genes to C. roseus Cr2141 
(AtCAD6, ELI3-1, and ELI3-2 in that order) (fig. 131). These three genes have been the subject of 
an investigation, and have been shown to have CAD/SAD activity (Kim et al., 2004). 
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Table 17: Plant species used in cluster duplication analysis
Lycopodiophyta Bryophyta Chlorophyta
Selaginella moellendorffii Physcomitrella patens Chlamydomonas reinhardtii
Asterids Rosids Monocots
Catharanthus roseus Vitis vinifera Oryza sativa Japonica
Solanum lycopersicum Theobroma cacao Setaria italica
Solanum tuberosum Prunus persica Hordeum vulgare
Populus trichocarpa Musa acuminata
Medicago truncatula Brachypodium distachyon




This section of the A. thaliana genome was then aligned to syntenic regions on the other plant 
genomes on the ensembl Plant Genomes Database (detailed in table 17). Not all plants were 
used due to redundancy; for example, Brassica napus and A. lyrata were not used because three 
other Brassicaceae were already used. out of a total of a total of 43 species with genomes hosted 
on ensembl 21 were used in this study, with most of the Rosids and all of the Asterids included. 
The syntenic regions to A. thaliana chromosome 4 section were displayed in parallel (fig. 131, 
pink regions). Overall there was good conservation of syntenic blocks at this locus among the 
species listed except for P. patens, S. moellendorffii, and C. reinhardtii. The cluster in G. max 
appears to be split between the first and the second gene. The synteny among these plants 
strongly suggests that this genomic locus is conserved and often presents duplicated MDRs.
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Figure 131: Syntenic regions between A. thaliana and other plant genomes at the Cr2141 
homolog locus on chromosome 4. Figure created in ensembl Plant Genome Database. The plants 
are listed on the left side of the figure. The A. thaliana genes are illustrated at the top of the 
figure with exon-intron structure indicated. The positive hits of Cr2141 are illustrated under the 
A. thaliana genes in orange blocks. The syntenic blocks of other organisms are indicated as pink 
bars below. The area of interest is boxed in a green dashed line. The species displayed in this 
figure are: Brachypodium distachyon, Medicago truncatula, Physcomitrella patens, Selginella 
moellendorffii, Populus trichocarpa, Prunus persica, Solanum lycopersicum, Glycine max, 
Theobroma cacao, and Vitis vinifera.
A phylogenetic analysis of these identified syntenic genes was carried out to investigate whether 
the syntenic blocks of duplicated MDRs are dynamically duplicating throughout evolution or 
if they have been inherited as a block and conserved over evolution. The A. thaliana 3-MDR 
cluster, which comprises 3 CAD genes (Kim et al., 2007), was aligned to various other plant 
genomes. Most organisms presented at least 2 copies, and one plant (P. persica) had 8 tandem 
duplications. Some organisms had more than one genome block aligning to the A. thaliana one, 
potentially arising through genome duplication, or duplication of a chromosome section during 
whole genome duplication (Barakat et al., 2009).
5.2.6 Phylogenetic analysis of syntenic blocks
The genes of these duplication blocks were collected from 21 plant species (table 17) and 
were annotated using the naming system: Species/cluster number/copy number. The aligned 
sequences were analysed using the online PhyML server with the automatic model selection. 
This resulted in a tree (fig. 132) with overall good support for the branches. 
In general, the monocots group together near the base of the tree, with SORBI1.1 and 3.1 
(S. bicolor) as a sister clade to all others (fig. 132, blue). The Rosids in general group together 
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(fig. 132, red), as do the Asterids. SOYBN1.2 (G. max) is very far removed from SOYBN1.1 and 
does not group with any of the Rosids or Asterids. This indicates this MDR might not be truly 
homologous to the others as it does not group with the Fabaceae or Rosids clade (fig. 132, 
brown and red respectively). Another striking finding is the presence in M. acuminata of an MDR 
copy (MUSAM1.2) that does not group with the monocots. This was placed as a sister clade 
to the majority of the Asterids, but is supported there by a low Bootstrap value (0.298). Thus 
MUSAM1.2 could represent a copy of an MDR at that locus which occurred before separation of 
eudicots from monocots. This analysis is biased however because 5 out of 6 monocots analysed 
all belong to the Poales monocot clade and only one, M. acuminata, belongs to another monocot 
clade, the Zingiberales. In fact, M. acuminata is the only non-Poales monocot with a genome on 
the ensembl Plant Genomes Database. Without other monocot genome sequences from phyla 
outside the Poales it is not possible to draw any conclusions about the split of M. acuminata 
MDRs. Therefore this gene in M. acuminata could be a copy which was lost in the Poales clade, 
but retained in the Zingiberales. Likewise, two C. roseus MDRs (Cr027235 1.5 and Cr2141 1.6) 
are positioned outside the Asterids/Rosids clade together with some of the Brassicaceae (Rosids) 
MDRs (fig. 132, pink and green clade). This could represent an ancient duplication that occurred 
before the divergence of Rosids and Asterids which was retained in C. roseus, A. thaliana, B. 
rapa, and B. oleracea. 
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Figure 132: Phylogenetic tree of cluster MDRs from plant genomes. This tree was constructed 
using PhyML; bootstrap support values are printed next to each node; in lilac: the Lycopodiophyta, 
Bryophyta, and Chlorophyta; blue: monocots; orange: Rosids; green: Brassicaceae (also Rosids); 
brown: Fabaceae (also Rosids); pink: Asterids (includes C. roseus). Bar at the bottom represents 
distance of 0.2 changes per site.
The MDRs in the clusters of A. thaliana, B. rapa, and B. oleracea, are split into two groups. 
One group contains ARATH1.1, BRAOL2.2, and BRARP1.2, and the other contains ARATH1.2, 
ARATH1.3, BRAOL1.1, BRAOL2.1, and BRARP1.1. This signifies that in B. oleracea and B. rapa the 
duplicated clusters have been differentially conserved. It also illustrates that the genes have not 
been duplicated locally and retained since at least the divergence of these 3 plant species.
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In T. cacao we observe two phyla containing MDRs; one which is a sister clade to the Fabaceae 
MDRs, and one which is positioned among the V. vinifera-containing clade. This suggests the 
cluster in this organism is composed of ancient duplications which have gone on to diverge 
enough so as to appear in two separate clades. V. vinifera and T. cacao group in the clade 
containing the other Rosids such as P. persica and P. tremuloides, and also the Fabaceae such as 
M. truncatula and G. max.  
Eight of the C. roseus MDRs group with the asterids (S. lycopersicum, Solanum tuberosum) which 
is expected, and in general the duplications have good support. S. lycopersicum appears to have 
a duplication of the cluster which is not found in S. tuberosum (SOLLC2.3 and SOLC2.4 do not 
have homologs in S. tuberosum).
The grouping of two C. roseus MDRs with some of the Brassicaceae MDRs indicates there is a lot 
of information missing in this analysis. There are relatively few Asterid genomes represented in 
the tree, compared to Rosids and Monocots. The two Asterid genomes other than C. roseus are 
relatively closely related and therefore do not provide a great deal of novel information about 
the Asterids clade. More sequences of plants in the same family as C. roseus could help resolve 
some of the nodes and provide a clearer Asterid/Rosid distinction.
Finally, it is apparent from this phylogenetic analysis that the copies of the MDRs are not present 
in a conserved duplicated block, but rather they are dynamically duplicating throughout the 
evolution of these plant species. The repartition of the copies mostly in groups of related 
plant species indicates the duplications have occurred at a later stage after the radiation of 
spermatophyta into the different clades. A similar conclusion was drawn by Barakat et al. (2009) 
when studying the genomic organisation of the CAD/SAD genes in the available plant genomes.
5.3 Discussion 
5.3.1 Genomic context of MDRs and SDRs in C. roseus 
The whole genome sequencing and assembly of C. roseus has revealed that MDRs and SDRs 
are often present in clusters of duplicated genes. Most notable in C. roseus is the cluster on the 
WGC number 126 which contains 10 MDRs (fig. 130). One of the copies in that cluster is THAS2, 
another one (Cr024234) has been shown by collaborators to produce a different product from 
strictosidine aglycon, and a third copy in the cluster (Cr023176) has been shown to have 10HGO 
activity (Krithika et al., 2015). Another interesting cluster is on WGC number 27 which presents 
6 copies of SDRs. These, conversely to the MDR cluster on WGC 126, are mostly not in tandem 
duplication. One of the SDRs in this cluster has been shown to reduce strictosidine aglycon and 
produce a product with yet another structural conformation (Chapter 4).
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5.3.2 Ortholog groups in MDRs and SDRs
The analysis of the Clusters of Orthologous Groups (COGs) of the MDRs and SDRs indicated the 
scope of variation present in these enzyme families. MDRs and SDRs of C. roseus appear to be of 
diverse origin based on the predicted COG for each predicted protein. This is in accordance with 
whole family studies that have been conducted with MDR and SDR sequences present in online 
databases (Persson et al., 2008, Jörnvall et al., 1999, Riveros-Rosas et al., 2003). 
5.3.3 Phylogeny of MDRs in C. roseus
The C. roseus MDRs were collected from the transcriptome and genome but it is possible some 
MDRs have not been included in the alignment and the phylogenetic analysis. Protein alignment 
showed the presence of large insertions-deletions at flexible loop regions, which presumably 
impact the catalytic function of these enzymes. A phylogenetic study of the C. roseus MDRs 
suggests that there are two distinct patterns of MDR evolution in this plant. The first is the 
largely non-duplicating MDRs placed on long branches (fig. 128, top half). These genes could be 
implicated in primary metabolism and are therefore under selective pressure to maintain both 
sequence and copy number. To verify this hypothesis, MDRs from those branches would have to 
be tested for their predicted activity.
The second pattern includes a more radially diverging group of MDRs that have undergone recent 
duplication. Ten of these highly duplicated MDRs are present in the large MDR cluster on the 
WGC number 126 which, in theory, arose through tandem duplications (discussed above). This 
supports the results of the phylogenetic analysis which places all these genes in clades near each 
other. Their recent divergence is evidenced from the short branches which reflect the number of 
changes to the protein sequence accrued since duplication. The MDRs in C. roseus which were 
shown to have activity with strictosidine aglycon (THAS1-4 and HYS) cluster on one clade of the 
MDR phylogeny tree (fig. 126 and 127), whereas the C. roseus homologs in the RsVR2 group 
cluster on another highly duplicated branch. Therefore, it is reasonable to suggest that this 
subfamily of MDRs has led, through duplication and neofunctionalisation in the Apocynaceae, to 
increased chemical diversity.
The tree produced here of the MDRs in C. roseus recalls the MDR tree constructed in Jörnvall 
et al. (1999) in which the plant MDRs cluster in a very highly duplicated branch. This behaviour 
of plant MDRs could be providing the primary material for neofunctionalisation and ultimately 
chemical diversity.
5.3.4 Phylogeny of SDRs in C. roseus
Conversely to the MDR phylogenetic tree, the SDR tree does not display any large differences in 
diversification rate. The tree however is about twice as long as that of the MDRs even though 
there are only 10 sequences more (54 protein sequences for SDRs vs. 44 for MDRs). The SDRs do 
not appear to have undergone a radial duplication and diversification recently, as evidenced by 
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the lack of highly duplicated branches such as that seen in the MDR phylogenetic tree (fig. 128). 
Instead, the SDR phylogenetic tree displays multiple clades with numerous duplication events in 
each one. The duplication of the ADH10 locus (Cr013447 and Cr016747) suggest these copies 
might be the material for further neofunctionalisation.
5.3.5 MDR duplication blocks in other plant genomes
To investigate whether the large duplicated MDR locus of WGC 126 was found more widely 
among the plant kingdom, one of the genes of this locus, Cr2141, was submitted to BLAST 
against the plant genome database on ensembl (Kersey et al., 2016). Cr2141 was chosen because 
homologs of this gene were found most widely among other plant species. A total of 21 plants 
were analysed, and a similar cluster of MDRs was identified through syntenic alignment in 18 
plants. This intriguing result could either suggest that an ancient duplication of an ancestral MDR 
had occurred before divergence and speciation and that it was conserved among all these plants, 
or it could suggest that this locus was constantly being duplicated and presents an example of 
active gene birth/death.
To answer this question, a phylogenetic tree was constructed using the protein sequences of 
the MDR gene homologs found in these loci. The results indicate that the second scenario is 
more likely, since the paralogs and orthologs display a grouping among species and not among 
orthologs. This suggests that repeatedly during evolution, MDRs were duplicated at that 
location. The repeated “duplication after speciation” across almost all plant species analysed 
signifies that the MDRs at this locus might be highly duplicating across the angiosperms. There 
are undoubtedly other examples in plants of this phenomenon, perhaps even in other MDR or 
SDR clusters.
Jörnvall et al. (1999) observed, when constructing a phylogenetic tree of the MDRs and SDRs from 
published genomes, that the MDRs appear to be more often recently duplicated with subsequent 
neofunctionalisation than the SDRs. This is also observed in the C. roseus MDR dataset (fig. 128) 
which illustrates the recent expansion through duplication of the CAD-like MDRs.
5.4 Conclusions
This chapter investigates the role of gene duplications as drivers for chemical diversity. 
Duplication and redundancy has been observed for other MDRs and specifically members of 
the CAD subfamily. The A. thaliana CAD5 is the most active isoform for sinapaldehyde but its 
knockout does not significantly hinder production and deposition of lignin, indicating that the 
redundancy of CAD and SAD in Arabidopsis is enough to result in the eventual full deposition 
of lignin up to wild-type levels (Kim et al., 2004). A similar enzymatic redundancy is observed 
in the HYSs of C. roseus (Chapter 2 and 3 and detailed in Stavrinides et al. (2016)). Therefore, a 
phylogenetic analysis of the enzyme family in C. roseus was carried out to better understand the 
evolution of this family. 
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The resulting phylogenetic trees of the C. roseus MDRs were in general well supported. To 
increase the confidence levels in the trees, comparison with a structure-based alignment would 
be ideal. However, there is not nearly enough structural data available for this analysis. In 
the C. roseus MDRs the main differences evidenced when the protein crystal structures were 
aligned were found mainly in the loop regions. These regions appeared to have undergone many 
insertion-deletions which makes alignment of the sequences difficult without additional support 
from crystal structure alignments. Diversification in these loop sections, brought about through 
genetic drift, is likely to be key for acquisition of novel enzyme functions. As described in Chapter 
3, loop sections above the active site of THAS1 and HYS played a key role in modulating the 
catalytic function of these enzymes.
The phylogenetic tree of the MDRs suggests that the HYSs enzymes have originated from a 
single ancestral enzyme that underwent several duplications. Numerous enzymes with HYS/
THAS activity have been identified from C. roseus and it is not clear what role this enzymatic 
redundancy has in the plant. It is apparently a stable state, given the divergent sequences of 
these enzymes. Stable duplication without subsequent co-option is possible in the case that 
an increase in dosage does not have a negative effect on the organism. Favourable selection 
of this dosage increase would result in the maintenance of the doubled gene and its role in 
the biological system (Ganfornina and Sánchez, 1999). This could be a driving force behind 
maintenance of all the HYSs in the C. roseus genome. Furthermore, the evidence suggests that 
downstream pathway genes such as T3R or Cr027234 might have evolved from duplications of 
a HYS gene or an ancestral HYS gene. This is expected, as an active site already suited to accept 
a certain type of substrate is primed for catalysis of a similar reaction on a slightly modified 
substrate (Gerlt and Babbitt, 2001). Therefore, it is hypothesized that it is likely the same group 
of genes will be duplicated again in the future and give rise to more chemical and functional 
diversity in the pathway.
Furthermore, the phylogenetic analysis of the MDRs suggests that THAS1-4 and HYS have 
originated from the same ancestral MDR. This information, combined with the information 
that the MDR copies on the duplicated block of WGC 126 have been constantly duplicating 
throughout the angiosperm evolution (described above in section 5.3.5), suggests WGC 126 was 
the original location of their ancestral genes. Indeed, THAS2 is still present on the WGC 126. 
Intriguingly, the location of THAS1 and THAS3 in close proximity on the WGC 371 to a copy of the 
indispensable iridoid biosynthetic gene Secologanin Synthase (SLS, (Irmler et al., 2000)) suggests 
this location could be the seed to generation of a biosynthetic cluster such as those observed in 
some other plants (Field and Osbourn, 2008). As discussed in Chu et al. (2011), it appears that 
biosynthetic cluster genesis in plants is effectively a recruitment process in which duplicated and 
neofunctionalised genes are slowly recruited to a genomic locus near the other genes of that 
pathway. As the MIA biosynthetic pathway in C. roseus is not unidirectional after generation of 
strictosidine, but rather can follow any of a multitude of pathways for generation of hundreds of 
MIAs, it is not clear if such a biosynthetic cluster would be “useful” for the plant. A more detailed 
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genomic analysis and a more complete genome sequence of C. roseus could help address this 
question of how clusters for complex, highly branched biosynthetic pathways are formed.
Overall this work indicates that actively duplicating loci in the medicinal plant C. roseus could 
provide the material for pathway diversification in secondary metabolism. Abundant duplication 
of HYS could signal a positive selection pressure for more of this enzyme. These duplicated genes 
could be undergoing mutational drift to give rise to new functions. As discussed by Kliebenstein 
(2008), tandem duplications are more commonly found for genes which are not part of the 
primary metabolism, but secondary metabolism can display and benefit from gene duplications. 
5.5 Materials and Methods
5.5.1 Reductase sequences
The transcriptome and genome annotations were searched manually for medium- and short-
chain dehydrogenases/reductases by searching for the GO terms characteristic of ADHs (‘cinnamyl 
alcohol dehydrogenase’, ‘Rossman-fold superfamily protein’, ‘elicitor-activated gene’, ‘zinc-
binding dehydrogenase’, etc.). The candidates were fetched from the transcriptome and their 
identity was verified by first determining the open reading frame of the gene (using the online 
server expasy.org (Gasteiger et al., 2003)) and then BLASTing the predicted protein sequence 
against the NCBI protein database to manually verify the protein family and the completeness 
of the sequence. 
The protein sequence of each reductase was subjected to a search against the Clusters of 
Orthologous Groups (COG, Tatusov et al. (1997)) database v.1 of NCBI (Marchler-Bauer et al., 
2015) to determine which family of MDR or SDR each protein belongs to. This was done to get a 
better idea of the general diversity of the MDRs and SDRs in this dataset.
The CDS, protein sequence, and genomic locus of the reductases were manually collected using 
the software Geneious v. 8 and the unpublished whole genome assembly version 2.A (Buell and 
Kim, in preparation). 
5.5.2 MDR phylogenetic analysis
The MDR protein sequences were aligned using different software which employ different 
algorithms. Alignment was done with the software Fast Statistical Alignment (fsa, (Bradley et al., 
2009)), using a gap open penalty of 1, with the software PRANK ((Whelan and Goldman, 2001), 
with the default parameters, using the software mafft v7.271 (Katoh and Standley, 2013) using 
the defaults. RAxML v8.2.8 (Stamatakis, 2014) was executed to test which model would best 
explain the protein alignment given empirical amino acid frequencies.
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The MDR protein alignment that was produced with ClustalOmega (Sievers et al., 2011) was used 
as input for a phylogenetic analysis using the PhyML online server (http://www.atgc-montpellier.
fr/phyml/) (Guindon et al., 2010). PhyML uses Maximum Likelihood estimation to select the 
most likely tree given the model and the data. The automatic model selection was used with 
Akaike Information Criterion as the selection criterion and NNI (Nearest Neighbor Interchange) 
as the tree improvement method. Bootstrap support was calculated based on 100 runs.
Bayesian inference was used in parallel to calculate a phylogeny of the MDRs protein sequences. 
MrBayes v. 3.2.0 (Ronquist et al., 2012) was used in an Ubuntu environment using the 
ClustalOmega alignment of the MDRs. Multiple-chain Markov chain Monte Carlo (MC3) is used in 
all analyses with 4 chains, unless otherwise specified. Initially the 4 chains were heated with the 
defaults. A test run was executed with two MC3 runs, setting the amino acid model to “mixed” 
to test which model best fit the data. The MC3 runs both converged to one model (WAG, Whelan 
and Goldman (2001)). Convergence was monitored by plotting the run results in Tracer (http://
tree.bio.ed.ac.uk/software/tracer/).
The simple “mixed” model (1000000 generations) was compared to the more complex model 
which allows for variation in evolutionary rates between sites “mixed + gamma” (713000 
generations). Again both runs converged on the WAG model but the fit to the data was slightly 
better when including the gamma factor in the model (log likelihood of -239887 for mixed + 
gamma compared to -243647 for simply mixed). Due to the high demands of Bayesian inference 
on computation time specific amino acid substitution models were not tested individually.
5.5.3 SDR phylogenetic analysis
The SDR protein sequences (54) were collected from the C. roseus transcriptome (Góngora-
Castillo et al., 2012) and the assembled WGC version 2.A. The sequences were aligned using 
ClustalOmega (Sievers et al., 2011) and the alignment was verified visually with SuiteMSA 
(Anderson et al., 2011). The alignment was used to infer a phylogenetic tree using both the 
PhyML online server (www.atgc-montpellier.fr/phyml) and the command-line based PhyML 
version 3.0 in an Ubuntu environment (Guindon et al., 2010). 
The online server was run with automatic model selection and 300 bootstrap iterations. In the 
command-line PhyML, where automatic model selection is not possible, the WAG amino acid 
substitution model (Whelan and Goldman, 2001) was selected, and branch support values were 
calculated using aLRT (cubic approximation, mixture of Chi2s distribution). In both cases the 
starting tree was inferred using BioNJ and was improved through NNI. The gamma was allowed 
to vary across 4 different classes to account for different substitution rates at different sites of 
the protein sequence. The resulting trees were visualised using Figtree (http://tree.bio.ed.ac.uk/
software/figtree).
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5.5.4 Phylogenetic analysis of syntenic blocks
The protein sequence of Cr2141 was submitted to BLAST against the genome of A. thaliana 
of the ensembl Plant Genome Database (http://plants.ensembl.org, release 32)(Kersey et al., 
2016). The A. thaliana positive hit region with the highest identity was studied in more detail. A 
syntenic alignment of this chromosomal section of A. thaliana was made to identify conserved 
duplication regions in other plant genomes. The identified loci from other organisms were 
collected after verifying they were MDRs. 
An alignment of the MDRs, together with the 10 C. roseus MDRs of the WGC 126 cluster, was 
made in MEGA using a ClustalW algorithm (Thompson et al., 2002) with a BLOSUM matrix. The 
gap open penalty was 10 and the gap extension penalty was 0.1. This was verified visually before 
using the alignment to construct a tree in MEGA. Tree construction was done by Maximum 
likelihood using the UPGMA (Unweighted Pair Group Method with Arithmetic Mean) hierarchy 
method with 300 bootstrap iterations. Two different amino acid models were tested; the PAM 
matrix (Dayhoff) (Dayhoff and Schwartz, 1978) and the JTT matrix (Jones et al., 1992). The 
mutation rates were allowed to vary across protein sites by setting a Gamma distribution.
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There and back again: a tale of scientific discovery from chemical to genetic diversity and back 
again
6.1 Heteroyohimbine synthases
In the 1970s it was first demonstrated that heteroyohimbines, a type of  monoterpene indole 
alkaloid (MIA), are the products of enzymatic reduction of strictosidine aglycon (Stöckigt et al., 
1976). Forty years later, the enzymes have finally been cloned and characterised, as described 
in Chapters 2 and 3. This discovery was made possible through a transcriptome database of C. 
roseus (Góngora-Castillo et al., 2012), a medicinal plant that produces hundreds of MIA, inlcuding 
several heteroyohimbines. The chemical structural diversity of the MIA in this and related 
plants stems from the reactivity of the pathway’s central intermediate, strictosidine aglycon. As 
discussed in detail in Chapters 1, 3, and 4 this intermediate can rearrange intramolecularly to 
yield structurally different MIA. How the reactivity of such compounds is controlled, or how it 
can be exploited, is of great interest to efforts in enzyme engineering, biocatalysis and genetic 
engineering of pathways in heterologous hosts.
The group of enzymes that catalyse the formation of the heteroyohimbines have been named 
heteroyohimbine synthases (HYS). Five HYSs were identified and were found to be related at 
the sequence and structural level. However, one enzyme produced dramatically different 
ratios of the three heteroyohimbines found in C. roseus: ajmalicine, 19-epiajmalicine, and 
tetrahydroalstonine (fig. 133). Site directed mutational analysis and structural characterisation 
allowed the identification of the active site elements that control the stereoselectivity among 
these enzymes (Chapter 3). 
The redundancy and the localisation of some of these HYSs to the same compartment as 
Strictosidine glucosidase, the enzyme that generates strictosidine aglycon, suggests that the 
HYSs could be part of a directed overflow metabolism (Frelin et al., 2015). In this model, the 
strictosidine aglycon is a reactive and toxic intermediate that, while playing a role in plant 
defence, can also pose a threat to the plant producing it. The reaction of the HYSs serves as a 
mechanism to neutralise excess strictosidine aglycone into an unreactive, non-toxic product. 
6.2 Enzymatic generation of the vallesiachotaman skeleton
The HYSs are alcohol dehydrogenases, specifically of the Medium-chain dehydrogenase/
reductases (MDRs) class. An alcohol dehydrogenase from the Short-chain dehydrogenase/
reductase (SDR) class was also discovered to reduce strictosidine aglycon to generate a 
skeleton unrelated to the heteroyohimbines. This enzyme, ADH10, acts on a different isomer 
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of the strictosidine aglycon substrate than the HYSs. ADH10 is the first enzyme discovered to 
generate the so-called vallesiachotaman skeleton of MIA (fig. 133). This has provided us with an 
unprecedented view into the dynamics of the strictosidine aglycon intermediate. This enzyme 
could form the basis of a search for similar enzymes taking part in MIA in C. roseus and other 
plants both at the central branchpoint of strictosidine aglycon and at other parts of the pathway.
Figure 133: The heteroyohimbines of C. roseus and vitrosamine.
6.3 Phylogenetics reveals evolution dynamics in the HYSs
Discovery of multiple HYSs raised questions about their evolution and role in the development 
of the downstream pathways in MIA biosynthesis. The whole genome sequencing of C. roseus 
revealed the genomic location of many enzymes related to HYSs, allowing an understanding 
of the genomic context of these genes. A phylogenetic analysis of the entire MDRs enzyme 
family revealed that the HYSs are part of a rapidly duplicating group which also appears to have 
produced other MIA biosynthetic enzymes such as T3R (Qu et al., 2015) and Cr027234 (Chapter 
5). This group of rapidly duplicating MDRs could be providing the primary material necessary for 
evolution of novel enzymes capable of acting at different parts of the pathway.
More specifically, the phylogenetics of the THAS and HYS enzymes (Chapter 5) suggests that 
these enzymes are descended from the same ancestor gene. The genome assembly v. 2.A places 
THAS1 and THAS3 in the same genomic locus as an upstream pathway gene, SLS. The distant 
relationship between THAS1 and THAS3 makes them unlikely to be locally duplicated. Instead, 
these genes appear to have been recruited by relocation to this genomic location. This could 
represent a novel finding in plant secondary metabolism research, as it has been posited that 
biosynthetic clusters in plants originate via piecewise recruitment to a common genomic locus 
(Chu et al., 2011). The “birth place” of THAS1 and THAS3 was most likely the highly duplicated 
MDR cluster on the WGC 126 (Chapter 5) as they both have similar paralogs in that cluster. The 
physical emergence of these clusters is not yet understood at the molecular level. The potential 
advantage a clustered pathway could have on the host plant (co-expression, co-inheritance) 
could be the driving force for the maintenance of the clusters (Chu et al., 2011). 
6.4 Future directions
The MIA pathway of C. roseus is still not fully elucidated. The enzymes discovered throughout 
this project and described in this thesis can act as a basis upon which to discover the missing 
enzymes of this pathway. Enzymes which have evolved from the same ancestral gene could show 
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different activities against MIA pathway intermediates. In fact, an MDR enzyme related to THAS 
has recently been discovered to act on a downstream part of an unrelated (sparagan type) MIA 
pathway in the related plant Rauvolfia serpentina (Geissler et al., 2015). A detailed investigation 
of such plants with diverging MIA pathways will only add to the rich diversity of enzyme function.
All of the enzymes described here in this thesis have been shown to be stereoselective imine 
reductases. There is industrial interest in stereoselective enzymes and the results described here 
could be built upon to expand the enzymatic toolbox. Exon shuffling is an efficient method used 
in protein engineering for developing novel functions. The loop swapping in HYS and THAS1 
described in Chapter 3, although not an entire exon swap, illustrates how swapping an active 
site loop from a specific enzyme into a promiscuous enzyme resulted in a new, stable, specific 
enzyme. Additional protein engineering strategies, such as DNA shuffling, could also be used to 
expand the substrate and product scope of these enzymes.
Finally, this work touches on the evolution of the MDRs and the related enzymes, Short-chain 
dehydrogenase/reductases. The phylogenetic tree of the MDRs suggests that a branch of these 
enzymes has been duplicated numerous times. This extensive duplication suggests that there 
has been a vast amount of neo-functionalisation in this group of enzymes. This branch of highly 
duplicating MDRs could serve as an excellent starting point when searching for reductases in 
other plant biosynthetic pathways.
6.5 Perspectives and outlook
The advancements of transcriptome and genome sequencing have allowed us to glean, for the 
first time, the mechanisms underlying adaptation and evolution in the context of secondary 
metabolism. It is remarkable to be able to discover and test the effects of each mutation and of 
each gene duplication. As it has been once said “nothing in biology makes sense except in the 
light of evolution” (Dobzhansky, 2013). In C. roseus we have now shown several examples of how 
the chemical diversity is a direct result of the genetic diversity. It is due to selective pressures 
that enzymes such as HYSs have evolved the ability to reduce strictosidine aglycone into different 
compounds and substrates from other parts of the MIA pathway.
The selective pressures that drive MIA evolution in C. roseus and other plants is still not known. 
It is not clear if these secondary metabolites of C. roseus take part in plant defence by deterring 
herbivore feeding or by preventing infection by pathogens. Although there have been some 
attempts to test the role of these alkaloids, the complexity of the mixture that is produced 
by the plant has greatly complicated these ecological studies. Feeding studies on insects with 
purified strictosidine and analogues did not show any clear effect on the lifecycle of a generalist 
herbivore (Spodoptera littoralis) but did have a slight growth-retardant effect at the young larval 
stage (Sudžuković et al., 2016). Similar questions have been posed about the enormous terpene 
chemical diversity and the role evolution has played in expanding the diversity of this family of 
compounds in plants. It is generally accepted that terpenes play a role in plant interactions with 
the environment, in particular in plant-insect interactions. The repeated appearance of increased 
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terpene chemical diversity in plant evolution suggests that chemical diversity is beneficial per se 
(Pichersky and Raguso, 2016). A similar driving force could well be responsible for the chemical 
diversity of indole alkaloids observed in the Apocynaceae. 
Since the discovery of plant secondary metabolites, many hypotheses have been proposed to 
explain why plants would produce such compounds. An early argument that these secondary 
metabolites were the waste products of the plant has fallen out of favour. Instead the prevailing 
current theory is that the plants have evolved the metabolites as a defence against predators 
(Zenk and Juenger, 2007). However, the work presented in this thesis suggests an additional, 
more nuanced explanation. I hypothesise that the heteroyohimbines initially appeared as the 
product of an overflow detoxification mechanism. Whether the heteroyohimbines fulfil an 
additional biological role in the plant remains unknown: the role of the heteroyohimbines in the 
plant (signalling, storage, defensive compound etc.) is not well understood and so conclusions 
cannot be drawn on this point. My hypothesis however does not explain why numerous 
HYSs are present in the plant, and why an enzyme has evolved (HYS) to produce a variety of 
heteroyohimbine stereoisomers. Explaining the enormous chemical diversity that is present in 
many plants remains a challenge.
It is not known whether evolution favours a secondary metabolism that is promiscuous or 
selective. What we can analyse at any point of time is a product of the life history of the species 
under study; the species, and the individual, is the result of a long line of successful ancestors. 
Unfavourable alleles are usually lost from the population. Therefore, the collection of genes and 
alleles that we discover in a modern organism must not carry a significant cost to them. To carry 
the argument to its logical conclusion, I argue that if there is no inherent detrimental effect for 
the plant to possess a diverse secondary metabolism, then that is what it will tend to naturally. 
Mutations will occur over its evolution which will increase chemical diversity. If the compounds 
produced do not promote a disadvantage to the host there will be no negative selection pressure 
to stop producing them. Inversely, if the new chemical diversity increases the fitness of the host 
then the new genes or alleles will increase in frequency in the population.
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Figure 1: Convergence graphs for MC3 run with “mixed + gamma” model. A: Log Likelihood of 
model, LnL; B: Tree length, TL; C: Log of the prior density, LnPr; D: estimation of the gamma 
factor, alpha; E: Mixing graph for parameter LnL.
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Figure 2: Phylogenetic tree of the SDR superfamily in C. roseus. Tree was constructed using 
PhyML through command-line in an Ubuntu environment; Branch support values (aLRT-based, 
combination of Chi2s) are printed next to the nodes; ADH10-like clade is illustrated in red; ISY-




Figure 3: COSY of ADH10 product, vitrosamine.
Figure 4: HSQC of ADH10 product, vitrosamine. Red cross-peaks depict to negative projections 
and correspond to carbons attached to an even number of hydrogens. Black cross-peaks depict 
positive projections and correspond to carbons attached to an odd number of hydrogens.
205
Figure 5: H2BC of ADH10 product, vitrosamine. Cross-peak correspond to proton and carbon 
spins separated by two covalent bonds.
Figure 6: HMBC of aliphatic region of ADH10 product, vitrosamine.
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